Document:

EX-10.18

 Exhibit 10.18 

Confidential 

Execution Copy 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 LICENSE AGREEMENT 

between 
 Genelux
Corporation 
 and 

Newsoara BioPharma Co. Ltd 

Dated as of September 27, 2021 
  

 Privileged & Confidential 

TABLE OF CONTENTS 
  

					
		
	 ARTICLE 1 DEFINITIONS
	  	 	1	 
		
	 ARTICLE 2 GRANT OF RIGHTS
	  	 	12	 
		
	 ARTICLE 3 GOVERNANCE
	  	 	16	 
		
	 ARTICLE 4 DEVELOPMENT, REGULATORY, TRANSITION AND COMMERCIALIZATION ACTIVITIES
	  	 	18	 
		
	 ARTICLE 5 PAYMENTS AND TAXES
	  	 	30	 
		
	 ARTICLE 6 INTELLECTUAL PROPERTY
	  	 	35	 
		
	 ARTICLE 7 CONFIDENTIALITY AND NON-DISCLOSURE
	  	 	42	 
		
	 ARTICLE 8 REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	47	 
		
	 ARTICLE 9 INDEMNITY
	  	 	48	 
		
	 ARTICLE 10 TERM AND TERMINATION
	  	 	52	 
		
	 ARTICLE 11 MISCELLANEOUS
	  	 	56	 

 Schedules 
  

			
	Schedule 1.43	  	Genelux Patents
	Schedule 1.60	  	Licensed Virus
	Schedule 1.104	  	V-VET1 Virus
	Schedule 2.4.2	  	Payments for Derived Product
	Schedule 4.1.4	  	Development Plan Proposal
	Schedule 4.1.5	  	NSCLC Multi-Center Trial Plan
	Schedule 4.1.5(f)	  	NSCLC Multi-Center Trial Budget
	Schedule 7.4	  	Public Announcements

  

 Privileged & Confidential 

LICENSE AGREEMENT 
 This License Agreement
(this “Agreement”) is made and entered into as of September 27, 2021 (the “Effective Date”) by and between Genelux Corporation, a company registered according to the laws of and incorporated in
Delaware, with its principal place of business at 2625 Townsgate Road, Suite 230, Westlake Village, CA (“Genelux”) and Newsoara BioPharma Co. Ltd, a company registered according to the laws of China and incorporated in Shanghai,
with its principal place of business at Room 413, Building 3, No. 1690 Cai Lun Road (“Newsoara”). Genelux and Newsoara are sometimes referred to herein individually as a “Party” and collectively as the
“Parties”. 
 RECITALS 

WHEREAS, Genelux possesses certain proprietary technology and intellectual property rights relating to the Licensed Viruses and
Licensed Products; and 
 WHEREAS, Newsoara is a private company based in Shanghai China and is a comprehensive group pharmaceutical
company that integrates pharmaceutical products research and development, production and business sales; and 
 WHEREAS, subject to
the terms and conditions of this Agreement, Genelux wishes to grant to Newsoara, and Newsoara wishes to receive from Genelux, an exclusive license to Develop, Manufacture and Commercialize Licensed Viruses or Licensed Products in the Field in the
Territory. 
 NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions set forth herein and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

ARTICLE 1 DEFINITIONS 

Unless otherwise specifically provided herein, the following terms shall have the following meanings: 

1.1. “Accounting Standard” means, with respect to a Party or its Affiliates or its or their sublicensees, GAAP, IFRS,
or such other similar national or international standards as such Party, Affiliates or its or their sublicensees adopts, in each case, consistently applied. 

1.2. “Affiliate” means, with respect to a Person, any Person that, directly or indirectly, controls, is controlled by
or is under common control with such first Person at any time for so long as such Person controls, is controlled by or is under common control with such first Person. For purposes of this definition, “control” and, with correlative
meanings, the terms “controlled by” and “under common control with” means: (a) the possession, directly or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of
voting securities, by contract relating to voting rights or corporate governance or otherwise; or (b) the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interests of a business
entity (or, with respect to a limited partnership or other similar entity, its general partner or controlling entity). 

  
 - 1 - 

 1.3. “Agreement” has the meaning set forth in the preamble hereto.

 1.4. “Anti-Corruption Laws” means the U.S. Foreign Corrupt Practices Act, the PRC Criminal Law and the PRC
Anti-unfair Competition Law, each as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism. 

1.5. “Applicable Law” means applicable laws, rules and regulations, including any rules, regulations, guidelines or
other requirements of the Regulatory Authorities that may be in effect from time to time, including the PRC Drug Administration Law, the Implementing Regulations on the PRC Drug Administration Law, the PRC Drug Registration Regulation, the FFDCA,
standards for Good Laboratory Practice (GLP), Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP), and guideline of The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
(ICH), and the Anti-Corruption Laws. 
 1.6. “Arbitrators” has the meaning set forth in
Section 11.4.3 (Arbitration Procedure). 
 1.7. “Arbitration Notice” has the meaning set
forth in Section 11.4.2 (Arbitration Notice). 
 1.8. “Business Day” means a day other
than (i) a Saturday or Sunday or (ii) a day on which banking institutions in Shanghai, mainland China or the State of California, US are permitted or required to be closed by Applicable Law or executive orders. 

1.9. “Breaching Party” has the meaning set forth in Section 10.2.1 (Termination for Material
Breach). 
 1.10. “US Dollars” or “USD” means United States dollars, the lawful currency of the
United States. 
 1.11. “Calendar Quarter” means each successive period of three (3) calendar months ending on
March 31, June 30, September 30 and December 31. 
 1.12. “Calendar Year” means each successive
period of twelve (12) calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the
Effective Date occurs and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term. 

1.13. “Change of Control” means, with respect to a Party, (a) a merger, reorganization, consolidation or other
transaction involving such Party and any entity that is not an Affiliate of such Party, which results in the voting securities of such Party outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined
voting power of the surviving entity immediately after such merger, reorganization, consolidation or other transaction, or (b) any entity that is not an Affiliate of such Party becoming the beneficial owner of fifty percent (50%) or more of the
combined voting power of the outstanding securities of such Party or otherwise acquiring the power (whether through ownership interest, contractual right or otherwise) to direct or cause the direction of the management or policies of such Party.

  
 - 2 - 

 1.14. “Clinical Trial” means any clinical trial in human subjects
that is designed to measure the safety and/or efficacy of a product and that is required by Applicable Law, or otherwise recommended by any Regulatory Authority, to obtain or maintain Regulatory Approval. 

1.15. “Combination Product” means [***]. 

1.16. “Commercialization” means, in respect of a pharmaceutical product, any and all activities directed to the
preparation for sale of, offering for sale of or sale of such product, including activities related to planning, market research, marketing, promoting, bidding and pricing, distributing and importing and exporting such product and interacting with
Regulatory Authorities regarding any of the foregoing, but shall exclude Development and Manufacturing. When used as a verb, “to Commercialize” and “Commercializing” means to engage in Commercialization and
“Commercialized” has a corresponding meaning. 
 1.17. “Commercially Reasonable Efforts” means,
with respect to the performance of Development, Commercialization or Manufacturing activities with respect to a Licensed Virus or a Licensed Product by Newsoara, the carrying out of such activities in a sustained and diligent manner and using
efforts and resources comparable to the efforts and resources commonly used in the pharmaceutical industry for virus products of similar market potential at a similar stage in development or product life. “Commercially Reasonable Efforts”
shall be determined on a country-by-country or region-by-region (where applicable) and Indication-by-Indication basis, without regard to the particular circumstances of Newsoara, including any other product opportunities of Newsoara (including Derived Molecules
and Derived Products) and without regard to any payments owed by Newsoara to Genelux under this Agreement, but, notwithstanding the foregoing, shall take into account the competitiveness of the marketplace, Newsoara’s proprietary position with
respect to such Licensed Virus or Licensed Product, applicable regulatory circumstances and the likelihood of success of Commercialization. 

1.18. “Confidential Information” has the meaning set forth in Section 7.1
(Confidentiality Obligations). 
 1.19. “Control” means, with respect to any item of Information, Regulatory
Documentation, material, Patent or other intellectual property right, possession of the right, whether directly or indirectly and whether by ownership, license or otherwise (other than by operation of the license and other grants in
Section 2.1 (Grants to Newsoara) or Section 2.4 (Grants to Genelux), to grant the other Party a license, sublicense or other right (including the right to reference Regulatory Documentation) to or
under such Information, Regulatory Documentation, material, Patent or other intellectual property right as provided for herein without violating the terms of any agreement with any Third Party; provided however that: 

  
 - 3 - 

 1.19.1. with respect to any item of Information, Regulatory Documentation, material,
Patent or other intellectual property right that is in-licensed, acquired or obtained by any Party or its Affiliate from a Third Party after the Effective Date, “Control” of such item by such Party
shall also be conditioned upon the other Party’s agreement that the other Party shall comply with the applicable terms and conditions of the agreement under which such Party or its Affiliates
in-licenses, acquires or obtains such item, and pay all amounts that such Party or its Affiliates would be obligated to pay to the Third Party solely due to the grant, maintenance or exercise of a sublicense
to the other Party under such item; and 
 1.19.2. in the event that any Party undergoes a Change of Control after the Effective
Date, then such Party shall not be deemed to Control any item of Information, Regulatory Documentation, material, Patent or other intellectual property right of the acquirer or its Affiliate, except to the extent ay such item is already under such
Party’s Control before such Change of Control transaction. 
 1.20. “Cost of Manufacturing” means, with respect
to the Licensed Virus and Licensed Product supplied by Genelux to Newsoara: 
 1.20.1. [***]; and 

1.20.2. [***]; 

in each case of 1.20.1 and 1.20.2, calculated in accordance with the applicable Accounting Standard; [***]. 

1.21. “Cover” means with respect to a particular subject matter at issue and a relevant Patent, but for rights granted
to a Person under such Patent, the manufacture, use, sale, offer for sale, or importation of such subject matter would infringe one or more Valid Claims in such Patent (if the Valid Claim is still pending, then as if such Valid Claim had been
issued). 
 1.22. “Cure Period” shall have the meaning set forth in Section 10.2.1
(Termination for Material Breach). 
 1.23. “Delivery System” means [***]. 

1.24. “Derived Molecule” means [***]. 

1.25. “Derived Product” means any pharmaceutical product in final form that is comprised of or contains Derived
Molecule as an active ingredient, [***]. 
 1.26. “Development” means, in respect of a pharmaceutical product, all
activities related to research, pre-clinical and other non-clinical testing, test method development and stability testing, toxicology, formulation, process development,
manufacturing scale-up, qualification and validation, quality assurance/quality control, clinical studies, including Manufacturing in support thereof, statistical analysis and report writing, the preparation
and submission of IND, Drug Approval Applications and amendments/supplements, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a
condition or in support of obtaining or maintaining a Regulatory Approval for such product. When used as a verb, “Develop” means to engage in Development. 

  
 - 4 - 

 1.27. “Disclosing Party” has the meaning set forth in
Section 7.1 (Confidentiality Obligations). 
 1.28. “Dispute” has the meaning set forth in
Section 11.4.1 (Escalation to Senior Officers). 
 1.29. “Drug Approval Application” means
a New Drug Application as defined in the FFDCA, a Biological License Application as defined in the U.S. Public Health Service (PHS) Act, or any corresponding application for marketing a drug in any country or region in the Territory. 

1.30. “Effective Date” has the meaning set forth in the preamble hereto. 

1.31. “Enforcing Party” has the meaning set forth in Section 6.3.2 (Enforcement of Patents).

 1.32. “Exploit” means, in respect of a pharmaceutical product, to make, have made, import, use, sell or offer for
sale, including to research, reproduce, create, perform, modify, provide access to, Develop, Commercialize, register, Manufacture, have Manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute,
promote, market or have sold or otherwise dispose of such product. “Exploitation” means the act of Exploiting a product. 

1.33. “FDA” means the United States Food and Drug Administration and any successor agency thereto. 

1.34. “FFDCA” means the United States Federal, Food, Drug, and Cosmetic Act, as amended from time to time, together
with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). 

1.35. “Field” means human diagnostic, prophylactic and therapeutic uses. 

1.36. “First Commercial Sale” means, with respect to a Licensed Product and a country or region, the first sale for
monetary value for use or consumption by the end user of such Licensed Product in such country or region after approval of a Drug Approval Application for such Licensed Product has been obtained in such country or region. 

1.37. “GAAP” means United States generally accepted accounting principles, consistently applied. 

1.38. “Genelux” has the meaning set forth in the preamble hereto. 

1.39. “Genelux Corporate Names” means those Trademarks, names and logos of Genelux or any of its Affiliates, as
determined by Genelux, use of which is legally required or otherwise reasonably necessary to Develop or Commercialize the Licensed Viruses or the Licensed Products in the Field in the Territory. 

  
 - 5 - 

 1.40. “Genelux Know-How”
means the Information Controlled by Genelux or any of its Affiliates as of the Effective Date or coming under Genelux’s or its Affiliate’s Control during the Term that is necessary for or actually used by Genelux in the Development,
Manufacture, use or Commercialization of the Licensed Viruses or Licensed Products. For clarity, Genelux Know-How includes Genelux New Invention and its share in the Joint Invention. 

1.41. “Genelux New Invention” has the meaning set forth in Section 6.1.1 (Ownership
of Inventions). 
 1.42. “Genelux New Patent” has the meaning set forth in Section 6.1.1
(Ownership of Inventions). 
 1.43. “Genelux Patents” means all Patents in the Territory (and, solely for the
purpose of the license granted to Newsoara in Section 4.1.5 (Clinical Trial for Indication of NSCLC), in the U.S.) Controlled by Genelux or its Affiliates as of the Effective Date or coming under Genelux’s or its
Affiliate’s Control during the Term that Covers Licensed Virus or Licensed Product (including the composition of matter and method of making and using thereof), including but not limited to all Patents listed on Schedule 1.43 (Genelux
Patents). For clarity, Genelux Patents includes Genelux New Patents and its share in the Joint Patents. 
 1.44.
“Genelux Regulatory Documentation” means Regulatory Documentation Controlled by Genelux or any of its Affiliates as of the Effective Date or coming under Genelux’s or its Affiliate’s Control during the Term relating
to the Licensed Viruses or the Licensed Products in the Field. 
 1.45. “Generic Version” means, with respect to a
particular Licensed Product and a particular country or region, any pharmaceutical product sold in such country or region by a Third Party (excluding any Affiliate of Newsoara, Newsoara’s Sublicensee, distributor or other subcontractor, or any
Person deriving any right to such product from Newsoara, its Affiliate or Sublicensee) that (a) contains substantially identical active ingredient(s) as such Licensed Product, including the nucleic acid sequence of the Licensed Virus contained
in such Licensed Product; and (b) has received Regulatory Approval in such country or region on an expedited or abbreviated basis in a manner that relied on data submitted by any Party, its Affiliate, licensees or sublicensees for such Licensed
Product in the Field in the Territory. 
 1.46. “Governmental Authority” means any federal, state, national,
provincial or local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing
authority or power (including any fiscal, revenue, customs, or exercise authority body or official anywhere in the world), any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body). 

1.47. “IFRS” means International Financial Reporting Standards, consistently applied. 

1.48. “Improvement” means any invention, discovery, development or modification with respect to a Licensed Virus or a
Licensed Product or relating to the Exploitation thereof, made by or on behalf of any Party after the Effective Date, and whether or not patented or patentable, including any enhancement in the efficiency, operation, Manufacture, ingredients,
preparation, presentation, formulation, means of delivery or dosage of such Licensed Virus or Licensed Product, any discovery or development of any new or expanded Indications for such Licensed Virus or Licensed Product, any diagnostic devices
relating to such Licensed Virus or Licensed Product, or any discovery or development that improves the stability, safety or efficacy of such Licensed Virus or Licensed Product. 

  
 - 6 - 

 1.49. “IND” means (a) an investigational new drug application
filed with the FDA for authorization to commence clinical studies and its equivalent in other countries or regulatory jurisdictions and (b) all supplements and amendments that may be filed with respect to the foregoing. 

1.50. “Indemnification Claim Notice” has the meaning set forth in Section 9.3.1 (Notice of
Claim). 
 1.51. “Indemnified Party” has the meaning set forth in Section 9.3.1 (Notice of
Claim). 
 1.52. “Indemnifying Party” has the meaning set forth in Section 9.3.1 (Notice
of Claim). 
 1.53. “Indication” means, with respect to a particular drug, a sign, a symptom or a medical condition
which makes the use of that drug for treatment advisable. In respect of cancer, different [***] (e.g. [***]) and different [***] for which [***] shall also be considered separate Indications for this Agreement, however, provided [***]. For clarity,
[***] (for example, [***] and [***] separate Indications. 
 1.54. “Information” means all technical, scientific and
other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance,
designs, drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including: biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical, safety, manufacturing and quality control data and information, including study designs and protocols, assays and biological methodology, business plans, sale projections, in each case
(whether or not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed. 

1.55. “Infringement” has the meaning set forth in Section 6.3.1 (Notice). 

1.56. “Invention” means any Information, Improvement, process, method, composition of matter, article of manufacture,
discovery or finding, patentable or otherwise, that is conceived or reduced to practice by a Party, either within or outside the scope of this Agreement. 

1.57. “Joint Invention” means an Invention in which a contribution has been made by one or more employees, agents or
contractors of Genelux and one or more employees, agents or contractors of the Newsoara, and which constitutes a joint invention under Applicable Law. 

1.58. “Joint Patent” has the meaning set forth in Section 6.1.1 (Ownership of Inventions).

 1.59. “Licensed Product” means any pharmaceutical product in final form that is comprised of or contains Licensed
Virus as an active ingredient, [***]. 

  
 - 7 - 

 1.60. “Licensed Virus(es)” means [***] 

1.61. “Losses” has the meaning set forth in Section 9.1 (Indemnification of Genelux). 

1.62. “Manufacture” and “Manufacturing” means, in respect of a pharmaceutical product, all activities
related to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of such product or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control. 

1.63. “Material Breach” has the meaning set forth in Section 10.2.1 (Termination for
Material Breach). 
 1.64. “Net Sales” means, with respect to a Licensed Product for any period, the gross amount
billed or invoiced by Newsoara, its Affiliates or its or their licensees to the first Third Parties for the sale of a Licensed Product (the “Invoiced Sales”), less the following deductions to the extent reasonable, customary and
allocable to the sale of such Licensed Product: 
 1.64.1. [***] 

1.64.2. [***] 

1.64.3. [***] 

1.64.4. [***] 

1.64.5. [***] 

1.64.6. [***] 

1.64.7. Any of the deductions listed above that involves a payment by Newsoara, its Affiliates or its or their licensees shall be taken
as a deduction in the Calendar Year in which the payment is accrued by such entity. [***] 
 Subject to the above, Net Sales shall be
calculated in accordance with the standard internal policies and procedures of Newsoara, its Affiliates or its or their licensees, which must be in accordance with the applicable Accounting Standard. 

1.65. “Newsoara” has the meaning set forth in the preamble hereto. 

1.66. “Newsoara Corporate Names” means the Trademarks, names and logos of Newsoara or any of its Affiliates. 

1.67. “Newsoara New Invention” has the meaning set forth in Section 6.1.1 (Ownership of
Inventions). 
 1.68. “Newsoara New Patent” has the meaning set forth in Section 6.1.1
(Ownership of Inventions). 

  
 - 8 - 

 1.69. “NMPA” means the National Medical Products
Administration of China and any successor agency thereto. 
 1.70. “Non-Breaching
Party” has the meaning set forth in Section 10.2.1 (Termination for Material Breach). 
 1.71.
“Notice of Breach” has the meaning set forth in Section 10.2.1 (Termination for Material Breach). 

1.72. “NSCLC” means Non-Small Cell Lung Cancer. 

1.73. “Olvi-Vec” means an oncolytic vaccinia virus containing three foreign
gene expression cassettes, which cassettes are [***]; [***]; and [***], that is designated internally by Genelux as of the Effective Date as “Olvi-Vec”. 

1.74. “Oncolytic Virus(es)” means any and all replication-competent viruses selected or engineered with a transgene to
preferentially infect and kill cancer cells. 
 1.75. “Party” and “Parties” have the meaning set
forth in the preamble hereto. 
 1.76. “Patents” means: (a) all national, regional and international patents
and patent applications, including provisional patent applications; (b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these,
including divisionals, continuations, continuations-in-part, provisionals, converted provisionals and continued prosecution applications; (c) any and all patents
that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents, innovation patents and design patents and certificates of invention; (d) any and all extensions or
restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of
the foregoing patents or patent applications ((a), (b) and (c)); and (e) any similar rights, including so-called pipeline protection or any importation, revalidation, confirmation or introduction patent
or registration patent or patent of additions to any of such foregoing patent applications and patents. 
 1.77.
“Payment” means any payment due from Newsoara to Genelux under or pursuant to this Agreement. 
 1.78.
“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association,
joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government. 

1.79. “Phase I Clinical Trial” means a human clinical study of a product, the principal purpose of which is a
preliminary determination of safety (whether in healthy individuals or in patients), as described in 21 C.F.R. 312.21(a) in the U.S., or other corresponding Applicable Law in a country or region in or outside the Territory. 

  
 - 9 - 

 1.80. “Phase II Clinical Trial” means a human clinical study that
has the primary purpose to determine the feasibility, safety or efficacy of a product in potential Indications, that is prospectively designed to generate sufficient data (if successful) to commence a Phase III Study (or equivalent outside the U.S.)
of such product, as further defined in 21 C.F.R. 312.21(b) in the U.S., or other corresponding Applicable Law in a country or region in or outside the Territory. 

1.81. “Phase III Clinical Trial” means, with respect to a product, a Pivotal Clinical Trial or a clinical study in
humans performed to gain evidence with statistical significance of the efficacy of such product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of
such product, to form the basis for approval of a Drug Approval Application (or equivalent marketing authorization) by a Regulatory Authority and to provide an adequate basis for physician labeling, as described in 21 C.F.R. 312.21(c) in the U.S.,
as amended from time to time, or other corresponding Applicable Law in a country or region in or outside the Territory. 
 1.82.
“Pivotal Clinical Trial” means, with respect to a particular Licensed Product, a pivotal clinical trial of such Licensed Product that is, or is designed to be, the final clinical trial conducted necessary to support the filing of a
Drug Approval Application for such Licensed Product in the applicable Territory. 
 1.83. “Product Trademarks” means
the Trademark(s) used or to be used by Newsoara or its Affiliates or its or their Sublicensees for the Commercialization of Licensed Product in the Territory and any registrations thereof or any pending applications relating thereto in the
Territory, but excluding, in any event, any Genelux Corporate Names, any Newsoara Corporate Names and any Trademarks that consist of or include any corporate name or corporate logo of the Parties or their Affiliates or its or their (sub)licensees).

 1.84. “PRROC” means Platinum-Resistant/Refractory Ovarian Cancer. Platinum status shall be based on Platinum-Free
Interval (PFI), which is defined as the time from last dose of the most recent platinum-based regimen to subsequent disease progression based on radiological assessment. Platinum-Refractory means PFI of less than one month (including progression
while on platinum-based therapy), and Platinum-Resistant means PFI of one to six months. 
 1.85. “Receiving Party”
has the meaning set forth in Section 7.1 (Confidentiality Obligations). 
 1.86. “Regulatory
Approval” means, with respect to a particular Licensed Product or Derived Product and a particular country or region, any and all approvals (including approvals of Drug Approval Applications), licenses, registrations or authorizations of
any Regulatory Authority necessary for the Exploitation of such a Licensed Product or Derived Product in such jurisdiction, including, where applicable, (a) any IND, clinical trial approval or notification, approval of Drug Approval
Application, and supplements and amendments thereto; (b) pricing or reimbursement approval in such jurisdiction, (c) pre-approval and post-approval marketing authorizations (including any
prerequisite Manufacturing or distribution approval or authorization related thereto), and (d) labeling approval. 

  
 - 10 - 

 1.87. “Regulatory Authority” means any applicable supra-national,
federal, national, regional, state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Exploitation of the Licensed
Viruses, Licensed Products, Derived Molecules or Derived Products anywhere in the world, including the FDA, and NMPA. 
 1.88.
“Regulatory Documentation” means: all (a) applications (including all INDs, , Drug Approval Applications and Drug Master Files (DMFs) and any amendments and supplements), registrations, licenses, authorizations and approvals
(including Regulatory Approvals); (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting
documents with respect thereto, including all regulatory drug lists, advertising and promotion documents, adverse event files and complaint files; and (c) preclinical, clinical and other data results, analyses, publications, and reports
contained or referred to in any of the foregoing; in each case ((a), (b) and (c)) relating to a Licensed Virus, Licensed Product, Derived Molecule or Derived Product. 

1.89. “Regulatory Exclusivity” means any exclusive marketing rights or data exclusivity rights (other than Patents)
conferred by any Governmental Authority with respect to a pharmaceutical product, including without limitation orphan drug exclusivity, new chemical entity exclusivity, data exclusivity, pediatric exclusivity, and rights similar thereto, provided
that, such Regulatory Exclusivity for a Licensed Product in a country or region shall be deemed to expire if any Generic Version of the Licensed Product receives all Regulatory Approvals necessary for the Commercialization of the such Generic
Version in such country or region and such Generic Version is commercially sold in such country or region. 
 1.90. “Royalty
Term” means, with respect to a Licensed Product, and each region in the Territory, the period beginning on the date of First Commercial Sale of such Licensed Product in such region and ending on the last to occur of: (a) the expiration
of the last to expire Genelux Patent (including any applicable patent term extension) in such region that contains either (i) an issued Valid Claim that Covers the Licensed Product (including the Licensed Virus contained therein, and including
the composition of matter and method of making and using thereof) or (ii) a pending Valid Claim that Covers the sequence of the Licensed Virus contained therein; (b) the tenth (10th) anniversary of the First Commercial Sale of such
Licensed Product in such region; and (c) the expiration of all Regulatory Exclusivity for such Licensed Product in such region. 

1.91. “Senior Officer” means, with respect to Genelux, its Chief Executive Officer (or equivalent) and with respect to
Newsoara, its Chief Executive Officer (or equivalent). 
 1.92. “Sublicensee” means a Person, other than Genelux or
Newsoara, that is granted a sublicense by Newsoara (directly or indirectly) as provided in Section 2.2.1 (Sublicense). 

1.93. “Tax” or “Taxes” means any and all applicable tax and taxes (including any value added tax or
sales tax, stamp or other duty, levy, impost, or withholding of any nature and howsoever called or described) by whomsoever and wheresoever imposed, levied, collected or assessed. 

1.94. “Term” has the meaning set forth in Section 10.1 (Term and Expiration). 

1.95. “Territory” means Mainland China, Taiwan, Hong Kong, and Macau. 

1.96. “Third Party” means any Person other than Genelux, Newsoara and their respective Affiliates. 

  
 - 11 - 

 1.97. “Third Party Claims” has the meaning set forth in
Section 9.1 (Indemnification of Genelux). 
 1.98. “Third Party Infringement Claim” has
the meaning set forth in Section 6.4 (Infringement Claims by Third Parties). 
 1.99. “Third Party
Patent Right” means any Patent of a Third Party, which the Exploitation of any Licensed Virus or any Licensed Product in the Field and in the Territory by Newsoara, any of its Affiliates or any of its or their Sublicensees or distributors
or customers infringes or is reasonably expected to infringe. 
 1.100. “Third Party Trademark Claim” has the
meaning set forth in Section 6.8.3 (Third Party Claims). 
 1.101. “Trademark” means any
word, name, symbol, color, shape, designation or any combination thereof, including any trademark, service mark, trade name, brand name, sub-brand name, trade dress, product configuration rights, program name,
delivery form name, certification mark, collective mark, logo, tagline, slogan, design or business symbol, that functions as an identifier of source, origin or quality, whether or not registered, and all statutory and common law rights therein and
all registrations and applications therefor, together with all goodwill associated with, or symbolized by, any of the foregoing. 

1.102. “United States” or “U.S.” means the United States of America and its territories and
possessions (including the District of Columbia and Puerto Rico). 
 1.103. “Valid Claim” means (a) a claim of
an issued and unexpired licensed patent related to a Licensed Product or Licensed Virus which has not been revoked or held invalid or unenforceable by a court or other government agency of competent jurisdiction by a final decision (which decision
is not appealable or has not been appealed within the time allowed for appeal), including through disclaimer or reissue or (b) a claim of a pending patent application that was filed and is being prosecuted in good faith and has not been
abandoned or finally disallowed without the possibility of appeal or re-filing of the application, provided that such patent application has not been pending for more than the greater of [***] years
since its earliest claimed priority date. If a claim ceases to be Valid Claim because it has been pending for more than [***] years, and such claim subsequent issues, then such claim shall again be considered a Valid Claim under this Agreement upon
its issuance. 
 1.104. “V-VET1 Virus” means the Oncolytic Virus set forth
in Schedule 1.104 (V-VET1 Virus). 
 ARTICLE 2 GRANT OF RIGHTS 

2.1. Grants to Newsoara. As of the Effective Date, subject to Sections 2.2 (Sublicenses), Sections 2.3
(Restrictions) and the other terms and conditions of this Agreement, Genelux hereby grants to Newsoara: 

  
 - 12 - 

 2.1.1. License Grant for Licensed Products. An exclusive (including with
regard to Genelux and its Affiliates but subject to Genelux’s retained rights as set forth in Section 2.5 (Genelux Retained Rights)), royalty-bearing license and right of reference, with the right to grant sublicenses
and further right of references through multiple tiers in accordance with Section 2.2.1 (Sublicenses), under the Genelux Patents and to use the Genelux Know-How and Genelux Regulatory
Documentations to Develop, Manufacture, Commercialize or otherwise Exploit the Licensed Viruses and the Licensed Products in the Field in the Territory; and 

2.1.2. License Grant for Derived Products. An exclusive (including with regard to Genelux and its Affiliates but subject to
Genelux’s retained rights as set forth in Section 2.5 (Genelux Retained Rights)), royalty-free license and right of reference, with the right to grant sublicenses and further right of references through multiple tiers
in accordance with Section 2.2.1 (Sublicenses), under the Genelux Patents and to use the Genelux Know-How and Genelux Regulatory Documentations to generate Derived Molecules in the
Field in the Territory and to Develop, Manufacture, Commercialize or otherwise Exploit the Derived Molecules and the Derived Products in the Field in the Territory. 

2.2. Sublicenses.

2.2.1. Sublicenses. Newsoara shall have the right to grant sublicenses (or further rights of reference) through multiple tiers
under the licenses and right of reference in Section 2.1 (Grants to Newsoara) to its Affiliates or Third Parties; provided that (a) each Sublicense must be consistent with the terms and conditions of this
Agreement, and Newsoara will remain responsible and liable for the performance of such Sublicensee under such sublicensed rights to the same extent as if such activities were conducted by Newsoara, and will cause the Sublicensee to comply with the
terms and conditions of this Agreement; and (b) Newsoara shall obtain prior written consent from Genelux for any sublicense to Third Parties, which consent shall not be unreasonably withheld, delayed or conditioned; except that such consent
shall not be required, [***]. Within [***] ([***]) days after the effective date of any Sublicense, Newsoara shall provide Genelux with a copy of the sublicense agreement, except that Newsoara may redact terms that are not necessary for Genelux to
confirm the Sublicense’s compliance with the terms and conditions of this Agreement. 
 2.3. Restrictions. 

2.3.1. Restrictions for Genelux. 

(a) Genelux shall not, and shall obligate any of its Affiliates or any of its and their licensees, sublicensees, (sub)contractors or
distributors to not, distribute, market, promote, offer for sale or sell any Licensed Virus, Licensed Product, Derived Molecule or Derived Product, [***]. Genelux shall, within [***] ([***]) days after learning that any Licensed Virus, Licensed
Product, Derived Molecule or Derived Product sold by or under authority of Genelux have been sold, distributed or dispensed within the Territory (except for supply to Newsoara), notify Newsoara in writing of all pertinent information relating to
such occurrence and the actions Genelux plans to take in response thereto. 

  
 - 13 - 

 (b) After the Effective Date and during the Term, Genelux shall not Develop or
Commercialize any Licensed Virus, Licensed Product, Derived Molecule or Derived Product in the Field in the Territory, and shall not grant any Third Party any right and license to do so, other than the performance of Genelux’s obligations and
exercise of Genelux’s rights hereunder in accordance with the terms of this Agreement. 
 (c) After the Effective Date and during the
Term, Genelux shall not Develop or Commercialize the V-VET1 virus in the Field in the Territory. 

2.3.2. Restrictions for Newsoara. 

(a) Newsoara shall not, and shall obligate any of its Affiliates or any of its and their licensees, sublicensees, (sub)contractors or
distributors to not, distribute, market, promote, offer for sale or sell any Licensed Virus, Licensed Product, Derived Molecule or Derived Product, [***]. Newsoara shall, within [***] ([***]) days after learning that any Licensed Virus, Licensed
Product, Derived Molecule or Derived Product sold by or under authority of Newsoara under this Agreement have been sold, distributed or dispensed outside of the Territory, notify Genelux in writing of all pertinent information relating to such
occurrence and the actions Newsoara plans to take in response thereto. 
 (b) After the Effective Date and during the Term, Newsoara shall
not Develop (except for the conduct of the NSCLC Multi-Center Trial in the US pursuant to Section 4.1.5 (Clinical Trial for Indication of NSCLC) or other obligations hereunder), Manufacture, or Commercialize any Licensed
Virus, Licensed Product, Derived Molecule or Derived Product outside the Field and/or the Territory, and shall not grant any Third Party any right and license to do so. 

2.4. Grants to Genelux. 

2.4.1. Grants to Genelux for Licensed Product. Newsoara hereby grants, and shall cause its Affiliates and its and their
Sublicensees to grant to, Genelux an exclusive, fully paid, royalty free, perpetual, irrevocable, and sublicensable (through multiple tiers) license and right of reference under all Patents, Information, Regulatory Documentations that are
(a) Controlled by Newsoara or its Affiliates and (b) developed or generated, or used or applied, submitted or received, by or on behalf of Newsoara, its Affiliates or Sublicensees in the Development, Manufacture, Commercialization or
Exploitation of the Licensed Viruses and Licensed Products to Develop, Manufacture, Commercialize or otherwise Exploit the Licensed Viruses and the Licensed Products outside the Field and/or Territory. Newsoara shall ensure that, except as required
by Applicable Laws, Newsoara Controls all Patents, Information, Regulatory Documentations that are developed or generated, submitted or received, by or on behalf of Newsoara, its Affiliates or Sublicensees in the Development, Manufacture,
Commercialization or Exploitation of the Licensed Viruses and Licensed Products so that Newsoara can license the same to Genelux as set forth above. For clarity, Genelux shall have the right to sublicense the rights obtained from Newsoara pursuant
to this Section 2.4.1 (Licensed Product) only with its Affiliates or sublicensees that agree to grant reciprocal rights to Newsoara. 

  
 - 14 - 

 2.4.2. Grants to Genelux for Derived Product.

(a) Newsoara hereby grants, and shall cause its Affiliates and its and their Sublicensees to grant to, Genelux an exclusive, royalty bearing,
and sublicensable (through multiple tiers) license and right of reference under all Patents, Information, Regulatory Documentations that are (i) Controlled by Newsoara or its Affiliates and (ii) developed or generated, or used or applied,
submitted or received, by or on behalf of Newsoara, its Affiliates or Sublicensees in the Development, Manufacture, Commercialization or Exploitation of the Derived Molecules and Derived Products to Develop, Manufacture, Commercialize or otherwise
Exploit the Derived Molecules and the Derived Products outside the Territory. 
 (b) Without limiting
Section 4.1.9 (Development Reports) or 4.1.10 (Data Sharing), Newsoara shall provide Genelux with access to its database that contains all data and results generated from the Development of the Derived Molecules and
Derived Products. After reviewing such data, if Genelux elects to Develop any Derived Molecule or Derived Product outside the Territory, Genelux shall notify Newsoara, and Newsoara shall provide reasonable technology transfer and assistance for such
Derived Molecule and Derived Product and Sections 4.1.1 (Technology Transfer) and 4.1.2 (Material Supply) shall apply mutatis mutandis to such technology transfer (except that only the initial [***] FTE hours of assistance shall
be free of charge).
 (c) If Genelux Develops, Manufactures and/or Commercializes any Derived Product outside the Territory, or notifies
Newsoara of its intention in accordance with Section 2.4.2(b), Genelux shall pay to Newsoara in accordance with Schedule 2.4.2 (Payments for Derived Product). 

2.5. Genelux Retained Rights. Notwithstanding the exclusive license granted to Newsoara under
Section 2.1 (Grants to Newsoara), Genelux hereby expressly retains the right under Genelux Patents, Genelux Know-How and Genelux Regulatory Documentation in the Field in the Territory
in order to perform its obligations under this Agreement, whether directly or through its Affiliates, licensees, sublicensees or contractors. For clarity, Genelux retains the exclusive right to use, practice, license and otherwise exploit the
Genelux Patents, Genelux Know-How and Genelux Regulatory Documentation outside the scope of the license granted to Newsoara under Section 2.1 (Grants to Newsoara), including the
exclusive right to develop, make, have made, use, sell, offer for sale and import the Licensed Viruses, Licensed Products, Derived Molecules and Derived Products outside the Territory. Genelux also retains the
non-exclusive right to make and have made the Licensed Viruses, Licensed Products, Derived Molecules and Derived Products in the Territory, provided that, before Genelux entrusts any Third Party to make or
have made the Licensed Viruses, Licensed Products, Derived Molecules or Derived Products in the Territory, Genelux shall provide a written notice of its intention to Newsoara, and if Newsoara intend to make or have made the Licensed Viruses,
Licensed Products, Derived Molecules or Derived Products in the Territory and supply to Genelux, then Newsoara shall have [***] ([***]) days to negotiate in good faith with Genelux to reach a supply agreement for the Licensed Viruses, Licensed
Products, Derived Molecules or Derived Products. 

  
 - 15 - 

 2.6. No Implied Licenses; Negative Covenant. Except as expressly set
forth herein, no license or other right or interest under any Patents, Information, Regulatory Documentation or other intellectual property of Genelux is granted (by implication or otherwise) to Newsoara under this Agreement. Newsoara shall not, and
shall not permit any of its Affiliates or Sublicensees to, use, practice or exploit any Genelux Patents, Genelux Know-How and Genelux Regulatory Documentation outside the scope of the license granted by
Genelux to Newsoara under Section 2.1 (Grants to Newsoara) of this Agreement. 
 2.7. Non-Compete. During the Term of this Agreement, except for the Development, Manufacture, Commercialization and Exploitation of the Licensed Viruses, Licensed Products, Derived Molecules and Derived Products in
the Field in the Territory in accordance with the terms and condition of this Agreement (including Section 2.8 (Limitation on Development of Derived Product)), neither Newsoara nor any of its Affiliates or Sublicensees
shall, directly or indirectly, develop, commercialize, promote, make, have made, sell, offer for sale, import and/or export, or enter into any collaboration or license agreement with any Third Party in connection with the development,
commercialization, promotion, manufacture, sale, offering for sale, importation and/or exportation of, (a) any vaccinia virus(es) anywhere in the world, and (b) any type of virus strain and virus product for NSCLC or PRROC anywhere in the
world, provided that, if the Parties permanently cease the Development of Olvi-Vec in NSCLC or PRROC or if Olvi-Vec has been approved in NSCLC or PRROC, then the
limitation under the (b) above for NSCLC or PRROC in which the Development of Olvi-Vec has ceased or Olvi-Vec has been approved shall no longer apply, and Newsoara,
its Affiliates and Sublicensees shall have the right to develop, commercialize, promote, make, have made, sell, offer for sale, import and/or export any type of virus strain and virus product other than vaccinia virus(es) in NSCLC or PRROC in which
the Development of Olvi-Vec has ceased or Olvi-Vec has been approved. 

2.8. Limitation on Development of Derived Product. Notwithstanding anything to the contrary, Newsoara shall not Develop any
Derived Molecule or Derived Product in NSCLC or PRROC unless and until the earlier of (a) the Parties permanently cease the Development of Olvi-Vec in such Indication or
(b) Olvi-Vec has been approved in such Indication in the Territory.
 ARTICLE 3 

GOVERNANCE 
 3.1.
Formation. Within [***] days following the Effective Date, the Parties shall establish a joint steering committee (“Joint Steering Committee” or “JSC”). [***] From time to time, each Party may substitute one
(1) or more of its representatives to the JSC on written notice to the other Party. Each Party shall ensure that, at all times during the existence of the JSC, such Party’s representatives (initial or replacement) on the JSC have
appropriate expertise for the then-current stage of Development, Regulatory Approval, Manufacture or Commercialization of Licensed Product and Derived Product and have the authority to bind such Party with respect to matters within the purview of
the JSC. 

  
 - 16 - 

 3.2. Duties. The JSC shall be responsible for: 

(a) to review, discuss and coordinate the overall strategy for the Development and Manufacturing of Licensed Products and Derived Products,
including related regulatory activities in different territory to ensure consistent global marketing of Licensed Products; 
 (b) to
review, discuss and approve any proposed amendments or revisions to the Development Plan, including protocol of Clinical Trials for the Licensed Products in the Field in the Territory; 

(c) to review and discuss (but not approve) the Commercialization Plan of Licensed Product in the Field in the Territory and any proposed
amendments or revisions to such plan; 
 (d) to coordinate the Commercialization of Licensed Products and Derived Products in different
territory to ensure consistent global marketing of Licensed Products; 
 (e) facilitating the transfer of Genelux Know-How; 
 (f) facilitating the exchange of data and know-how
related to the Licensed Products and Derived Products, including the clinical data and safety data; 
 (g) facilitating the exchange of
other information related to the Development, Regulatory Approval, Manufacture and Commercialization of Licensed Products and Derived Products; 

(h) establish joint project teams to manage the execution of NSCLC Multi-Center Trial of Olvi-Vec and
collaboration regarding the Development of Olvi-Vec in Ovarian Cancer in the Territory; and 
 (i)
undertaking or approving such other matters as are specifically assigned to the JSC in this Agreement. 
 3.3. JSC General
Provisions. The JSC shall meet at such times as are agreed to by the representatives of each Party, but no less than once each month during the first year after the Effective Date and once each quarter thereafter, and on an ad hoc basis as and
when necessary as reasonably requested by a Party. Such meetings may be either in person or via telephone or videoconference. The location of in-person meetings will alternate between US and China unless
otherwise agreed to by the Parties. The responsibility for keeping minutes shall alternate between the Parties, beginning with Genelux. [***]. Each Party may from time to time invite a reasonable number of participants, in addition to its
representatives, to attend the JSC meetings in a non-voting capacity; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide
prior written notice to the other Party and shall also ensure that such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement. A quorum of the JSC shall
exist whenever there is present at a meeting at least one (1) representative appointed by each Party. If the quorum is met, the JSC shall take action by consensus of the representatives present at a meeting with each Party having a single vote
irrespective of the number of representatives of such Party in attendance, or by a written resolution signed by at least one (1) representative appointed by each Party. All the written or verbal communications by the JSC shall be made in
English, including but not limited to the meetings, agenda, presentations, meeting minutes, follow up email and report exchanges. 

  
 - 17 - 

 3.4. Disputes. If there is a matter within the JSC’s authority for which
the JSC is unable to reach unanimous approval within [***] ([***]) Business Days after such issue or lack of consensus was raised at a JSC meeting, then Newsoara will have the final decision making authority with respect to all matters concerning
the Development, Manufacture or Commercialization of the Licensed Products in the Field in the Territory; provided, however, that [***]. For clarity, the JSC may discuss but shall have no decision-making authority with respect to the
Development, Manufacture or Commercialization of the Licensed Products outside the Field and/or outside the Territory. 
 3.5.
Limitation of JSC Authority. The JSC shall only have the powers expressly assigned to it in this Article 3 (Governance) and elsewhere in this Agreement and shall not have the authority to: (a) modify or amend the terms and
conditions of this Agreement; (b) waive either Party’s compliance with the terms and conditions of this Agreement; or (c) determine any such issue in a manner that would conflict with the express terms and conditions of this
Agreement. 
 3.6. Discontinuation of JSC. The activities to be performed by the JSC shall solely relate to governance
under this Agreement, and are not intended to be or involve the delivery of services. The JSC shall continue to exist until the first to occur of: (a) the Parties mutually agreeing to disband the JSC; or (b) Genelux providing written
notice to Newsoara of its intention to disband and no longer participate in the JSC. Once the Parties mutually agree or Genelux has provided written notice to disband the JSC, the JSC shall have no further obligations under this Agreement and,
thereafter, each Party shall designate a contact person for the exchange of information under this Agreement and decisions of the JSC shall be decisions as between the Parties, subject to the same respective decision-making rights and limitations
set forth in Section 3.4 (Disputes) and other terms and conditions of this Agreement. 
 ARTICLE 4 DEVELOPMENT,
REGULATORY, TRANSITION AND 
 COMMERCIALIZATION ACTIVITIES 

4.1. Development.  

4.1.1. Technology Transfer. Within [***] days of the Effective Date of the Agreement, the Parties shall coordinate and agree to
a technology transfer plan, pursuant to which Genelux shall disclose and make available to Newsoara the Genelux Know-How that is [***]. Upon Newsoara’s request, Genelux will provide reasonable technical
assistance in connection with such transfer (either at Genelux’s facility or by teleconference). Newsoara shall reimburse Genelux for both out-of-pocket cost and
internal cost incurred by Genelux to provide such technical assistance, except for the internal cost of the first [***] hours of assistance, which shall be provided at Genelux’s cost. For clarity, all Genelux
Know-How and technical assistance (including those related Manufacturing transfer under Section 4.4.1 (Manufacture Transfer)) will be provided only in the English language, and
Newsoara shall be responsible for the translation of Genelux Know-How into the Chinese language at Newsoara’s own cost and expense. For clarity, the technology transfer under this
Section 4.1.1 (Technology Transfer) shall not include Genelux Know-How related to the Manufacture of the Licensed Viruses and Licensed Products, which will be transferred pursuant to
Section 4.4.1 (Manufacture Transfer). 

  
 - 18 - 

 4.1.2. Material Supply. Upon Newsoara’s request and to the extent
specifically set forth in the technology transfer plan, Genelux shall provide to Newsoara reasonable amount of certain materials (including but not limited to [***] in Genelux’s possession and created by or on behalf of Genelux in connection
with Newsoara’s (or its Affiliates) Development of the Licensed Viruses and Licensed Products. Newsoara shall reimburse Genelux for both out-of-pocket cost and
internal cost incurred by Genelux to provide such materials. [***]. All such materials will be provided AS IS without any warranty and will be delivered to Newsoara EXW (Incoterms 2020) at Genelux’s facility. Genelux shall retain ownership and
title to such materials at all times, and Newsoara (a) shall use such materials solely for the purpose to Develop the Licensed Viruses, Licensed Products, Derived Molecules and Derived Products under this Agreement, and (b), unless otherwise
specified in this Agreement, shall not transfer or provide access to such materials to any Third Party other than its subcontractors (subject to the requirements set forth in Section 4.5, and excluding [***] and Regulatory Authorities (to the
extent required by Applicable Laws) without Genelux’s prior written consent. For clarity, Newsoara acknowledges the proprietary nature of the materials provided by Genelux, including Licensed Virus(es), even though some or all of the sequence
of the virus may be publicly available. 
 4.1.3. Diligence. 

(a) After the Effective Date, as between the Parties, Newsoara shall be solely responsible for all aspects of the Development of the Licensed
Viruses and the Licensed Products in the Field in the Territory at Newsoara’s own cost and expense. Newsoara shall use Commercially Reasonable Efforts to Develop, and obtain and maintain Regulatory Approvals for Licensed Product in the Field in
the Territory. 
 (b) Without limiting the foregoing, Newsoara shall: (i) [***] within [***] months after [***]; (ii) [***]
within [***] months after [***]; and (iii) maintain active clinical Development for the Licensed Products through submission of the first Drug Approval Application to NMPA. For the purpose of clause (iii), “active clinical
Development” shall require Newsoara to [***] during any consecutive [***] period [***]. The deadlines and time period set forth in clauses (i), (ii) and (iii) may be extended to the extent that Newsoara’s inability to [***] is caused
by delay outside of Newsoara’s reasonable control, including [***]; provided that Newsoara shall immediately notify Genelux of any such delay, and shall promptly undertake and continue all Commercially Reasonable Efforts necessary to [***] as
soon as reasonably practicable. Failure to meet the deadlines set forth above due to delay outside Newsoara’s reasonable control shall not be considered a breach of this Agreement by itself. 

(c) Subject to the terms and conditions of this Agreement, Newsoara may elect, in its sole discretion, at any time during the Term of this
Agreement, to Develop any Derived Molecule and Derived Product in the Field in the Territory at Newsoara’s own cost and expense. Newsoara shall have no diligence obligations with respect to any Derived Molecules or Derived Product, but any
decision or efforts by Newsoara to Develop or Exploit any Derived Molecules and Derived Products must not reduce the efforts, resources, and other commitments devoted by Newsoara to the Development and Commercialization of Olvi-Vec in the Field in the Territory, and Newsoara may not prioritize the Development or Commercialization of any Derived Molecule or Derived Product over the Development and Commercialization of Olvi-Vec. 

  
 - 19 - 

 (d) If Newsoara conducts clinical Development of other Oncolytic Virus product, in order to
ensure that Newsoara prioritizes the Development of Olvi-Vec over other Oncolytic Virus products, Newsoara shall ensure that (i) [***]; (ii) [***]; and (iii) Newsoara shall [***]. 

4.1.4. Development Plan. 

(a) All Development of the Licensed Viruses and Licensed Products by or on behalf of Newsoara under this Agreement (except for the NSCLC
Multi-Center Trial, which shall be conducted pursuant to Section 4.1.5 (Clinical Trial for Indication of NSCLC)) shall be conducted pursuant to a comprehensive written Development plan that sets forth the timeline, budget
and other details of all clinical and regulatory activities to be conducted by or on behalf of Newsoara to obtain Regulatory Approval of the Licensed Products in the Field in the Territory (the “Development Plan”). As of the
Effective Date, Newsoara has proposed an initial Development Plan, which is attached hereto as Schedule 4.1.4 (Development Plan Proposal); after the Effective Date, the JSC will meet and review the Development Plan Proposal in accordance with
Article 3. From time to time, [***], Newsoara shall propose updates or amendments to the Development Plan in consultation with Genelux and submit such proposed updated or amended plan to the JSC for review, discussion, and approval. Once approved by
the JSC, the updated or amended Development Plan shall become effective. 
 (b) The Parties contemplate that the Development of the
Licensed Viruses and Licensed Products in the Field in the Territory shall initially be focused on the Development of Olvi-Vec. Therefore, Newsoara agrees that the technology transfer and material supply under
Sections 4.1.1 (Technology Transfer) and 4.1.2 (Material Supply) shall initially be limited to those related to Olvi-Vec, and technology transfer and material supply for other Licensed Virus(es)
shall be provided only in accordance with Section 4.1.4(c) below. 
 (c) Upon Newsoara’s request, Genelux
shall provide Newsoara with access to its database that contains all data and results Controlled by Genelux and related to the Licensed Viruses in Genelux’s library of Oncolytic Viruses. After reviewing such data, through the JSC, the Parties
shall discuss and agree on an initial screening protocol, which may include screening of the virus library to be conducted by Genelux or by a mutually agreed Third Party laboratory, at Newsoara’s cost and expense, and may include a visiting
scientist from Newsoara. Newsoara then shall prepare an update to the Development Plan that includes such mutually agreed screening protocol and further Development of Licensed Viruses selected from such screening work. Based on such updated
Development Plan, the Parties shall discuss and agree on the number of viruses in Genelux’s library to be transferred to Newsoara on an annual basis, which shall be based on mutual capacity of the Parties. For clarity, Newsoara’s final
decision-making authority in the JSC shall not apply to the decision on the screening protocol and the number of viruses to be transferred, and Genelux shall not be required to transfer the entire virus library to Newsoara. 

4.1.5. Clinical Trial for Indication of NSCLC. Newsoara shall use Commercially Reasonable Efforts to conduct a multi-center
Phase II Clinical Trial for Olvi-Vec with regard to the Indication of NSCLC in mainland China and the US (“NSCLC Multi-Center Trial”) at Newsoara’s own cost and expense in accordance with
the plan of NSCLC Multi-Center Trial, which is set forth in Schedule 4.1.5 (NSCLC Multi-Center Trial Plan). For clarity, the plan 

  
 - 20 - 

 
of NSCLC Multi-Center Trial shall not be changed without the mutual consent of both Parties. Subject to this Schedule 4.1.5 (NSCLC Multi-Center Trial Plan). and other terms and conditions
of this Agreement, and in addition to the license under Section 2.1 (Grants to Newsoara), Genelux hereby grants to Newsoara a non-exclusive license under Genelux Patents, Genelux Know-How and Genelux Regulatory Documentations solely to conduct the NSCLC Multi-Center Trial in the US as set forth below. 

(a) A project team will be formed and managed by the JSC for the NSCLC Multi-Center Trial under this Section 4.1.5
(Clinical Trial for Indication of NSCLC), and the project team shall consist of at least one (1) representative from Genelux; 
 (b)
The project team shall, under the oversight of the JSC, conduct the site selection and sample size allocation in the US/China and exert every effort to design a study (e.g., treatment regimen, inclusion/exclusion criteria) to meet the requirements
of both the US FDA and China NMPA, to support Regulatory Approval in both the US and China; 
 (c) The project team shall, under the
oversight of the JSC, utilize systems of Third Parties, e.g. [***], for global data management and safety reporting; 
 (d) Under the
oversight of the project team, Newsoara will engage and manage [***] or another mutually agreed contract research organization (the “CRO”) for the NSCLC Multi-Center Trial under this Section 4.1.5 (Clinical
Trial for Indication of NSCLC) on an operational basis; 
 (e) Genelux shall be the sponsor of the NSCLC Multi-Center Trial in the US.
Unless otherwise required by the Applicable Laws, Genelux shall also be the sponsor of the NSCLC Multi-Center Trial in China. Through the JSC, the Parties shall jointly prepare the protocol of the NSCLC Multi-Center Trial and Genelux shall have the
right to approve such protocol (such approval shall not be unreasonably delayed, withheld or conditioned). Each Party shall prepare and submit IND and other Regulatory Documentations for the NSCLC Multi-Center Trial in its territory (i.e., Genelux
in the US and Newsoara in China). As the sponsor of the trial, Genelux shall have the right to review and approval selection of clinical sites, investigators and Regulatory Documentations prepared by Newsoara; 

(f) Newsoara shall bear all costs and expenses of the NSCLC Multi-Center Trial, including investigators, and institutional review board
payments; CRO and pass-through payments; central and hospital lab payments; clinical supply (study drug) payments to cover Genelux’s Cost of Manufacturing for the Licensed Products, placebos and other study materials, if any, but excluding the
cost and expenses of regulatory filing in the US; provided, however, that if the Parties agree to change or broaden the design of the NSCLC Multi-Center Trial that increases the cost and expense of the trial above the budget set forth
in Schedule 4.1.5(f) (NSCLC Multi-Center Trial Budget), then the Parties shall discuss a mechanism to share the extra cost in good faith; 

(g) As part of the initial technology transfer under Section 4.1.1 (Technology Transfer), Genelux shall provide
reasonable technical support to Newsoara and CRO, if required in order to initiate the NSCLC Multi-Center Trial; 

  
 - 21 - 

 (h) Newsoara shall initiate the NSCLC Multi-Center Trial promptly after receiving approval
for the conduct of such Clinical Trial from either the FDA or NMPA, whichever is earlier (i.e. if FDA approves the NSCLC Multi-Center Trial first, Newsoara shall initiate such Clinical Trial in the US first while waiting for NMPA approval). If
additional study or clinical trial is required by NMPA to initiate the NSCLC Multi-Center Trial in China, Newsoara shall conduct such study or clinical trial at its own cost and expense (for clarity, such cost and expense shall not come from the
budget of the NSCLC Multi-Center Trial as set forth in Schedule 4.1.5(f) (NSCLC Multi-Center Trial Budget)). 
 (i) Notwithstanding
Section 6.1 (Ownership of Intellectual Property) or anything to the contrary herein, between Parties, all data and results generated from the NSCLC Multi-Center Trial shall be jointly owned by the Parties unless otherwise
required by the Applicable laws. Each Party shall and hereby does assign to the other Party one half undivided interest in and to all such data and results. For clarity, each Party’s joint interest (or sole interest if joint ownership is not
permitted by Applicable Law) in such data and results are subject to the licenses granted to the other Party under this Agreement. 
 (j)
If the NSCLC Multi-Center Trial is not completed for any reason, the full amount budgeted for the NSCLC Multi-Center Trial on Schedule 4.1.5 (NSCLC Multi-Center Trial Plan) has not been expanded on such Clinical Trial, and Genelux wishes to
conduct an alternative Clinical Trial of Olvi-Vec or an alternative Licensed Product or Derived Product, within [***] of such termination of the NSCLC Multi-Center Trial, Genelux shall propose to conduct such
alternative Clinical Trial jointly with Newsoara as a multi-center trial that includes sites both in and outside the Territory. If Newsoara agrees to jointly conduct such alternative Clinical Trial (which agreement shall include agreement on the
alternative Licensed Product or Derived Product that is the subject of such trial, and not be unreasonably withheld, delayed or conditioned), Newsoara shall contribute the remaining amount of the budget to the cost of such alternative Clinical
Trial. If Newsoara does not agree to jointly conduct such a multi-center trial (including disagreement regarding the alternative Licensed Product or Derived Product that is the subject of such trial), then Genelux shall have the right to conduct
such alternative Clinical Trial outside the Territory on its own, and Newsoara shall reimburse Genelux for the cost of such alternative Clinical Trial up to the remaining amount of the budget. 

4.1.6. Clinical Trial for Indication of Ovarian Cancer. Except pursuant to a protocol for PRROC approved by Genelux in
accordance with Section 3.4(iii), Newsoara shall not initiate any Clinical Trial of Olvi-Vec in the Indication of Ovarian Cancer in the Territory until Genelux obtains the Regulatory
Approval of Olvi-Vec for any Ovarian Cancer in the US. Through a joint project team established by the JSC, the Parties shall collaborate and Genelux shall have the right to review and provide comments
regarding the Development of Olvi-Vec in Ovarian Cancer in the Territory. 
 4.1.7. New
Indications. Any new Indications (other than NSCLC and Ovarian Cancer as set forth in Sections 4.1.5 (Clinical Trial for Indication of NSCLC) and 4.1.6 (Clinical Trial for Indication of Ovarian Cancer)) of the Licensed Products may
be investigated in the Territory after completion of two Clinical Trials in Sections 4.1.5 (Clinical Trial for Indication of NSCLC) and 4.1.6 (Clinical Trial for Indication of Ovarian Cancer), or at the time mutually agreed to by
Genelux and Newsoara. Genelux shall consider in good faith Newsoara’s request to initiate the Development of Licensed Products in such new Indications before the completion of the two Clinical Trials in Sections 4.1.5 (Clinical Trial for
Indication of NSCLC) and 4.1.6 (Clinical Trial for Indication of Ovarian Cancer). 

  
 - 22 - 

 4.1.8. Development Records. Newsoara shall maintain complete, current and
accurate records of all Development activities for Licensed Product and Derived Product conducted by or on behalf of Newsoara hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect
all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes. Newsoara shall document all non-clinical studies
and Clinical Trials in formal written study reports according to Applicable Laws and national and international guidelines (e.g., ICH, GCP, GLP, and cGMP). Genelux shall have the right to review and copy such records maintained by Newsoara at
reasonable times and to obtain access to the original to the extent necessary for regulatory purposes or for other legal proceedings. 

4.1.9. Development Reports. Newsoara shall keep Genelux reasonably informed as to the progress and results of its and its
Affiliates’ and Sublicensees’ Development of the Licensed Products and Derived Products. Without limiting the foregoing, at each regularly scheduled JSC meeting, Newsoara shall provide Genelux with a detailed written report (including
plans, budgets, progress and results of such Development work) for review and discussion of such Development activities it has performed, or caused to be performed, since the preceding report (or, with respect to the first such report, since the
Effective Date), its Development activities in process and the future activities it expects to initiate during the following twelve (12)-month period. 

4.1.10. Data Sharing. Subject to all Applicable Law of China, the US, and any other relevant jurisdiction, including
those relating to privacy and protection of personal data, Newsoara will provide Genelux with all data, including: (a) [***]; (b) [***] (collectively, “Sharing Data”), in each case of (a) and (b), Controlled by Newsoara and
generated by or on behalf of Newsoara or its Affiliates, contractors, or Sublicensees through the Development of the Licensed Products and Derived Products for use by Genelux, its Affiliates and sublicensees with respect to the Development,
Manufacture, Regulatory Approval and Commercialization of Licensed Products and Derived Products outside the Field and/or the Territory. Subject to all Applicable Law, including those relating to privacy and protection of personal data, Genelux will
provide Newsoara with Sharing Data that are Controlled by Genelux and generated by or on behalf of Genelux or its Affiliates or licensees through the Development of the Licensed Products and Derived Products for use by Newsoara, its Affiliates and
Sublicensees with respect to the Development, Manufacture, Regulatory Approval and Commercialization of Licensed Products and Derived Products in the Field in the Territory. Each Party shall have the right to share the data obtained from the other
Party pursuant to this Section 4.1.10 (Data Sharing) only with its Affiliates or sublicensees that undertake the same obligations regarding data sharing, in particular pursuant to the foregoing sentences. 

  
 - 23 - 

 4.2. Regulatory Activities. 

4.2.1. Regulatory Approvals. Newsoara shall have the sole right, at Newsoara’s own cost and expense, to prepare, submit,
obtain, and maintain Drug Approval Applications (including the setting of the overall regulatory strategy therefor), Regulatory Approvals, and other submissions (including INDs) to Regulatory Authorities, and to conduct communications with the
Regulatory Authorities, for Licensed Products and Derived Products in the Field in the Territory, in the name of Newsoara (except for the NSCLC Multi-Center Trial, which shall be in the name of Genelux as the sponsor of the trial), or if required or
advisable under any Applicable Law, jointly with its designee. Genelux shall, and shall cause its Affiliates or sublicensees to, reasonably cooperate with Newsoara, at Newsoara’s reasonable request and at Newsoara’s cost and expense, with
respect to any regulatory matters for which Newsoara is responsible. If Newsoara pursues Regulatory Approval of a Licensed Product through the import drug registration pathway in the Territory, Newsoara shall be responsible for filing each
regulatory filing in the Territory for each Licensed Product as an imported product in Genelux’s name and Genelux shall initially be the holder of the Regulatory Approval for each Licensed Product as an imported product in the Territory, and
Genelux hereby designates Newsoara or Newsoara’s designee as Genelux’s regulatory agent and exclusive general distributor for such Licensed Products in Territory; provided that Newsoara shall reimburse Genelux for all costs and expenses
incurred, and indemnify Genelux against all Losses, in connection with any regulatory activities conducted by Newsoara or its designee in Genelux’s name (for clarity, Newsoara shall not have the right to incur any obligations or waive any
rights for Genelux). However, upon Newsoara’s reasonable request, Genelux shall promptly assist and cooperate with Newsoara and use commercially reasonable effort to submit an application for changing a Licensed Product into a domestic drug
registration pathway in Territory. Newsoara shall not (a) communicate with any Regulatory Authority having jurisdiction outside the Territory regarding the Licensed Products or Derived Products, unless so ordered by such Regulatory Authority,
in which case Newsoara shall immediately notify Genelux of such order; or (b) submit any Regulatory Documentations or seek Regulatory Approvals for the Licensed Products or Derived Products outside the Field or Territory. As between the
Parties, Genelux shall be responsible for all regulatory activities relating to the Licensed Products and Derived Products outside the Territory, including those related to the NSCLC Multi-Region Trial, and Newsoara shall reasonably cooperate with
and assist Genelux in connection with such regulatory activities. 
 4.2.2. Regulatory Documentations. Newsoara shall provide
Genelux with drafts of all Regulatory Documentations (including IND and Drug Approval Application) prepared by Newsoara, its Affiliates and Sublicensees relating to the Licensed Products and Derived Products no later than a reasonable time (no less
than [***] ([***]) Business Days in any event) prior to submission for review and comment, and shall consider and implement in good faith any comments received from Genelux. In addition, Newsoara shall provide Genelux with copies (electronic and/or
hard copies at Genelux’s request) of any Regulatory Documentations relating to the Licensed Products and Derived products submitted to or received from any Regulatory Authority within [***] ([***]) Business Days after submission or receipt, and
shall notify Genelux of any other material communication relating to the Licensed Products or Derived Products with any Regulatory Authority within [***] ([***]) Business Days after such communication. If any such Regulatory Documentation is not in
the English language, per the request of Genelux, Newsoara shall also provide Genelux with an English translation thereof as soon as practicable at Genelux’s own cost and expense, except that Newsoara shall provide English translation of
correspondence (including notes of oral communications) with the Regulatory Authority related to the NSCLC Multi-Center Trial (excluding information in the IND dossier that is provided by Genelux, but Newsoara shall provide English translation of
new information added by Newsoara in the IND dossier) at Newsoara’s own cost and expense, which shall be accompanied by a certificate that the translation is true, accurate and complete. 

  
 - 24 - 

 4.2.3. Regulatory Meetings. Newsoara shall provide Genelux with reasonable
advance notice (no less than [***] ([***]) Business Days in any event) of any meeting or discussion with any Regulatory Authority related to the Licensed Products or Derived Product, and Genelux or its designee shall have the right, but not the
obligation, to attend and participate in such meeting or discussion, to the extent permitted by the Regulatory Authorities (Newsoara shall reasonably cooperate with Genelux to obtain such permission). If Genelux elects not to attend such meeting or
discussion, Newsoara shall promptly provide Genelux with a written English summary of such meeting or discussion. 
 4.2.4. Right
of Reference. Each Party hereby grants to the other Party the right of reference to all Regulatory Documentations pertaining to the Licensed Products and Derived Products submitted by or on behalf of such Party. Newsoara may use such
right of reference to Genelux’ Regulatory Documentations for the purpose of seeking, obtaining and maintaining Regulatory Approval of the Licensed Products and Derived Products in the Field in the Territory. Genelux may use such right of
reference to Newsoara’s Regulatory Documentations for the purpose of seeking, obtaining and maintaining Regulatory Approval of the Licensed Products outside the Field and/or outside the Territory. 

4.2.5. Regulatory Audits and Inspection. 

(a) Upon reasonable advance notice, Genelux or its representatives shall have the right to audit the regulatory, safety, quality and
compliance systems, procedures and practices of Newsoara, its Affiliates, Sublicensees or subcontractors (including clinical trial sites) relating to the [***]. Such audit shall be conducted at Genelux’s cost and, for audit of Newsoara’s
subcontractors, shall be subject to reasonable terms and conditions of the agreement between Newsoara and the subcontractor. Newsoara shall promptly notify Genelux of any audit or inspection of Newsoara, its Affiliates, Sublicensees or
subcontractors by any Regulatory Authority relating to [***] and shall provide Genelux with all information pertinent thereto (including all copies of all notices, filings and correspondences received from or submitted to the Regulatory Authority in
connection therewith). Genelux shall have the right, but not the obligation, to be present at any such audit or inspection. 
 (b) Newsoara
shall permit the Regulatory Authorities outside the Territory to conduct audits and inspections of Newsoara, its Affiliates, Sublicensees or subcontractors relating to the Licensed Products and Derived Products, and shall cause its Affiliates,
Sublicensees, and shall contractually obligate (and shall use Commercially Reasonable Effects to enforce such obligations) its subcontractors, to permit and cooperate with such audits and inspections. 

4.2.6. Compliance. Newsoara shall comply with all Applicable Laws as well as all applicable Regulatory Approvals for each
Licensed Product and Derived Product. In addition, Newsoara warrants that none of Newsoara or its Affiliates or Sublicensees shall use in any capacity in the Development, use, manufacture or Commercialization of any Licensed Product and Derived
Product, any person or entity who has been debarred pursuant to Section 306 of the 

  
 - 25 - 

 
U.S. Food Drug and Cosmetic Act (or similar law outside of the U.S.), or to its knowledge who is the subject of a conviction described in such section, and Newsoara shall inform Genelux in
writing immediately upon becoming aware that it or any person or entity who is performing services for Newsoara or its Affiliates or Sublicensees hereunder is debarred or is the subject of a conviction described in Section 306 (or similar law
outside of the U.S.), or, to Newsoara’s knowledge, if any action, suit, claim, investigation or legal administrative proceeding is pending or is threatened, relating to the debarment of Newsoara or any person or entity used in any capacity by
Newsoara or its Affiliates or Sublicensees relating to the Licensed Products and Derived Products. 
 4.2.7. Recalls, Suspensions
or Withdrawals. Each Party will notify the other Party immediately, and promptly confirm such notice in writing, if it obtains information indicating that any Licensed Product or Derived Product (including Licensed Product and Derived Product
for use in Clinical Trials as well as commercial sale) may be subject to any recall, corrective action or other regulatory action with respect to such product taken by virtue of applicable law (a “Remedial Action”). The Parties will
assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action. As between the Parties, Newsoara shall have the right to make the final determination whether to voluntarily
implement any Remedial Action in the Field in the Territory. If a Remedial Action of a Licensed Product and Derived Product in the Field in the Territory is mandated by a Regulatory Authority in the Territory, then, as between the Parties, Newsoara
shall initiate such Remedial Action in compliance with Applicable Law. For all Remedial Action undertaken pursuant to this Section 4.2.7 (Recalls, Suspensions or Withdrawals) in the Territory, as between the Parties,
Newsoara shall be solely responsible for the execution thereof. Newsoara shall be responsible for all costs of any such Remedial Action in the Territory, provided, however, that if such Remedial Action is attributable to Genelux’s
fraud (including falsified certificate of analysis or certificate of compliance of the Licensed Product supplied by Genelux), Genelux shall be responsible for such costs. 

4.2.8. Pharmacovigilance; Global Safety Database. Promptly following the Effective Date, but in any event no later than
the initiation of any Clinical Trial of the Licensed Products by Newsoara, its Affiliate or Sublicensee, the Parties shall enter into a pharmacovigilance and adverse event reporting agreement setting forth the worldwide pharmacovigilance procedures
for the Parties with respect to the Licensed Products, such as safety data sharing, adverse events reporting and prescription events monitoring (the “Pharmacovigilance Agreement”). Such procedures shall be in accordance with, and
enable the Parties to fulfill, local and national regulatory reporting obligations under Applicable Laws. Each Party agrees to comply with its respective obligations under the Pharmacovigilance Agreement and to cause its Affiliates, licensees and
sublicensees to comply with such obligations. Genelux shall establish, hold and maintain the global safety database for Licensed Products in accordance with all Applicable Laws. Newsoara shall provide safety information (together with certified
English translation if such information is not in the English language) of the Licensed Products in the Field in the Territory to Genelux according to the Applicable Laws. If Genelux exercises the right to Develop any Derived Product outside the
Territory, the Parties shall enter into a similar pharmacovigilance agreement for the Derived Product before Genelux initiates any Clinical Trial of the Derived Product outside the Territory. 

  
 - 26 - 

 4.2.9. Regulatory Exclusivity. If any Regulatory Exclusivity is available to
any Licensed Product in any region in the Territory, Newsoara shall, at its own cost and expense, use Commercially Reasonable Efforts to seek and maintain such Regulatory Exclusivity protection for such Licensed Product. If Newsoara does not seek or
maintain such Regulatory Exclusivity protection, then Genelux shall have the right (but not the obligation) to do so at Genelux’s own cost and expense; provided that if Genelux successfully obtains such Regulatory Exclusivity protection,
Newsoara shall reimburse Genelux for all cost and expense incurred. 
 4.3. Commercialization. 

4.3.1. Diligence. As between the Parties, Newsoara shall be solely responsible for Commercialization of the Licensed Products in
the Field in the Territory at Newsoara’s own cost and expense. Newsoara shall use Commercially Reasonable Efforts to Commercialize the Licensed Products in the Field in each region in the Territory in which it receives Regulatory Approval. 

4.3.2. Booking of Sales; Distribution. Newsoara shall invoice and book sales, establish all terms of sale (including pricing and
discounts), and warehouse and distribute the Licensed Products in the Territory and perform or cause to be performed all related services. Newsoara shall handle all returns, recalls or withdrawals, order processing, invoicing, collection,
distribution, and inventory management with respect to the Licensed Products in the Territory. 
 4.3.3. Commercialization
Plan. No later than [***] ([***]) months before the anticipated date of the submission of the first Drug Approval Application for the Licensed Products in the Field in the Territory, Newsoara shall submit to the JSC (or a joint
Commercialization subcommittee established by the JSC) for review and discussion a written Commercialization plan that sets forth the timeline and details of all major Commercialization activities planned for the Licensed Products in the Field in
the Territory (the “Commercialization Plan”). Thereafter, from time to time, [***], Newsoara shall prepare updates or amendments to the Commercialization Plan to reflect changes in such plans, including those in response to changes
in the marketplace, relative success of the Licensed Products, and other relevant factors influencing such plan and activities, and submit such update or amendment to JSC for review and discussion before adopting such update or amendment. The
Commercialization of the Licensed Products in the Territory shall be conducted pursuant to the Commercialization Plan. 
 4.3.4.
Coordination of Commercialization Activities. The Parties recognize that they may benefit from the coordination of certain activities in support of the Commercialization of the Licensed Products across their respective territories. As such,
the Parties may coordinate such activities where appropriate, including scientific and medical communication and product positioning. If the Parties agree to jointly conduct any specific Commercialization activities for the benefit of the Licensed
Products in both Parties’ territories, the Parties shall negotiate and agree on the details of such activities, including allocation of responsibilities, budget and cost sharing. In addition, in order to ensure consistency across the
territories, Newsoara shall submit to Genelux for comment on any materials to be used in connection with the promotion and other Commercialization activities for the Licensed Products in the Field in the Territory and Newsoara shall consider
Genelux’s comments in good faith. 

  
 - 27 - 

 4.3.5. Pricing. Newsoara shall advise the JSC of its proposed pricing for the
Licensed Products in the Territory in advance of commencing price discussions with Regulatory Authorities or parties involved in reimbursement decisions. Newsoara shall consider in good faith any comments received from Genelux with respect to
pricing of the Licensed Products and shall keep Genelux informed on the status of any application for pricing or reimbursement approval for the Licensed Products in the Territory, including any discussion with a Regulatory Authority with respect
thereto. Newsoara shall have the sole right to determine the price of the Product(s) sold in the Territory, provided however that if Newsoara (or its Affiliate or Sublicensee) sells multiple products (including the Licensed Product), Newsoara shall
set the prices of the products fairly, and shall not lower the price of the Licensed Product in order to increase the sale of other products. . 

4.3.6. Commercialization Records. Newsoara shall maintain complete and accurate books and records pertaining to
Commercialization of Licensed Product hereunder, in sufficient detail to verify compliance with its obligations under this Agreement, which shall be in compliance with Applicable Law and properly reflect all significant work done and results
achieved in the performance of its Commercialization activities. 
 4.3.7. Commercialization Reports. Newsoara shall keep
Genelux reasonably informed of its, its Affiliates’ and Sublicensees’ Commercialization activities with respect to the Licensed Products in the Field in the Territory. Without limiting the foregoing, at each regularly scheduled JSC
meeting, Newsoara shall provide Genelux with a detailed written report for review and discussion of such Commercialization activities it has performed, or caused to be performed, since the preceding report, its Commercialization activities in
process and the future activities it expects to initiate during the following twelve (12)-month period. 
 4.4. Manufacture and
Supply. 
 4.4.1. Manufacture Transfer. After the completion of the manufacturing technology transfer set forth in
this Section 4.4.1 (Manufacture Transfer), Newsoara shall have rights, at its expense, to Manufacture (or have Manufactured), either by itself or through its Affiliates, its and their Sublicensees or Third Party contract
manufacturers. After the Upfront Payment is paid in full (i.e. [***]), upon Newsoara’s request, Genelux shall promptly (and in no event later than [***] ([***]) days after such request) transfer to Newsoara or a Third Party contract
manufacturer designated by Newsoara any Genelux Know-How relating to Manufacture of the Licensed Viruses or Licensed Products, and provide any assistance (including
on-site assistance) reasonably required to ensure an orderly transfer of the relevant manufacturing processes. During any such transfer, Genelux shall also make available (either at Genelux’s facility or
by teleconference, unless otherwise mutually agreed by the Parties) its qualified technical personnel on a reasonable basis to consult with Newsoara or such Third Party contract manufacturer with respect to such Genelux Know-How. Newsoara shall reimburse Genelux for both out-of-pocket costs and internal costs incurred by Genelux to provide such
technical assistance, except for the internal cost of the first [***] FTE hours of assistance, which shall be provided at Genelux’s cost. If Newsoara makes any improvement to the Manufacture of the Licensed Viruses or Licensed Products,
Newsoara shall make such improvement available to Genelux and provide Manufacture technology transfer to Genelux as set forth in this Section 4.4.1 (Manufacture Transfer) (mutatis mutandis). 

  
 - 28 - 

 4.4.2. Clinical Supply. Per the request of Newsoara, Genelux shall use
Commercially Reasonable Efforts to supply to Newsoara, the Licensed Virus or Licensed Product at clinical grade [***] for Newsoara to conduct any pre-clinical study and clinical trial, consistent with
Sections 4.1.5 (Clinical Trial for Indication of NSCLC), 4.1.6 (Clinical Trial for Indication of Ovarian Cancer) and 4.1.7 (New Indications), for obtaining Regulatory Approval for such Licensed Virus or Licensed Product in the
Field in the Territory. The Parties shall negotiate in good faith a clinical supply agreement for Olvi-Vec to be executed within [***] days after the Effective Date. The Parties agree that all Olvi-Vec for use in the NSCLC Multi-Center Trial shall be Manufactured and supplied by Genelux. With respect to any Licensed Virus or Licensed Product other than Olvi-Vec or a
Licensed Product containing Olvi-Vec, per the request of Newsoara, after the initiation of the Development of such License Virus or Licensed Product pursuant to Section 4.1.4(c), the
Parties shall negotiate in good faith a clinical supply agreement for the Manufacture and supply of such Licensed Virus and Licensed Product, which may be supplied directly by Genelux or through Genelux’s contract manufacturer and the supply
price for such Licensed Virus and Licensed Product shall be [***]. For clarity, Newsoara shall not have the right to Manufacture or have Manufactured any Licensed Virus or Licensed Product for clinical use prior to the completion of the
manufacturing technology transfer set forth in Section 4.4.1 (Manufacture Transfer). 
 4.4.3.
Commercial Supply. Prior to the completion of the manufacture technology transfer contemplated in Section 4.4.1 (Manufacture Transfer), Newsoara shall purchase from Genelux, and Genelux shall use Commercially
Reasonable Efforts to supply to Newsoara, the Licensed Viruses or Licensed Products, [***] for Newsoara to use for commercial purposes in the Field in the Territory. The Parties shall negotiate in good faith a commercial supply agreement for each
Licensed Product to be executed reasonably prior to, but in any event at least [***] prior to the anticipated date of First Commercial Sale of each Licensed Product. For clarity, Newsoara shall not have the right to Manufacture or have Manufactured
any Licensed Virus or Licensed Product for commercial use prior to the completion of the manufacturing technology transfer set forth in Section 4.4.1 (Manufacture Transfer). The Licensed Products shall have remaining
shelf-life to be determined as part of a Commercial Supply Agreement, based on the principle that such remaining shelf-life shall be a reasonable time period for Newsoara to Commercialize the Licensed Products in the Territory. 

4.4.4. Manufacture by Newsoara. After the completion of the manufacture technology transfer pursuant to
Section 4.4.1 (Manufacture Transfer) above, Newsoara shall have right, either by itself or through its Affiliates, Sublicensees or Third Party contractors, to Manufacture and supply all or a part of Newsoara’s and its
Affiliates’ and Sublicensees’ requirements for the Licensed Viruses and Licensed Products for Development and Commercialization use in the Field in the Territory, at Newsoara’s own cost and expense. 

4.4.5. Manufacture of Derived Products. Newsoara shall be solely responsible for the Manufacture of Derived Molecules and
Derived Products for Development and Commercialization use in the Field in the Territory. If Genelux exercises the right to Develop any Derived Product outside the Territory, Newsoara shall provide manufacture technology transfer and assistance to
enable Genelux to Manufacture the Derived Product outside the Territory and Section 4.4.1 (Manufacture Transfer) shall apply mutatis mutandis to such technology transfer. 

  
 - 29 - 

 4.5. Subcontracting. Newsoara may subcontract with a Third Party to perform
any or all of its obligations hereunder (including by appointing one or more distributors); provided, that (a) [***]; (b) [***], and (c) [***]. For clarity, the following subcontracting shall not be deemed as a Sublicense under
Section 2.2.1 (Sublicenses): (i) Newsoara subcontracts CRO, CMO, clinical trial sites or any other Third Party to perform portions of the Development or Manufacture of a Licensed Product on Newsoara’s, its Affiliates
or its Sublicensee’s behalf; (ii) Newsoara subcontracts any Third Party (including contract sales force) to distribute and resell a Licensed Product; and (iii) Newsoara subcontracts any Third Party to
re-package a Licensed Product for resale. 
 ARTICLE 5 PAYMENTS AND TAXES 

5.1. Upfront Payment. Newsoara shall pay to Genelux an upfront payment of eleven Million US Dollars ($11,000,000)
(“Upfront Payment”), of which five Million US Dollars ($5,000,000) is payable within [***] ([***]) days of Newsoara’s receipt of invoice issued by Genelux after the Effective Date, and remaining six Million US Dollars
($6,000,000) is payable within [***] ([***]) days of Newsoara’s receipt of invoice issued by Genelux upon FDA clearance of Genelux’ Phase III Clinical Trial for the Indication of ovarian cancer (for clarity, FDA clearance means that FDA
does not put the study protocol for such Clinical Trial on hold within [***] ([***]) days after submission, or if put on hold, when the hold is lifted by the FDA). In the event that Newsoara is unable to make the Upfront Payment in time due to delay
in government approval, Newsoara shall immediately notify Genelux and the payment deadline shall be extended for up to additional [***] ([***]) days so long as Newsoara takes all necessary steps and efforts to obtain such government approval in a
timely manner. 
 5.2. Milestone Payment. 

5.2.1. Development Milestones. In partial consideration of the rights granted by Genelux to Newsoara hereunder, on a
Licensed Product-by-Licensed Product basis, Newsoara shall pay to Genelux the following payments in total of [***] within [***] ([***]) days of Newsoara’s receipt
of invoice issued by Genelux for the corresponding payments after the first achievement or occurrence of each of the following Development Milestone Events described in this Section 5.2.1 (Development Milestones) by
Newsoara or any of its Affiliates or Sublicensees with respect to each Licensed Virus or Licensed Product, as the case may be (each such milestone event, a “Development Milestone Event,” and each such milestone payment, a
“Development Milestone Payment”). For clarity, for each Licensed Product, each Development Milestone Payment set forth in this Section 5.2.1 (Development Milestones) will be payable only once in any case.

 (a) In the event that [***] without [***], then the milestone for [***] shall be deemed achieved at the time of [***]. 

(b) If [***], then the corresponding milestone payment for such [***] shall be paid as follows: [***] due upon [***]; [***] due on [***]; and
[***] due on [***]; provided, however, that, if [***], then all remaining amount shall be [***]; further provided, however, that, if [***], [***] the remainder of the milestone payment for such [***]. 

  
 - 30 - 

			
	 Development Milestone Events for the Territory
	  	Development
Milestone Payments
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 5.2.2. Commercial Milestones. In partial consideration of the rights granted by Genelux to
Newsoara hereunder, Newsoara shall pay to Genelux the following commercial milestone payments in total of one hundred and seven Million and five Hundred Thousand US Dollars ($107,500,000) within [***] ([***]) days of Newsoara’s receipt of
invoice issued by Genelux for the corresponding payments after the first achievement or occurrence of each of the following commercial milestone events by Newsoara or any of its Affiliates or its or their Sublicensees with respect to the Licensed
Products (each such milestone event, a “Commercial Milestone Event,” and each such milestone payment, a “Commercial Milestone Payment”). If in a given Calendar Year more than one Commercial Milestone Events are
achieved, Newsoara shall pay to Genelux a separate Commercial Milestone Payment with respect to each Commercial Milestone Event achieved. For clarity, each of the Commercial Milestone Payments set forth in this
Section 5.2.2 (Commercial Milestones) will be payable only once. 
  

			
	 Commercial Milestone Events
	  	Commercial Milestone
Payments
	 The annual Net Sales of all Licensed Product(s) in the Territory in any Calendar Year exceeds
[***]
	  	[***]
	 The annual Net Sales of all Licensed Product(s) in the Territory in any Calendar Year exceeds
[***]
	  	[***]
	 The annual Net Sales of all Licensed Product(s) in the Territory in any Calendar Year exceeds
[***]
	  	[***]
	 The annual Net Sales of all Licensed Product(s) in the Territory in any Calendar Year exceeds
[***]
	  	[***]
	 The annual Net Sales of all Licensed Product(s) in the Territory in any Calendar Year exceeds
[***]
	  	[***]
	 The annual Net Sales of all Licensed Product(s) in the Territory in any Calendar Year exceeds
[***]
	  	[***]

 5.2.3. Determination That Milestones Have Occurred. Within [***] ([***]) days of Newsoara’s
awareness of the occurrence of any Milestone Event set forth in Section 5.2.1 (Development Milestones) or Section 5.2.2 (Commercial Milestones), Newsoara shall notify (by fax or email, with receipt
confirmed) Genelux of Newsoara’s, its Affiliate’s and/or its Sublicensee’s achievement of such Milestone Event. In the event that, notwithstanding the fact that Newsoara has not provided Genelux such a notice, Genelux believes that
any such Milestone Event has been achieved, it shall so notify Newsoara in writing and the Parties shall promptly meet and discuss in good faith whether such Milestone Event has been achieved. Any dispute under this
Section 5.2.3 (Determination That Milestones Have Occurred) regarding whether or not such a Milestone Event has been achieved shall be subject to resolution in accordance with Section 11.4 (Dispute
Resolution). 

  
 - 31 - 

 5.3. Royalties. 

5.3.1. Royalty Payments. During the Royalty Term, on a Licensed
Product-by-Licensed Product basis, Newsoara shall pay Genelux a royalty based on the corresponding amount of Net Sales of such Licensed Product in the Territory
multiplied by the applicable royalty rate in each Calendar Year, as set forth below. For each Calendar Year, the below tiered royalties shall be calculated such that the higher tiered royalty rates are only used after Net Sales in such Calendar Year
exceed the top threshold of the previous tier and such higher tiered royalty rate will only apply to the portion of Net Sales that falls within that tier. 
  

			
	 Annual Net Sales of a Licensed Product:
	  	Royalty Rate for such
Licensed Product
	 On the increment of annual Net Sales of any Licensed Product less than or equal to [***]
	  	[***]
	 On the increment of annual Net Sales of Licensed Product greater than [***] and less than or equal
to [***]
	  	[***]
	 On the increment of annual Net Sales of Licensed Product greater than [***] and less than or equal
to [***]
	  	[***]
	 On the increment of annual Net Sales of Licensed Product greater than [***] and less than or equal
to [***]
	  	[***]
	 On the increment of annual Net Sales of Licensed Product greater than [***] and less than or equal
to [***]
	  	[***]
	 On the increment of annual Net Sales of Licensed Product greater than [***]
	  	[***]

 5.3.2. Royalty Reductions. 

(a) If at any time during the Royalty Term for a particular Licensed Product in a particular country or region in the Territory, either
(i) any Third Party (other than Newsoara’s Sublicensees and subcontractors) makes Generic Version of such Licensed Product commercially available in such country or region; or (ii) there is neither (A) any Valid Claim of Genelux
Patent (other than Joint Patent) that Covers such Licensed Product (including the Licensed Virus contained therein, and including the composition of matter and method of making and using thereof) in such country or region, nor (B) any
Regulatory Exclusivity for such Licensed Product in such country or region, then the royalty rate applicable to Net Sales of such Licensed Product in such country or region at such time shall be reduced to [***] of the royalties otherwise payable
under Section 5.3.1 (Royalty Payments) without regard to the operation of this Section 5.3.2 (Royalty Reductions) to such Licensed Product in such country or region at such time. 

  
 - 32 - 

 (b) If Newsoara or Genelux enters into an agreement with a Third Party in order to obtain a
license to a Third Party Patent Right that Covers a Licensed Virus or a Licensed Product (not including any modification or improvement made by Newsoara to the Licensed Virus or Licensed Product provided by Genelux) in a country or region in the
Territory, Newsoara shall be entitled to deduct from royalties payable hereunder in a given Calendar Quarter with respect to such Licensed Product in such country or region an amount equal to [***] of the royalty payments paid by Newsoara to such
Third Party on account of the sale of such Licensed Product in such country or region in such Calendar Quarter under such license; provided that such deduction shall not be more than [***] of the amount that would otherwise have been due
pursuant to Section 5.3.1 (Royalty Payments) without regard to the operation of this Section 5.3.2 (Royalty Reductions).

(c) Notwithstanding the foregoing, in no event shall the operation of Section 5.3.2(a) and 5.3.2(b),
individually or in combination, reduce the royalties paid to Newsoara with respect to the Net Sales of any Licensed Product in any country or region in the Territory in any Calendar Quarter to less than [***] of the amount that would otherwise have
been due pursuant to Section 5.3.1 (Royalty Payments) without regard to the operation of this Section 5.3.2 (Royalty Reductions). 

5.3.3. Royalty Report and Payment. Within [***] ([***]) days after the end of each Calendar Quarter, commencing with the first
Calendar Quarter in which there is any sale of any Licensed Product anywhere in the Territory, Newsoara shall provide (by fax or email, with receipt confirmed) Genelux with a report that contains the following information for the applicable Calendar
Quarter, on a product-by-product and region-by-region basis: [***]. Concurrent with the
delivery of the applicable royalty report, Newsoara shall pay to Genelux in Dollars the royalties owed with respect to Net Sales for such Calendar Quarter. 

5.4. Mode of Payment. All Payments shall be made by deposit of USD in immediately available cleared funds in the requisite
amount to such bank account in the U.S. as Genelux may from time to time designate by notice to Newsoara. For the purpose of calculating any sums due under, or otherwise reimbursable pursuant to, this Agreement, Newsoara shall convert any amount
expressed in a foreign currency into USD equivalents using its, its Affiliate’s or Sublicensee’s standard conversion methodology that uses a widely published exchange rate (such as Wall Street Journal) and is consistent with the applicable
Accounting Standard. As between the Parties, Newsoara shall be solely responsible for any foreign exchange requirements for converting a foreign currency into a Dollar equivalent. Newsoara shall take, or shall cause its Affiliates or their
Sublicensees to take, all actions required by Applicable Law for the purpose of transferring, or having transferred on its behalf, milestones or any other payments to Genelux, directly or indirectly, pursuant to this Agreement, or to Newsoara
pursuant to the applicable sublicense agreement, including filing or registration of the relevant sublicense agreement(s) between Newsoara and its Affiliates or Sublicensees with the competent Governmental Authority and obtaining any required
approval, permit or license for the payment transfer from the competent Governmental Authority. For payments other than the upfront, milestone and royalty payments set forth above, such as cost reimbursement for technology transfer and assistance,
supply of materials, and cost of the NSCLC Multi-Center Trial, Genelux shall invoice Newsoara for such payment on a monthly basis, and Newsoara shall pay such payment to Genelux within [***] ([***]) days after the receipt of the invoice. 

  
 - 33 - 

 5.5. Tax. 

5.5.1. Tax Cooperation. The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax
withholding or similar obligations in respect of upfront payment, milestone payments, royalties, and other payments made under this Agreement, including preparing and submitting in a timely manner any tax form that may be necessary or useful for
Newsoara to avoid tax withholding or to withhold tax at a reduced rate under an applicable bilateral income tax treaty, and providing cooperation and assistance to enable the recovery of the tax withheld from the payment made under this Agreement.

 5.5.2. Income Tax Withholding. To the extent Newsoara is required by Applicable Laws in the Territory to deduct and withhold
income tax on any payment to Genelux, Newsoara shall (a) notify Genelux at least [***] ([***]) days before making the payment, (b) deduct from the remittable payment an amount equal to the income tax that is required to be withheld by
Applicable Laws in the Territory, (c) pay the amount so deducted to the proper tax authority in a timely manner, (d) promptly send proof of such tax payment to Genelux, and (e) provide all reasonable assistance to enable the recovery,
to the extent permitted by Applicable Laws, of the income tax withheld from the payments made under this Agreement, such recovery to be for the benefit of Genelux. 

5.5.3. VAT Withholding. If Newsoara is required by applicable Laws in the Territory to deduct and withhold value-added tax
(“VAT”) on any payment to Genelux, Newsoara shall use its reasonable efforts to seek a waiver of the VAT withholding before making the payment. If Newsoara is unable to obtain such a waiver, then, to the extent Newsoara is required
by Applicable Laws in the Territory to deduct and withhold VAX on any such payment to Genelux, Newsoara shall (a) notify Genelux at least [***] ([***]) days before making the payment, (b) deduct from the remittable payment an amount equal
to the VAT that is required to be withheld by applicable Laws in the Territory, (c) pay the amount so deducted to the proper tax authority in a timely manner, and (d) promptly send proof of such tax payment to Genelux; (e) Newsoara
shall then use its reasonable efforts to seek recovery of the VAT payment for Genelux’s benefit; and (f) if Newsoara is unable to obtain recovery of the VAT payment for Genelux’s benefit within [***] ([***]) months, then Newsoara
shall pay to Genelux an additional amount equal to [***] of the VAT payment and, if Newsoara subsequently recovers the VAT payment (including using the VAT payment as tax credit to reduce Newsoara’s other tax), Newsoara shall pay to Genelux
[***] of the recovery. 
 5.6. Interest on Late Payments. If any payment due to either Party under this Agreement is
not paid when due, then such paying Party shall pay interest thereon (before and after any judgment) at an annual rate equal to the lessor of (i) [***], and (ii) the maximum rate permitted under Applicable Law. Any interest will accrue from day
to day and is calculated based on the actual number of days elapsed from the payment due date to the actual payment date and a year of 360 days. 

  
 - 34 - 

 5.7. Financial Records and Audits. Newsoara shall (and shall ensure
that its Affiliates and Sublicensees will) maintain complete and accurate records in accordance with Accounting Standard and in sufficient detail to permit Genelux to confirm the accuracy of Net Sales reported by Newsoara, the achievement of
Commercial Milestone Events, and amounts payable under this Agreement. Upon no less than [***] ([***]) days prior notice, such records shall be open for examination, during regular business hours, for a period of [***] from the end of the Calendar
Year to which any individual record pertains, and not more often than once each Calendar Year, by an independent certified public accountant selected by Genelux and accepted by Newsoara (which acceptance shall not be unreasonably withheld, delayed
or conditioned), and for the sole purpose of verifying for Genelux the accuracy of the Net Sales and the royalty report provided by Newsoara in accordance with Section 5.3.3 (Royalty Report and Payment). Genelux shall bear
the cost of such audit unless such audit reveals an underpayment by Newsoara of more than [***] of the amount actually due for the period of time being audited, in which case Newsoara shall reimburse Genelux for the costs of such audit. If such
audit concludes that (i) additional amounts were owed by Newsoara, then Newsoara shall pay to Genelux any underpayment discovered by such audit within [***] ([***]) days after receipt of a corresponding invoice issued by Genelux, plus interest
(as set forth in Section 5.6 (Interest on Late Payments)) from the original due date; or (ii) excess payment were made by Newsoara, then Newsoara may credit any overpayment discovered by such audit against future
payment due to Genelux. Newsoara shall include in each sublicense agreement a provision requiring the Sublicensee to maintain records and grant access to the records to the same extent and under the same obligations as required of Newsoara under
this Agreement. 
 ARTICLE 6 INTELLECTUAL PROPERTY  

6.1. Ownership of Intellectual Property. 

6.1.1. Ownership of Inventions. Each Party shall own any Invention made solely by its employees, agents or contractors in
connection with the performance of this Agreement and all Intellectual Property Rights therein (each such Invention, a “Newsoara New Invention” or “Genelux New Invention” and the patent rights therein, a
“Newsoara New Patent” or “Genelux New Patents”). Any Joint Invention and the patent right therein (“Joint Patent”) shall be jointly owned by the Parties in accordance with Applicable Law or as
otherwise mutually agreed by the Parties. Except to the extent restricted by the licenses and other rights granted to the other Party under this Agreement or any other agreement between the Parties, each Party, as joint owners, shall be entitled to
practice, license, assign and otherwise exploit its interest in any jointly owned Inventions and patent rights therein without the duty of accounting or seeking consent from the other Party. Each Party shall notify the other Party of any Invention
in writing promptly after such Party invents such Invention. For clarity, Genelux New Invention and Genelux’s interest in the Joint Inventions are automatically included in the license granted by Genelux to Newsoara under
Section 2.1 (Grants to Newsoara), and Newsoara New Invention and Newsoara’s interest in the Joint Inventions are automatically included in the license granted by Newsoara to Genelux under
Section 2.4 (Grants to Genelux). 

  
 - 35 - 

 6.1.2. Determination of Inventorship. The determination of whether any
Inventions are conceived, discovered, developed or otherwise made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other intellectual property rights) therein, shall, for purposes of this Agreement and
notwithstanding Section 11.5 (Governing Law), be made in accordance with the principles of U.S. patent laws as such law exists as of the Effective Date irrespective of where or when such conception, discovery,
development or making occurs. 
 6.1.3. Ownership of Trademarks. As between the Parties, Newsoara shall own all rights, title
and interests to the Product Trademarks in the Field in the Territory, and Genelux shall own all right, title and interest to the Genelux Trademarks. 

6.1.4. Ownership of Corporate Names. As between the Parties, Genelux shall retain all rights, title and interests in and to
Genelux Corporate Names and Newsoara shall retain all rights, title and interests in and to Newsoara Corporate Names. 
 6.2.
Maintenance and Prosecution of Patents. 
 6.2.1. In General. 

(a) As between the Parties, Genelux shall, through counsel of its choice, have the first right (but not the obligation) to prepare, file,
prosecute, maintain, and have final decision-making authority with respect to the preparation, filing, prosecution and maintenance of all Genelux Patents and Joint Patents within the Territory. Newsoara shall have the right to offer to Genelux
Newsoara’s advice and input on all material patent prosecution matters related to the Genelux Patents and Joint Patents and Genelux shall consider the same in good faith. 

(b) Genelux shall bear all costs and expenses in connection with all Genelux Patents and Joint Patents within the Territory, including all
costs and expenses in connection with the preparation, filing, prosecution and maintenance thereof. In the event that Genelux elects not to seek patent protection for or decides to abandon any Genelux Patent or Joint Patent in any country or region
within the Territory, Genelux shall notify Newsoara in writing sufficiently in advance so that Newsoara may have the right (but not the obligation), at its expense, to seek, prosecute and maintain patent protection on such Genelux Patents or Joint
Patents in such country or region. Genelux shall use Commercially Reasonable Efforts to make available to Newsoara and its authorized attorneys, agents or representatives, such of its employees as are reasonably necessary to assist Newsoara in the
preparation, filing, prosecution and maintenance of such patent described under this Section 6.2.1(b). Genelux shall sign or use Commercially Reasonable Efforts to have signed all legal documents necessary for Newsoara to
transfer the prosecution and maintenance of such Genelux Patents and Joint Patents in such country or region from Genelux to Newsoara. Newsoara’s prosecution or maintenance of such Genelux Patent or Joint Patent in such country or region shall
not require Genelux to assign such Patent to Newsoara and shall not change the Parties’ respective rights and obligations under this Agreement with respect to such Patent other than those expressly set forth in this
Section 6.2.1(b). If Newsoara’s prosecution efforts lead to the grant of such Patent in the Territory, Newsoara shall have the right to recoup the reasonable cost incurred by Newsoara to prosecute and maintain such
Patent from royalty payments due to Genelux hereunder. 

  
 - 36 - 

 (c) As between the Parties, Genelux shall, through counsel of its choice, have the sole
right (but not the obligation) to prepare, file, prosecute, maintain, and have final decision-making authority with respect to the preparation, filing, prosecution and maintenance of all Genelux Patents and Joint Patents outside the Territory, at
Genelux’s own cost and expense. 
 6.2.2. Cooperation. Newsoara shall, and shall cause its Affiliates to, assist and
cooperate with Genelux, as Genelux may reasonably request from time to time, in the preparation, filing, prosecution and maintenance of the Genelux Patents and Joint Patents. Without limiting the foregoing, Newsoara shall, and shall cause its
Affiliates to (a) offer its or their comments, if any, promptly and (b) provide access to relevant documents and other evidence and make its or their employees available at reasonable business hours, to the extent reasonably necessary for
the preparation, filing, prosecution and maintenance of the Genelux Patents and Joint Patents; provided, however, that neither Party shall be required to provide legally privileged information with respect to such intellectual property
unless and until procedures reasonably acceptable to such Party are in place to protect such privilege; and provided, further, that Genelux shall reimburse Newsoara for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection with the prosecution and maintenance of the Genelux Patents and Joint Patents outside the Territory. 

6.2.3. Patent Term Extension and Supplementary Protection Certificate. As between Genelux and Newsoara, Genelux shall have the
first right (but not the obligation) to apply for patent term extensions for any Genelux Patent or Joint Patent at its own expense, in all jurisdictions within the Territory with respect to any extensions that are now or become available in the
future, wherever applicable, for the Genelux Patents and Joint Patents. In the event that Genelux elects not to seek patent term extension for any Genelux Patent or Joint Patent in any country or region within the Territory, Genelux shall notify
Newsoara in writing sufficiently in advance so that Newsoara may have the right (but not the obligation), at its expense, to seek patent term extension for such Genelux Patents or Joint Patents in such country or region. Each Party shall provide
prompt and reasonable assistance, at no cost to the other Party except for any out-of-pockets costs or fees, as reasonably requested by the Party seeking patent term
extension, including by taking such action as is required of the Regulatory Approval holder under any Applicable Law to obtain such extension or supplementary protection certificate. 

6.2.4. Prosecution of Patents for Derived Product. If Genelux elects (in its sole discretion) to Develop any Derived Product
outside the Territory, then this Section 6.2 (Maintenance and Prosecution of Patents) shall apply mutatis mutandis to the Patents licensed by Newsoara to Genelux under Section 2.4.2(a)
(i.e., Newsoara shall have the first right to prosecute and maintain such Patents and Genelux shall have the backup prosecution rights set forth above with respect to such Patents outside the Territory). 

6.3. Enforcement of Patents and Know-How. 

6.3.1. Notice. Each Party shall promptly notify the other Party in writing of any actual, alleged or threatened infringement or
misappropriation of the Genelux Patents, Joint Patents and Genelux Know-How in the Territory of which such Party becomes aware, and any related declaratory judgment, opposition, or similar action alleging the
invalidity, unenforceability, non-infringement, non-misappropriation of any of the Genelux Patents, Joint Patents and Genelux
Know-How in the Territory (an “Infringement”). 

  
 - 37 - 

 6.3.2. Enforcement of Patents and
Know-How. As between the Parties, Newsoara shall have the first right, but not the obligation, to bring and control any legal action to enforce the Genelux Patents or Joint Patents or Genelux Know-How, as applicable using counsel of its choice, against any Infringement that involves the development, manufacture or sale of any Oncolytic Virus(es) in the Field in the Territory (“Product
Infringement”). If Newsoara fails to bring any such action or proceeding within [***] ([***]) days of a request by Genelux to do so (or such short time as necessary to preserve the right to bring such action under Applicable Laws) or if
Newsoara earlier notifies Genelux in writing of its intent not to bring such action or proceeding, then Genelux will have the right (but not the obligation) to bring any such action or proceeding by counsel of its own choice. From and after the date
of such assumption, such Party shall be deemed to be the “Enforcing Party” for the purposes of this Section 6.3 (Enforcement of Patents and Know-How) (but not for
purposes of any other Section of this Agreement) with respect to such Patent. 
 6.3.3. Costs of Enforcement. The Enforcing
Party shall solely bear the cost and expenses incurred by it, or by the other Party (or any Affiliate of such Party) to provide cooperation and assistance requested by the Enforcing Party, in connection with any enforcement actions taken pursuant to
this Section 6.3 (Enforcement of Patents and Know-How). 
 6.3.4.
Cooperation. The Parties shall cooperate fully in any Infringement action pursuant to this Section 6.3 (Enforcement of Patents and Know-How), including by making the inventors,
applicable records, and documents (including laboratory notebooks) with respect to the relevant Patents and know-how available to the Enforcing Party on the Enforcing Party’s request. With respect to an
action controlled by the applicable Enforcing Party, the other Party shall, and shall cause its Affiliates to, assist and cooperate with the Enforcing Party, as the Enforcing Party may reasonably request from time to time, in connection with its
activities set forth in this Section 6.3 (Enforcement of Patents), including, where necessary, furnishing a power of attorney solely for such purpose or joining in, or being named as a necessary party to, such action,
providing access to relevant documents and other evidence, and making its employees available at reasonable business hours; provided that the Enforcing Party shall reimburse such other Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith. Unless otherwise set forth herein, the Enforcing Party shall have the right to settle such claim;
provided that neither Party shall have the right to settle any Infringement litigation under this Section 6.3 (Enforcement of Patents) in a manner that has a material adverse effect on the rights or interests of the
other Party or in a manner that imposes any costs or liability on, or involves any admission by, the other Party, without the express written consent of such other Party (which consent shall not be unreasonably withheld, conditioned or delayed). In
connection with any activities with respect to an Infringement action prosecuted by the applicable Enforcing Party pursuant to this Section 6.3 (Enforcement of Patents and Know-How)
involving Patents or know-how exclusively licensed under Article 2 (Grant of Rights) to the other Party, the Enforcing Party shall (a) consult with the other Party as to the strategy for the
prosecution of such claim, suit, or proceeding, (b) consider in good faith any comments from the other Party with respect thereto, and (c) keep the other Party reasonably informed of any material steps taken, and provide copies of all
material documents filed, in connection with such action. 

  
 - 38 - 

 6.3.5. Recovery. Except as otherwise agreed by the Parties in writing in
connection with a cost sharing arrangement, any recovery realized as a result of such litigation against a Product Infringement described above in this Section 6.3 (Enforcement of Patents) (whether by way of settlement or
otherwise) with respect to Genelux Patents and Joint Patents or Genelux Know-How shall be first allocated to reimburse the Parties for their costs and expenses in making such recovery (which amounts shall be
allocated pro rata if insufficient to cover the totality of such costs and expenses). Any remainder after such reimbursement is made shall be allocated to the Enforcing Party; provided that if Newsoara is the Enforcing Party, such remainder shall be
deemed Net Sales and subject to royalty payment under Section 5.3 (Royalties). 
 6.3.6. Other
Infringement. As between the Parties, Genelux shall have the exclusive right (but not the obligation) to bring and control any legal action to enforce the Genelux Patents and Joint Patents or Genelux
Know-How against any infringement or misappropriation that is not a Product Infringement (including any infringement or misappropriation outside the Field and/or outside the Territory), at Genelux’ own
expense and as Genelux reasonably determines appropriate, and Genelux shall have the right to retain all recoveries therefrom. 

6.3.7. Enforcement of Patents for Derived Product. If Genelux elects (in its sole discretion) to Develop any Derived Product
outside the Territory, then this Section 6.3 (Enforcement of Patents and Know-How) shall apply mutatis mutandis to the Patents licensed by Newsoara to Genelux under
Section 2.4.2(a) (i.e., Genelux shall have the first right to enforce such Patents against Infringement outside the Territory, and Genelux shall pay royalty on recovery obtained by Genelux through such enforcement action in
excess of enforcement cost). 
 6.4. Infringement Claims by Third Parties. If the Exploitation of the Licensed Viruses or the
Licensed Products in the Field in the Territory results in, or is reasonably expected to result in, any claim, suit or proceeding by a Third Party alleging Infringement of a Third Party Patent Right that Covers the Licensed Virus or the Licensed
Product (not including any modification or improvement made by Newsoara to the Licensed Virus or the Licensed Product provided by Genelux) by Newsoara or any of its Affiliates or its or their Sublicensees, distributors or customers, including any
defense or counterclaim in connection with an Infringement action initiated pursuant to Section 6.3.2 (Enforcement of Patents) (a “Third Party Infringement Claim”), the Party first becoming aware of such
alleged Infringement shall promptly notify the other Party thereof in writing. As between the Parties, Newsoara shall have the first right to defend against any such Third Party Infringement Claim, using counsel of Newsoara’s choice, and the
Parties shall share [***] all reasonable costs and expenses (including any damages, awards, royalties, settlement amounts and other liabilities) incurred by Newsoara or any of its Affiliates or its or their Sublicensees, distributors or customers in
connection with such Third Party Infringement Claim. Genelux may participate in any such claim, suit or proceeding with counsel of its choice, and all reasonable costs and expenses incurred by Genelux or its Affiliates in connection therewith shall
be shared [***]; provided that Newsoara shall retain the right to control such claim, suit or proceeding. Genelux shall, and shall cause its Affiliates to, assist and cooperate with Newsoara, as Newsoara may reasonably request from time to
time, in connection with its activities set forth in this Section 6.4 (Infringement Claims by Third Parties), including, where necessary, furnishing a power of attorney solely for such purpose or joining in, or being named
as a necessary party to, such action, providing access to relevant documents and other evidence, and making its employees available at reasonable business hours, and the reasonable costs and expenses incurred by Genelux or its Affiliate in
connection with such assistance and cooperation shall be shared [***]. Newsoara shall keep Genelux reasonably informed of all material 

  
 - 39 - 

 
developments in connection with any such claim, suit or proceeding. Newsoara agrees to provide Genelux with copies of all material pleadings filed in such action and to consider in good faith and
not unreasonably refuse to incorporate into its pleadings any timely and reasonable comments from Genelux with respect thereto. If Newsoara or its designee does not take commercially reasonable steps to defend against such claim, suit or proceeding
within [***] ([***]) days following the first notice provided above with respect to such Third Party Infringement Claim or, provided such date occurs after the first such notice of such Third Party Infringement Claim is provided, [***]
([***]) Business Days before the time limit, if any, set forth in Applicable Law for filing of such actions, whichever comes first, then (a) Newsoara shall so notify Genelux and (b) Genelux may defend at its discretion against such Third
Party Infringement Claim at its sole cost and expense, in which case Newsoara shall cooperate with and provide all reasonable assistance to Genelux in connection with such defense action. For clarity, Third Party Infringement Claim does not include
claims for Infringement of Third Party Patent Rights due to (a) any modification or improvement made by Newsoara to the Licensed Virus or Licensed Product provided by Genelux; or (b) any Derived Product, and in each case of (a) and
(b), Newsoara shall be solely responsible for the defense of such claims at its own cost and expense. If either Party becomes aware that the Exploitation of the Licensed Viruses or the Licensed Products or Derived Molecules or Derived Product by
such Party results in, or is reasonably expected to result in, any claim, suit or proceeding by a Third Party alleging infringement of a Third Party Patent Right that is reasonably expected to materially and adversely affect the Exploitation of the
Licensed Virus or the Licensed Product or Derived Molecules or Derived Product by the other Party, such Party shall promptly notify the other Party thereof. 

6.5. Invalidity or Unenforceability Defenses or Actions. Each Party shall promptly notify the other Party in writing of any
alleged or threatened assertion of invalidity or unenforceability of any of the Genelux Patents and Joint Patents in the Territory by a Third Party of which such Party becomes aware. Genelux shall have the first right, but not the obligation to
defend and control the defense of the validity and enforceability of the Genelux Patents and Joint Patents, as applicable, using counsel of its choice, including when such invalidity or unenforceability is raised as a defense or counterclaim in
connection with an Infringement action initiated pursuant to Section 6.3 (Enforcement of Patents). Genelux shall solely bear the cost and expense of such defenses that it elects to undertake worldwide, including for any
costs and expenses incurred in connection with any such defense in the Territory in the Field. If Genelux decides not to defend and control the defense of the validity or enforceability of any Genelux Patent or Joint Patent in the Territory, then
Genelux shall so notify Newsoara and Newsoara may choose to defend and control the defense of the validity or enforceability of any Genelux Patent or Joint Patent in the Territory at its sole cost and expense. Genelux shall use Commercially
Reasonable Efforts to make available to Newsoara and its authorized attorneys, agents or representatives, such of its employees as are reasonably necessary to assist Newsoara in defending the patent protection described under this
Section 6.5 (Invalidity or Unenforceability Defenses or Actions). Genelux shall sign or use Commercially Reasonable Efforts to have signed all legal documents necessary for Newsoara to defend such Genelux Patents and Joint
Patents in the Territory. If Newsoara’s efforts lead to successful defense of such Patent in the Territory, Newsoara shall have the right to recoup the reasonable cost incurred by Newsoara from royalty payments due to Genelux hereunder. 

  
 - 40 - 

 6.6. Product Marking. Newsoara shall mark each Licensed Product sold in the
Territory in accordance with the applicable patent marking laws, and shall require all of its Affiliates and Sublicensees to do the same. To the extent permitted by Applicable Laws and requested by Genelux, Newsoara shall consider in good faith
Genelux’s request (Newsoara’s approval of such request shall not be unreasonably withheld, delayed or conditioned) to indicate on the product packaging, advertisement and promotional materials that such Licensed Product is licensed from
Genelux. 
 6.7. Genelux Trademarks. 

6.7.1. Newsoara acknowledges that Genelux may develop a global branding strategy for a Licensed Product and adopt the key distinctive
colors, logos, images, symbols, and trademarks to be used in connection with the Commercialization of such Licensed Product throughout the world (collectively and including any Chinese language versions thereof, the “Genelux
Trademarks”). Genelux shall own all rights in the Genelux Trademarks and shall have the sole right (but not the obligation) to register, maintain and enforce the Genelux Trademarks in any country in the world as it determines appropriate,
at Genelux’ own cost and expense. 
 6.7.2. Subject to the terms and conditions of this Agreement and for no additional
considerations, Genelux hereby grants to Newsoara an exclusive license to use the Genelux Trademarks solely in connection with the Commercialization of the Licensed Products in the Field in the Territory during the Term of this Agreement, and
Newsoara has right to Commercialize Licensed Products in the Field in the Territory using the Genelux Trademarks in a manner consistent with Genelux’s global branding strategy for each such Licensed Product. 

6.8. Product Trademarks. 

6.8.1. Prosecution of Product Trademarks. Newsoara shall have the right to brand the Licensed Products in the Territory using
Product Trademarks selected by Newsoara in consultation with Genelux. Newsoara shall have the sole right to register, prosecute and maintain the Product Trademarks using counsel of its own choice. All costs and expenses of registering, prosecuting
and maintaining the Product Trademarks in the Territory shall be borne solely by Newsoara. 
 6.8.2. Enforcement of Product
Trademarks. Each Party shall provide to the other Party prompt written notice of any actual or threatened Infringement of the Product Trademarks in the Territory and of any actual or threatened claim that the use of the Product Trademarks in the
Territory violates the rights of any Third Party, in each case, of which such Party becomes aware. Newsoara shall have the first right, but not the obligation, to take such action as Newsoara deems necessary against a Third Party based on any
alleged, threatened or actual Infringement, dilution, misappropriation or other violation of or unfair trade practices or any other like offense relating to, the Product Trademarks by a Third Party in the Territory at its sole cost and expense and
using counsel of its own choice. Newsoara shall retain any damages or other amounts collected in connection therewith. Subject to the foregoing, Genelux may elect at its sole cost and expense to participate in the enforcement of the Product
Trademarks in the Territory. 

  
 - 41 - 

 6.8.3. Third Party Claims. As between the Parties, Newsoara shall defend
against and settle any alleged, threatened or actual claim, suit or proceeding by a Third Party that the use or registration of the Product Trademarks in the Territory infringes, dilutes, misappropriates or otherwise violates any Trademark or other
right of that Third Party or constitutes unfair trade practices or any other similar offense or any other claims, suits or proceedings as may be brought by a Third Party in connection with the use of the Product Trademarks with respect to a Licensed
Product in the Territory (“Third Party Trademark Claim”), using counsel of its choice, and Newsoara shall solely bear all costs and expenses (including any damages, awards, royalties, settlement amounts and other liabilities)
incurred by Newsoara or any of its Affiliates or its or their Sublicensees, distributors or customers in connection with such Third Party Trademark Claim. Genelux may participate in any such claim, suit or proceeding in the Territory with counsel of
its choice at its sole cost and expense; provided that Newsoara shall retain the right to control such claim, suit or proceeding in the Territory. Genelux shall, and shall cause its Affiliates to, assist and cooperate with Newsoara, as
Newsoara may reasonably request from time to time, in connection with its activities set forth in this Section 6.8 (Product Trademarks); provided that Newsoara shall reimburse Genelux for its reasonable and
verifiable out-of-pocket costs and expenses incurred in connection therewith. 

6.8.4. Cooperation. Genelux shall, and shall cause its Affiliates to, assist and cooperate with Newsoara, as Newsoara may
reasonably request from time to time, in connection with its activities set forth in this Section 6.8 (Product Trademarks), including where necessary, furnishing a power of attorney solely for such purpose or joining in, or
being named as a necessary party to, such action, providing access to relevant documents and other evidence and making its employees available at reasonable business hours; provided that Newsoara shall reimburse Genelux for its and its
Affiliates’ reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith. 

ARTICLE 7 CONFIDENTIALITY AND NON-DISCLOSURE 

7.1. Confidentiality Obligations. At all times during the Term and for a period of [***] years following termination or
expiration hereof in its entirety, each Party shall and shall cause its officers, directors, employees and agents to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or indirectly, for any purpose other
than for the purposes of performing its obligations or exercising its rights under this Agreement, any Confidential Information furnished or otherwise made known to it, directly or indirectly, by the other Party, except to the extent such disclosure
or use is expressly permitted by the terms of this Agreement. “Confidential Information” means any technical, business or other Information provided by or on behalf of one Party (the “Disclosing Party”) to the other
Party (the “Receiving Party”) in connection with this Agreement, whether prior to, on or after the Effective Date, including Information relating to the terms of this Agreement (subject to
Section 7.4 (Public Announcements)), information relating to any Licensed Virus, Licensed Product, Derived Molecule, or Derived Product (including the Regulatory Documentation), any Development or Commercialization of any
Licensed Virus, Licensed Product, Derived Molecule, or Derived Product, any know-how with respect thereto developed by or on behalf of the Disclosing Party or its Affiliates or the scientific, regulatory or
business affairs or other activities of either Party. All Information disclosed by a Party to the other Party under that certain Mutual Confidentiality and 

  
 - 42 - 

 
Non-Disclosure Agreement between the Parties dated [***] shall be deemed Confidential Information of such Party and shall be subject to the terms of this
Article 7. Notwithstanding the foregoing, the terms of this Agreement shall be deemed to be the Confidential Information of both Parties and both Parties shall be deemed to be the Receiving Party and the Disclosing Party with respect thereto.
Notwithstanding the foregoing, the confidentiality and nonuse obligations under this Section 7.1 (Confidentiality Obligations) with respect to any Confidential Information shall not include any information that: 

(a) is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no breach of this
Agreement by the Receiving Party; 
 (b) can be demonstrated by documentation or other competent proof to have been in the Receiving
Party’s (or its Affiliates’) possession prior to disclosure by the Disclosing Party without any obligation of confidentiality with respect to such information; 

(c) is subsequently received by the Receiving Party from a Third Party who is not bound by any obligation of confidentiality with respect to
such information; or 
 (d) can be demonstrated by documentation or other competent evidence to have been independently developed by or for
the Receiving Party without reference to the Disclosing Party’s Confidential Information. 
 Specific aspects or details of Confidential Information
shall not be deemed to be within the public domain or in the possession of the Receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the Receiving Party (for
clarity, the virus strains provided by Genelux to Newsoara shall remain Genelux’s proprietary material at all times and shall not be used by Newsoara or transferred by Newsoara to any Third Party for any purpose other than this Agreement, even
if some or all of the sequence of the virus may be publicly available). Further, any combination of Confidential Information shall not be considered in the public domain or in the possession of the Receiving Party merely because individual
elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the combination and its principles are in the public domain or in the possession of the Receiving Party. 

7.2. Permitted Disclosures. Each Party may disclose Confidential Information to the extent that such disclosure is: 

7.2.1. made in response to a valid order of a court of competent jurisdiction or other supra-national, federal, national, regional,
state, provincial and local governmental or regulatory body of competent jurisdiction or, if in the reasonable opinion of the Receiving Party’s legal counsel, such disclosure is otherwise required by Applicable Law, including by reason of
filing with securities regulators; provided, however, that the Receiving Party shall first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash such order or to obtain a protective order
or confidential treatment requiring that the Confidential Information and documents that are the subject of such order be held in confidence by such court or agency or, if disclosed, be used only for the purposes for which the order was issued; and
provided, further, that the Confidential Information disclosed in response to such court or governmental order shall be limited to that information which is legally required to be disclosed in response to such court or governmental order;

  
 - 43 - 

 7.2.2. made by or on behalf of the Receiving Party to the Regulatory Authorities as
required in connection with any filing, application or request for Regulatory Approval; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information to the extent practicable and consistent
with Applicable Law; 
 7.2.3. made by or on behalf of the receiving Party to a patent authority as may be reasonably necessary or
useful for purposes of obtaining or enforcing a Patent pursuant to Article 6; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available; 

7.2.4. made by or on behalf of the Receiving Party to potential or actual acquirers, investor or licensees, sublicensee of one or more
Licensed Products or Derived Products as may be necessary in connection with their evaluation of such potential or actual transaction; provided, however, that such persons shall be subject to obligations of confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of confidentiality and non-use of the receiving Party pursuant to this
Article 7 (Confidentiality and Non-Disclosure) (provided that in the case of disclosure to investors, the duration of confidentiality and non-use obligations may
be shorter but no less than [***] years from the date of disclosure); or 
 7.2.5. made by or on behalf of the Receiving Party to the
Receiving Party’s directors, attorneys, independent accountants or financial advisors for the sole purpose of enabling such directors, attorneys, independent accountants or financial advisors to provide advice to the Receiving Party;
provided, however, that such persons shall be subject to obligations of confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of
confidentiality and non-use of the receiving Party pursuant to this Article 7 (Confidentiality and Non-Disclosure). 

7.3. Use of Name. Except as expressly provided herein, neither Party shall mention or otherwise use the name, logo or Trademark
of the other Party or any of its Affiliates or any of its or their (sub)licensees (or Sublicensees) (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material or other form of publicity without
the prior written approval of such other Party. The restrictions imposed by this Section 7.3 (Use of Name) shall not prohibit (a) either Party from making any disclosure identifying the other Party to the extent
required in connection with its exercise of its rights or obligations under this Agreement, or (b) either Party from making any disclosure identifying the other Party that is required by Applicable Law or the rules of a stock exchange on which
the securities of the disclosing Party are listed (or to which an application for listing has been submitted). 

  
 - 44 - 

 7.4. Public Announcements. 

7.4.1. The Parties have agreed on language of a joint press release announcing this Agreement, which is attached hereto as Schedule
7.4 (Public Announcements), to be issued by the Parties promptly after the Effective Date. Subject to the rest of this Section 7.4 (Public Announcements), neither Party shall issue any other public announcement, press
release or other public disclosure regarding this Agreement or its subject matter without the other Party’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, except for any such disclosure that is, in
the opinion of the Disclosing Party’s counsel, required by Applicable Law or the rules of a stock exchange on which the securities of the Disclosing Party are listed (or to which an application for listing has been submitted). In the event a
Party is, in the opinion of its counsel, required by Applicable Law or the rules of a stock exchange on which its securities are listed (or to which an application for listing has been submitted) to make such a public disclosure, such Party shall
submit the proposed disclosure in writing to the other Party as far in advance as reasonably practicable (and in no event less than [***] ([***]) Business Days prior to the anticipated date of disclosure) so as to provide a reasonable opportunity to
comment thereon. Neither Party shall be required to seek the permission of the other Party to repeat any information regarding the terms of this Agreement or any amendment hereto that has already been publicly disclosed by such Party or by the other
Party, in accordance with this Section 7.4 (Public Announcements); provided that such information remains accurate as of such time and provided the frequency and form of such disclosure are reasonable. 

7.4.2. Notwithstanding the foregoing, Newsoara has right to issue any other public announcement, press release or other public
disclosure regarding the Development and Commercialization of the Licensed Products and Derived Products in the Territory without Genelux’s prior written consent, provided that such disclosure does not include any confidential information of
Genelux, if such disclosure includes any confidential information of Genelux, before such disclosure, Newsoara shall obtain prior consent of Genelux, such consent not to be unreasonably withheld, delayed or conditioned.

7.4.3. Notwithstanding the foregoing, Genelux has the right to publicly disclose the achievement of any milestones under this
Agreement, and the commencement and completion of Clinical Trials conducted under this Agreement and otherwise the right to repeat such information disclosed by Newsoara in Section 7.4.2. Genelux shall provide Newsoara with
a reasonable opportunity to review and comment on such disclosure and shall consider Newsoara’s comments in good faith. Public disclosure of material data and key results of Clinical Trials conducted under this Agreement by Newsoara that has
not been disclosed by Newsoara shall be subject to Newsoara’s consent, such consent not to be unreasonably withheld, delayed or conditioned. 

7.5. Publications. 

7.5.1. The Parties recognize the desirability of publishing and publicly disclosing the results of and information regarding activities
under this Agreement. Accordingly, Newsoara shall be free to publicly disclose the results of and information regarding Newsoara’s activities under this Agreement in a manner consistent with Applicable Law and industry practices, subject to
Genelux’s prior review and approval as provided in this Section 7.5 (Publications). 

  
 - 45 - 

 7.5.2. Newsoara shall deliver to Genelux for review and approval a copy of any
proposed publication or presentation relating to the Licensed Viruses, Licensed Products, Derived Molecules, or Derived Products at least [***] ([***])) days before its intended submission for publication. [***] 

7.6. Return of Confidential Information. Upon the effective date of the expiration or termination of this Agreement for any
reason, either Party may request in writing and the non-requesting Party shall either, with respect to Confidential Information to which such non-requesting Party does
not retain rights under the surviving provisions of this Agreement, at the requesting Party’s election, (a) promptly destroy (with written confirmation) all copies of such Confidential Information in the possession or control of the non-requesting Party and confirm such destruction in writing to the requesting Party or (b) promptly deliver to the requesting Party, at the non-requesting Party’s
sole cost and expense, all copies of such Confidential Information in the possession or control of the non-requesting Party. Notwithstanding the foregoing, the
non-requesting Party shall be permitted to retain such Confidential Information (a) to the extent necessary or useful for purposes of performing any continuing obligations or exercising any ongoing rights
hereunder and, in any event, a single copy of such Confidential Information for archival purposes and (b) any computer records or files containing such Confidential Information that have been created solely by such non-requesting Party’s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such
non-requesting Party’s standard archiving and back-up procedures, but not for any other uses or purposes. All Confidential Information shall continue to be subject
to the terms of this Agreement for the period set forth in Section 7.1 (Confidentiality Obligations). 

7.7. Privileged Communications. In furtherance of this Agreement, it is expected that the Parties may, from time to time,
disclose to one another privileged communications with counsel, including opinions, memoranda, letters and other written, electronic and verbal communications. Such disclosures are made with the understanding that they shall remain confidential in
accordance with this Article 7 (Confidentiality and Non-Disclosure), that they will not be deemed to waive any applicable attorney-client or attorney work product or other privilege and that they are
made in connection with the shared community of legal interests existing between Genelux and Newsoara, including the community of legal interests in avoiding Infringement of any valid, enforceable patents of Third Parties and maintaining the
validity of the Genelux Patents. In the event of any litigation (or potential litigation) with a Third Party related to this Agreement or the subject matter hereof, the Parties shall, upon either Party’s request, enter into a reasonable and
customary joint defense agreement. In any event, each Party shall consult in a timely manner with the other Party before engaging in any conduct (e.g., producing information or documents) in connection with litigation or other proceedings
that could conceivably implicate privileges maintained by the other Party. Notwithstanding anything contained in this Section 7.7 (Privileged Communications), nothing in this Agreement shall prejudice a Party’s ability
to take discovery of the other Party in disputes between them relating to the Agreement and no information otherwise admissible or discoverable by a Party shall become inadmissible or immune from discovery solely by this
Section 7.7 (Privileged Communications). 

  
 - 46 - 

 ARTICLE 8 REPRESENTATIONS, WARRANTIES AND COVENANTS 

8.1. Mutual Representations and Warranties. Genelux and Newsoara each represents and warrants to the other, as of the Effective
Date that: 
 8.1.1. it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its
organization and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement; 

8.1.2. the execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly
authorized by all necessary corporate action and do not violate: (a) such Party’s charter documents, bylaws or other organizational documents; (b) in any material respect, any agreement, instrument or contractual obligation to which
such Party is bound; (c) any requirement of any Applicable Law; or (d) any order, writ, judgment, injunction, decree, determination or award of any court or Governmental Authority presently in effect applicable to such Party; 

8.1.3. this Agreement is a legal, valid and binding obligation of such Party enforceable against it in accordance with its terms and
conditions, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity
(whether enforceability is considered a proceeding at law or equity); and 
 8.1.4. it is not under any obligation, contractual or
otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder. 

8.2. Additional Representations and Warranties of Genelux. Genelux further represents and warrants to Newsoara that, as of the
Effective Date: 
 8.2.1. (a) Genelux or one of its Affiliates Controls the Genelux Patents and the Genelux Know-How as of the Effective Date and Genelux has the right to grant the licenses and sublicenses granted to Newsoara under this Agreement; (b) Genelux has not received any written claim or demand alleging that
any of the Genelux Patents are invalid or unenforceable; (c) to Genelux’s knowledge, no Person is infringing or threatening to infringe the Genelux Patents in the Territory; and (d) to Genelux’s knowledge, all Genelux Patents
have been filed in accordance with the applicable formal requirements and none of such patent applications or patents have lapsed by reason of abandonment or non-payment of any fees, and Genelux or its
applicable Affiliate has paid all maintenance fees, which are due and payable with respect to such Genelux Patents; 
 8.2.2. To
Genelux’s knowledge, no Genelux Patent is subject to any lien or other encumbrance in favor of any Third Party; 
 8.2.3. To
Genelux’s knowledge, no patent application or registration with respect to the Genelux Patents is the subject of any pending interference, opposition, cancellation, or patent protest pursuant to any Applicable Law; 

8.2.4. To Genelux’s knowledge, the Schedule 1.43 (Genelux Patents) includes all Patents Controlled by Genelux or its
Affiliates as of the Effective Date that Cover the composition of matter, methods of making or using of Olvi-Vec in the Territory; 

  
 - 47 - 

 8.2.5. To Genelux’s knowledge, other than licenses granted by a vendor or other
service provider to Genelux in the ordinary course of business, there is no agreement between Genelux or its Affiliates, on the one hand, and any Third Party, on the other, pursuant to which Genelux or its Affiliates has in-licensed any Genelux Patent or Genelux Know-How; 

8.2.6. To Genelux’s knowledge, Genelux has not received any written notice from any Third Party, asserting or alleging
(i) that the Exploitation of any Licensed Virus or Licensed Product prior to the Effective Date infringed or misappropriated the intellectual property rights of such Third Party, or (ii) that the Exploitation of the Licensed Viruses and
Licensed Products as contemplated under this Agreement will infringe or misappropriate the intellectual property rights of such Third Party; 

8.2.7. To Genelux’s knowledge, the Manufacturing, Development and Commercialization of
Olvi-Vec in the Territory does not infringe any intellectual property rights of any Third Party; 

8.2.8. To Genelux’s knowledge, Genelux has complied, in material aspects, with all Applicable Law applicable to (a) the
prosecution and maintenance of Genelux Patents and (b) its Development, Commercialization or other Exploitation of the Licensed Viruses and Licensed Products in the Field; 

8.2.9. Genelux has not granted to any Person any currently effective license, sublicense or other rights, entered into any currently
effective agreement or understanding or undertaken any obligation that in any way conflicts or is inconsistent with this Agreement or the rights and licenses granted to Newsoara under this Agreement; 

8.2.10. There is no outstanding unresolved safety issue in any written communication received by Genelux from the FDA regarding Olvi-Vec that would result in a clinical hold or that would prohibit approval. 
 8.3.
DISCLAIMER OF WARRANTIES. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE. NEWSOARA
ACKNOWLEDGES AND AGREES THAT THE LICENSED VIRUSES AND LICENSED PRODUCTS ARE THE SUBJECT OF ONGOING RESEARCH AND DEVELOPMENT AND THAT GENELUX CANNOT ASSURE THE SAFETY, USEFULNESS OR SUCCESSFUL DEVELOPMENT OR COMMERCIALIZATION OF ANY LICENSED PRODUCT.

 ARTICLE 9 INDEMNITY 

9.1. Indemnification of Genelux. Subject to Section 6.4 (Infringement Claims by Third Parties),
Newsoara shall indemnify Genelux, its Affiliates, its or their (sub)licensees and its and their respective directors, officers, employees and agents and defend and save each of them harmless, from and against any and all losses, damages,
liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims or demands of Third Parties (collectively, “Third
Party Claims”) arising from or occurring as a result of: (a) the breach of any representation, warranty, covenant or other term of this Agreement by Newsoara; or (b) the fraud, gross negligence or willful misconduct

  
 - 48 - 

 
on the part of Newsoara or its Affiliates or its or their Sublicensees or its or their distributors or contractors or its or their respective directors, officers, employees or agents in
performing its or their obligations under this Agreement; (c) any Development, Manufacture, Commercialization, or Exploitation of the Licensed Viruses, Licensed Products, Derived Molecules and Derived Products by Newsoara, its Affiliates and
Sublicensees in the Territory; or (e) any failure to adhere to the protocol or failure to comply with Applicable Laws in the conduct of the NSCLC Multi-Center Trial in the U.S.; except, in each case of clauses (a), (b) and (c), for those
Losses for which Genelux has an obligation to indemnify Newsoara pursuant to Section 9.2 (Indemnification of Newsoara), as to which Losses each Party shall indemnify the other to the extent of their respective liability for
the Losses. 
 9.2. Indemnification of Newsoara. Genelux shall indemnify Newsoara, its Affiliates and their respective
Sublicensees, directors, officers, employees and agents and defend and save each of them harmless, from and against any and all Losses in connection with any and all Third Party Claims arising from or occurring as a result of: (a) the breach of
any representation, warranty, covenant or other term of this Agreement by Genelux; (b) the fraud, gross negligence or willful misconduct on the part of Genelux or its Affiliates or their respective directors, officers, employees or agents in
performing its or their obligations under this Agreement or (c) any Development, Manufacture, Commercialization, or Exploitation of the Licensed Viruses, Licensed Products, Derived Molecules and Derived Products by Genelux, its Affiliates,
licensees (other than Newsoara, its Affiliates and Sublicensees) outside the Territory; except, in each case of clauses (a), (b) and (c), for those Losses for which Newsoara has an obligation to indemnify Genelux pursuant to
Section 9.1 (Indemnification of Genelux), as to which Losses each Party shall indemnify the other to the extent of their respective liability for the Losses.

9.3. Indemnification Procedures. 

9.3.1. Notice of Claim. All indemnification claims in respect of a Party, its Affiliates or its or their (sub)licensees or their
respective directors, officers, employees and agents shall be made solely by such Party to this Agreement (the “Indemnified Party”) against the other Party to this Agreement (the “Indemnifying Party”). The
Indemnified Party shall give the Indemnifying Party prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under
this Article 9 (Indemnity); provided that no failure or delay in providing such notice shall relieve the Indemnifying Party of any liability it may have to the Indemnified Party, except to the extent that such failure or delay
materially prejudices the Indemnifying Party with respect to its defense of such claim. Each Indemnification Claim Notice must contain a description of the Third Party Claim and the nature and amount of such Loss (to the extent that the nature and
amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims. 

9.3.2. Control of Defense. The Indemnifying Party shall have the right to assume the defense of any Third Party Claim at its
sole costs and expenses by giving written notice to the Indemnified Party within [***] ([***]) days after the Indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party Claim by the
Indemnifying Party shall not be construed as an acknowledgment that the Indemnifying Party is 

  
 - 49 - 

 
liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against the Indemnified
Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying Party and reasonably
acceptable to the Indemnified Party. In the event the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall immediately deliver to the Indemnifying Party all original notices and documents (including court
papers) received by the Indemnified Party in connection with the Third Party Claim. Should the Indemnifying Party assume the defense of a Third Party Claim, except as provided in Section 9.3.3 (Right to Participate in
Defense), the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim unless specifically
requested in writing by the Indemnifying Party. 
 9.3.3. Right to Participate in Defense. Any Indemnified Party shall be
entitled to participate in the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnified Party’s sole cost and expense unless (a) the
employment thereof has been specifically authorized by the Indemnifying Party in writing (in which case, the defense shall be controlled as provided in Section 9.3.2 (Control of Defense)), (b) the Indemnifying Party has
failed to assume the defense and employ counsel in accordance with Section 9.3.2 (Control of Defense) (in which case the Indemnified Party shall control the defense), or (c) the Indemnifying Party has assumed the
defense and selected its defense counsel, but the interests of the Indemnified Party and the Indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the representation by the same counsel of both Parties under
Applicable Law, ethical rules or equitable principles (in which case, the Indemnifying Party shall control its defense). 
 9.3.4.
Settlement. With respect to any Losses relating solely to the payment of money damages by the Indemnifying Party in connection with a Third Party Claim and that shall not result in the applicable indemnitee(s) becoming subject to injunctive
or other relief or otherwise adversely affecting the business of the Indemnified Party in any manner, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such
Loss, on such terms as the Indemnifying Party, in its sole discretion, shall deem appropriate. With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in
accordance with Section 9.3.2 (Control of Defense), the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided it
obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). If the Indemnifying Party does not assume and conduct the defense of a Third Party Claim as provided above, the
Indemnified Party may defend against such Third Party Claim; provided that the Indemnified Party shall not settle any Third Party Claim without the prior written consent of the Indemnifying Party (which consent shall not be unreasonably
withheld, conditioned or delayed). 

  
 - 50 - 

 9.3.5. Cooperation. Regardless of whether the Indemnifying Party chooses to
defend or prosecute any Third Party Claim, the Indemnified Party shall, and shall cause each indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend
such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to and reasonable
retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim and making Indemnified Parties and other employees and agents available on a mutually convenient basis to provide additional
information and explanation of any material provided hereunder and the Indemnifying Party shall reimburse the Indemnified Party for all its, its Affiliates’ and its and their (sub)licensees’ or their respective directors’,
officers’, employees’ and agents’, as applicable, reasonable and verifiable out-of-pocket expenses in connection therewith. 

9.3.6. Expenses. Except as provided above, the costs and expenses, including fees and disbursements of counsel, incurred by the
Indemnified Party and its Affiliates and its and their (sub)licensees and their respective directors, officers, employees and agents, as applicable, in connection with any claim shall be reimbursed on a monthly basis by the Indemnifying Party,
without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified
Party. 
 9.4. Special, Indirect and Other Losses. EXCEPT (A) IN THE EVENT OF FRAUD OF A PARTY OR OF A PARTY’S
BREACH OF ITS OBLIGATIONS UNDER ARTICLE 7 (CONFIDENTIALITY AND NON-DISCLOSURE), SECTION 2.3 (RESTRICTIONS) OR SECTION 2.7 (NON-COMPETE), OR BREACH
OF THE RESTRICTION ON THE TRANSFER AND USE OF MATERIALS PROVIDED BY GENELUX UNDER SECTION 4.1.2 (MATERIAL SUPPLY), OR (B) AS PROVIDED UNDER SECTION 11.9 (EQUITABLE RELIEF), OR (C) TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED
TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 9 (INDEMNITY), NEITHER PARTY NOR ANY OF ITS AFFILIATES OR (SUB)LICENSEES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF
STATUTORY DUTY OR OTHERWISE FOR ANY INDIRECT, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, PROVIDED THAT NOTHING IN THIS AGREEMENT SHALL LIMIT OR EXCLUDE ANY PARTY’S LIABILITY FOR DEATH OR
PERSONAL INJURY, FRAUDULENT MISREPRESENTATION OR ANYTHING ELSE FOR WHICH ITS LIABILITY CANNOT BY APPLICABLE LAW BE LIMITED OR EXCLUDED. 

9.5. Insurance. Newsoara shall procure and maintain insurance, including product liability insurance, with respect to its
activities hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which any Licensed Product or Derived Product is being clinically tested in human subjects or commercially
distributed or sold. For clarity, such insurance shall not be construed to create a limit of Newsoara’s liability under this Agreement. 

  
 - 51 - 

 ARTICLE 10 TERM AND TERMINATION 

10.1. Term and Expiration. This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance
herewith, and shall expire upon the expiration of the Royalty Term (such period, the “Term”). On a country-by-country and Licensed Product-by-Licensed Product basis, upon the expiration of a Royalty Term in a country, the license grants to Newsoara under Section 2.1 (Grants to
Newsoara) will become fully paid-up, perpetual, and irrevocable for such Licensed Product for such country. 

10.2. Termination. 

10.2.1. Termination for Material Breach. In the event that either Party (the “Breaching Party”) is in material
breach of this Agreement (a “Material Breach”), in addition to any other right and remedy the other Party (the “Non-Breaching Party”) may have, the Non-Breaching Party may provide written notice (the “Notice of Breach”) to the Breaching Party specifying the Material Breach and unless the Breaching Party cures the Material Breach specified in
the Notice of Breach within [***] ([***]) days (the “Cure Period”), the Non-Breaching Party may terminate the Agreement in its entirety effective immediately upon written notice to the
Breaching Party. 
 10.2.2. Termination by Newsoara for Convenience. [***] 

10.2.3. Termination for Insolvency. In the event that either Party (or any Affiliate that controls (as defined in the definition
of Affiliate) such Party), (a) files for protection under bankruptcy or insolvency laws, (b) makes an assignment for the benefit of creditors, (c) appoints or suffers appointment of a receiver or trustee over substantially all of its
property that is not discharged within [***] ([***])) days after such filing, (d) proposes a written agreement of composition or extension of its debts, (e) proposes or is a party to any dissolution or liquidation, (f) files a
petition under any bankruptcy or insolvency act or has any such petition filed against that is not discharged within [***] ([***]) days of the filing thereof or (g) admits in writing its inability generally to meet its obligations as they fall
due in the general course, then the other Party may terminate this Agreement in its entirety effective immediately upon written notice to such Party. 

10.2.4. Termination for Patent Challenge. Except to the extent the following is unenforceable under the laws of
a particular jurisdiction, if Newsoara or any of its Affiliates or Sublicensees, individually or in association with any other person or entity, commences a legal action challenging the validity, enforceability or scope of any Genelux Patent
anywhere in the world (collectively, a “Patent Challenge”), Genelux may (i) with respect to Patent Challenge by Newsoara or its Affiliates, immediately terminate this Agreement in its entirety upon written notice to Newsoara;
or (ii) with respect to Patent Challenge by Newsoara’s Sublicensee, unless Newsoara terminates all licenses or other agreements with such Sublicensee pursuant to which rights under this Agreement have been sublicensed by Newsoara as soon
as possible or such Sublicensee or Affiliate abandons such Patent Challenge within [***] ([***]) days following the Patent Challenge, terminate this Agreement in its entirety upon written notice to Newsoara. 

  
 - 52 - 

 10.3. Rights in Bankruptcy. All rights and licenses granted under or pursuant
to this Agreement by Newsoara or Genelux are and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses of right to
“intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and
elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S.
Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the Party that is not a party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property
and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy
proceeding upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement or, (b) if not
delivered under clause (a) above, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party. 

10.4. Consequences of Termination. In the event of a termination of this Agreement for any reason: 

10.4.1. Licenses Grants by Genelux. All rights and licenses granted by Genelux hereunder shall immediately terminate, except
that the licenses granted by Genelux under Section 2.1.2 (License Grant for Derived Products) with respect to the Derived Molecules and the Derived Products generated by Newsoara or its Affiliates before the effective date
of termination shall become an exclusive, fully paid, royalty free, perpetual, irrevocable, and sublicensable (through multiple tiers) license, if this Agreement is terminated by Newsoara in accordance with Section 10.2.1
(Termination for Material Breach), or 10.2.3 (Termination for Insolvency). 
 10.4.2. License Grants by Newsoara. 

(a) Effective as of the effective date of termination, Newsoara shall and hereby does, and shall cause its Affiliates and its and their
Sublicensees to, grant to Genelux an exclusive, fully paid, royalty free, perpetual, irrevocable, and sublicensable (through multiple tiers) license under all Patents and Information that are (a) Controlled by Newsoara or its Affiliates and
(b) developed or generated, or used or applied, by or on behalf of Newsoara, its Affiliates or Sublicensees in the Development, Manufacture, Commercialization or Exploitation of the Licensed Viruses and Licensed Products to Develop,
Manufacture, Commercialize or otherwise Exploit the Licensed Viruses and the Licensed Products in the Field in the Territory. 
 (b) The
license granted by Newsoara to Genelux under Section 2.4.1 (Grants to Genelux for Licensed Product) shall continue. 

(c) The license granted by Newsoara to Genelux under Section 2.4.2 (Grants to Genelux for Derived Product) shall
continue, except that if this Agreement is terminated by Newsoara due to Genelux’s uncured material breach related to Genelux’s obligations to make payment to Newsoara under Section 2.4.2(c), then such license
shall terminate and neither Genelux 

  
 - 53 - 

 
nor Newsoara (whether by itself or through Affiliate or licensees) shall Develop or Commercialize any Derived Molecule or Derived Product outside the Territory. Further, if this Agreement is
terminated by Genelux in accordance with Section 10.2.1 (Termination for Material Breach), 10.2.3 (Termination for Insolvency), or 10.2.4 (Termination for Patent Challenge), then the license under
Section 2.4.2 (Grants to Genelux for Derived Product) shall become fully paid and royalty free. 
 10.4.3.
Regulatory Documentation. Effective as of the effective date of termination, Newsoara shall and hereby does, and shall cause its Affiliates and its and their Sublicensees to, assign to Genelux all rights, title and interests in and to all
Regulatory Documentation (including any Regulatory Approvals) applicable to the Licensed Products Controlled by Newsoara or any of its Affiliates or any of its or their Sublicensees. If any such Regulatory Documentation or Regulatory Approval is not
immediately transferrable in a country or region, Newsoara shall provide Genelux with all benefit of such Regulatory Documentation or Regulatory Approval, as applicable, and such assistance and cooperation as necessary or reasonably requested by
Genelux to timely transfer such Regulatory Documentation or Regulatory Approval, as applicable, to Genelux or its designee or, at Genelux’s option, to enable Genelux to obtain a substitute for such Regulatory Documentation or Regulatory
Approval, as applicable, without disruption to Genelux’s Development, Manufacture and Commercialization of the applicable Licensed Product. Such assignment of Regulatory Documentation will be conducted at no cost to Genelux, except that if this
Agreement is terminated by Newsoara in accordance with Section 10.2.1 (Termination for Material Breach), or 10.2.3 (Termination for Insolvency), Genelux shall bear all costs for such assignment. The Parties shall
discuss and establish appropriate arrangements with respect to safety data exchanges. 
 10.4.4. Data. Effective as of the
effective date of termination, Newsoara shall and hereby does, and shall cause its Affiliates and its and their Sublicensees to, transfer and assign to Genelux, all data generated from the Development of the Licensed Products, including all Clinical
Trials conducted by or on behalf of Newsoara, its Affiliates and Sublicensees, and all pharmacovigilance data (including all adverse event databases) relating to the Licensed Products in the Territory. Such transfer of Data will be conducted at no
cost to Genelux, except that if this Agreement is terminated by Newsoara in accordance with Section 10.2.1 (Termination for Material Breach), or 10.2.3 (Termination for Insolvency), Genelux shall bear all costs for
such transfer. If the assignment of any such data is prohibited by Applicable Laws, then Newsoara shall (and hereby does, but effective only upon such termination) grant to Genelux an exclusive, exclusive, fully paid, royalty free, perpetual,
irrevocable, and sublicensable (through multiple tiers) license to use such data. 
 10.4.5. Product Trademarks. Effective as
of the effective date of termination, Newsoara shall and hereby does, and shall cause its Affiliates and its and their Sublicensees to, assign to Genelux all rights, title and interests in and to all Product Trademarks (excluding any such Trademarks
that include, in whole or in part, any Newsoara Corporate Names). Such assignment of Product Trademarks will be conducted at no cost to Genelux, except that if this Agreement is terminated by Newsoara in accordance with
Section 10.2.1 (Termination for Material Breach), 10.2.3 (Termination for Insolvency), Genelux shall bear all costs for such assignment. 

  
 - 54 - 

 10.4.6. Ongoing Clinical Trials. Unless expressly prohibited by any Regulatory
Authority, at Genelux’s written request, Newsoara shall and hereby does, and shall cause its Affiliates and its and their Sublicensees to, (i) transfer control to Genelux of any or all clinical studies involving the Licensed Product being
conducted by or on behalf of Newsoara, an Affiliate or a Sublicensee as of the effective date of termination, and (ii) continue to conduct such clinical studies, at Genelux’s cost (except that if the Agreement is terminated before the
completion of the NSCLC Multi-Center Trial and the termination of the Agreement is not due to Genelux’s uncured material breach or bankruptcy, then Newsoara shall remain responsible for the cost of the NSCLC Multi-Center Trial for [***] ([***])
months after the effective date of Termination), for as long as necessary to enable such transfer to be completed without interruption of any such clinical study; provided that with respect to each clinical study for which such transfer is
expressly prohibited by the applicable Regulatory Authority, if any, Newsoara or the relevant Affiliate or Sublicensee shall, at Genelux’s written request, continue to conduct such clinical study to completion, at Genelux’s cost and
expense (except that if the Agreement is terminated before the completion of the NSCLC Multi-Center Trial and the termination is not due to Genelux’s uncured material breach or bankruptcy, then Newsoara shall remain responsible for the cost of
the NSCLC Multi-Center Trial for [***] ([***]) months after the effective date of Termination). Genelux shall have no obligation to request the transfer or continuation of any clinical study. For any clinical study that Genelux does not request
transfer or continuation, Newsoara shall (shall cause its Affiliates and its and their Sublicensees to) orderly wind down, or complete (if required by Applicable Laws), such clinical study in compliance with all Applicable Laws and at
Newsoara’s own cost and expense, except that if this Agreement is terminated by Newsoara in accordance with Section 10.2.1 (Termination for Material Breach), or 10.2.3 (Termination for Insolvency), Genelux shall
bear all costs for such activity. 
 10.4.7. Further Assistance. Newsoara shall duly execute and deliver, or cause to be duly
executed and delivered, such instruments and shall do and cause to be done such acts and things, including the filing of such assignments, agreements, documents, and instruments with Governmental Authorities, as may be necessary under, or as Genelux
may reasonably request in connection with, or to carry out more effectively the purpose of, or to better assure and confirm unto Genelux its rights under, this Section 10.4 (Consequences of Termination), which shall be at
Genelux’s expense and cost except as expressly set forth in Sections 10.4.1 to 10.4.6 above. In addition, upon Genelux’s request, Newsoara shall, at Newsoara’s expense and cost (unless this Agreement is terminated by
Newsoara in accordance with Section 10.2.1 (Termination for Material Breach), or 10.2.3 (Termination for Insolvency), then Genelux shall bear all costs for such activity, (a) assign or amend, as appropriate, any
agreements or arrangements with Third Party vendors (including distributors) to Develop, Manufacture, supply, promote, distribute, sell or otherwise Commercialize the Licensed Products or, to the extent any such Third Party agreement or arrangement
is not assignable to Genelux or relates to the Licensed Product and any other product, reasonably cooperating with Genelux to arrange to continue to provide such services for a reasonable time after termination; (b) to the extent that Newsoara
or its Affiliate or Sublicensee is performing any activities described above in clause (a), reasonably cooperating with Genelux to transfer such activities to Genelux or its designee, and continuing to perform such activities on Genelux’s
behalf for a reasonable time after termination until such transfer is completed. 

  
 - 55 - 

 10.5. Remedies. Except as otherwise expressly provided herein, termination of
this Agreement in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity. 

10.6. Accrued Rights; Surviving Obligations. Termination or expiration of this Agreement for any reason shall be without
prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are expressly indicated to survive the termination or
expiration of this Agreement. Without limiting the foregoing, Sections 5.5.3 (VAT Withholding) with respect to recovery of VAT payment, 5.7 (Financial Records and Audit), 8.3 (Disclaimer of Warranties), 10.3 (Rights in
Bankruptcy), 10.4 (Consequences of Termination), 10.5 (Remedies), 11.3 (Severability), 11.4 (Dispute Resolution), 11.5 (Governing Law), 11.6 (Notices), 11.9 (Equitable Relief), 11.10 (Waiver and Non-Exclusion of Remedies), 11.11 (No Benefit to Third Parties), 11.12 (Further Assurance), 11.13 (Relationship of the Parties), 11.15 (References), 11.16 (Construction),
11.17 (Counterparts), this Section 10.6 (Accrued Rights; Surviving Obligations), Article 1 (Definitions), Article 7 (Confidentiality and Non-Disclosure),
and Article 9 (Indemnity) of this Agreement shall survive the termination or expiration of this Agreement for any reason. 

ARTICLE 11 MISCELLANEOUS 

11.1. Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or
breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement (other than an obligation to make payments) when such failure or delay is caused by or results from events beyond the reasonable control of the
nonperforming Party, including fires, floods, earthquakes, hurricanes, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections, riots, civil commotion, strikes, lockouts or other
labor disturbances (whether involving the workforce of the non-performing Party or of any other Person), acts of God or acts, omissions or delays in acting by any Governmental Authority (except to the extent
such delay results from the breach by the non-performing Party or any of its Affiliates of any term or condition of this Agreement). The non-performing Party shall
notify the other Party of such force majeure within [***] ([***]) days after such occurrence by giving written notice to the other Party stating the nature of the event, its anticipated duration and any action being taken to avoid or minimize its
effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary and the non-performing Party shall use commercially reasonable efforts to remedy its inability to
perform. When the force majeure no longer exists, the non-performing Party shall promptly resume performance under this Agreement. 

11.2. Assignment. 

11.2.1. Right to Assign. Neither Party may assign this Agreement, assign its rights or, except as expressly provided in this
Agreement, delegate its obligations under this Agreement, whether by operation of law or otherwise, in whole or in part without the prior written consent of the other Party, except that each Party shall have the right, without such consent,
(i) to perform any or all of its obligations and exercise any or all of its rights under this Agreement through any of its Affiliates or its or their (sub)licensees, and (ii) assign this Agreement and all of

  
 - 56 - 

 
its rights and all of its obligations hereunder to any of its Affiliates or to any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all
of such Party’s business to which this Agreement relates; provided that such Party shall provide written notice to the other Party within [***] ([***]) days after such assignment or delegation. Any permitted successor of a Party or any
permitted assignee of all of a Party’s rights under this Agreement that has also assumed all of such Party’s obligations hereunder in writing shall, upon any such succession or assignment and assumption, be deemed to be a Party to this
Agreement as though named herein in substitution for the assigning Party, whereupon the assigning Party shall cease to be a Party to this Agreement and shall cease to have any rights or obligations under this Agreement. All validly assigned rights
of a Party shall inure to the benefit of and be enforceable by, and all validly delegated obligations of such Party shall be binding on and be enforceable against, the permitted successors and assigns of such Party. Any attempted assignment or
delegation in violation of this Section 11.2.1 (Right to Assign) shall be void and of no effect.  

11.3. Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or
future law and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully severable, (b) this Agreement shall be construed and enforced as if
such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable
provision or by its severance herefrom, and (d) the Parties will use their best efforts to replace such illegal, invalid or unenforceable provision with a legal, valid and enforceable provision as similar in terms to such illegal, invalid or
unenforceable provision that implements the purposes of this Agreement to the fullest extent practical. To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision hereof illegal,
invalid or unenforceable in any respect. 
 11.4. Dispute Resolution. 

11.4.1. Escalation to Senior Officers. Except as provided in Section 11.9 (Equitable Relief), if a
dispute, controversy, difference or claim arises between the Parties in connection with or relating to this Agreement, including the existence, validity, interpretation, performance, breach or termination thereof or any dispute regarding any
obligations arising out of or relating to it, or any document or instrument delivered in connection herewith (a “Dispute”), then either Party shall refer such Dispute to the Senior Officers or their designee for attempted resolution
by good faith negotiations during a period of [***] ([***]) Business Days. Any final decision mutually agreed to by the Senior Officers shall be conclusive and binding on the Parties. 

11.4.2. Arbitration Notice. If such Senior Officers are unable to resolve any such Dispute within such [***] ([***]) -Business
Day period set forth in Section 11.4.1 (Escalation to Senior Officers), subject to Sections 11.4.5 (Injunction and Other Remedy) and 11.9 (Equitable Relief), either Party shall refer such Dispute to be
resolved by arbitration in accordance with Section 11.4.3 (Arbitration Procedure) upon written notice to the other Party (an “Arbitration Notice”). 

  
 - 57 - 

 11.4.3. Arbitration Procedure. Upon receipt of an Arbitration Notice by a
Party, the applicable Dispute shall be resolved by final and binding arbitration before a panel of three (3) experts with relevant industry experience (the “Arbitrators”). Each of Newsoara and Genelux shall promptly select one
(1) Arbitrator, which selections shall in no event be made later than [***] ([***]) days after the Arbitration Notice. The third Arbitrator shall be chosen promptly by mutual agreement of the Arbitrator chosen by Newsoara and the Arbitrator
chosen by Genelux, but in no event later than [***] ([***]) days after the date that the last of such Arbitrators was appointed. The Arbitrators shall determine what discovery will be permitted, consistent with the goal of reasonably controlling the
cost and time that the Parties must expend for discovery; provided that the Arbitrators shall permit such discovery as they deem necessary to permit an equitable resolution of the Dispute. The arbitration shall be administered by the [***]
according to the then effective arbitration rules of [***]. The arbitration will be held in [***] and conducted in English. The Arbitrators shall, within [***] ([***]) days after the conclusion of the arbitration hearing, issue a written award and
statement of decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded. The decision or award rendered by the Arbitrators shall be final and non-appealable, and judgment may be entered upon it in accordance with Applicable Law in any court of competent jurisdiction. The Arbitrators shall be authorized to award compensatory damages, but shall not be
authorized to reform, modify or materially change this Agreement or any other agreements contemplated hereunder. 
 11.4.4. Cost
Sharing and Continued Performance. Each Party shall bear its own counsel fees, costs, and disbursements arising out of the dispute resolution procedures described in this Section 11.4 (Dispute Resolution), and shall pay
an equal share of the fees and costs of the Arbitrators and all other general fees related to any arbitration described in Section 11.4.3 (Arbitration Procedure); provided, however, the Arbitrators shall be
authorized to determine whether a Party is the prevailing Party, and if so, to award to that prevailing Party reimbursement for its reasonable counsel fees, costs and disbursements (including expert witness fees and expenses, photocopy charges, or
travel expenses), or the fees and costs of the Arbitrators. Unless the Parties otherwise agree in writing, during the period of time that any arbitration proceeding described in Section 11.4.3 (Arbitration Procedure) is
pending under this Agreement, the Parties shall continue to comply with all those terms and provisions of this Agreement that are not the subject of such pending arbitration proceeding. All arbitration proceedings and decisions of the Arbitrator
under this Section 11.4 (Dispute Resolution) shall be deemed Confidential Information of both Parties under Article 7 (Confidentiality and Non-Disclosure). 

11.4.5. Injunction and Other Remedy. Nothing contained in this Agreement shall deny any Party the right to seek injunctive or
other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing arbitration proceeding. In addition, in
the event of a dispute with respect to the validity, scope, enforceability or ownership of any Patent or other intellectual property rights, and such dispute is not resolved by the Senior Officers as set forth in
Section 11.4.1 (Escalation to Senior Officers), such dispute shall not be submitted to an arbitration proceeding and instead, unless otherwise agreed by the Parties in writing, either Party may initiate litigation in a
court of competent jurisdiction in any country in which such rights apply. 

  
 - 58 - 

 11.5. Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the California, U.S., excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Parties
agree to exclude the application to this Agreement of the United Nations Convention on Contracts for the International Sale of Goods. 

11.6. Notices. 

11.6.1. Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required
under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or (if applicable) sent by facsimile transmission (with transmission confirmed) or by internationally recognized
overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section 11.6.2 (Address for Notice) or to such other address as the Party to whom notice is
to be given may have provided to the other Party in accordance with this Section 11.6.1 (Notice Requirements), with a courtesy copy sent by email, which will not constitute notice. Such notice shall be deemed to have been
given as of the date delivered by hand or (if applicable) transmitted by facsimile (with transmission confirmed) or on the [***] Business Day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. Any
notice delivered by facsimile (if applicable) shall be confirmed by a hard copy delivered as soon as practicable thereafter. This Section 11.6.1 (Notice Requirements) is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. 

11.6.2. Address for Notice. 

If to Newsoara, to: 
 [***] 

Attention: Benny Li 
 Email:
[***] 
 Facsimile: [***] 

If to Genelux, to: 
 2625
Townsgate Road 
 Suite 230 

Westlake Village, CA 91361 

Attention: Thomas D. Zindrick 

Email: [***] 
 Facsimile: 

  
 - 59 - 

 with a copy (which shall not constitute notice) to: 

Cooley LLP 
 4401 Eastgate Mall

 San Diego, CA 92121-1909 

Attention: Jason Kent 
 Email:
[***] 
 11.7. Entire Agreement; Amendments. This Agreement, together with the Schedules attached hereto, sets forth and
constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are superseded
hereby. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth in this Agreement. No amendment, modification, release or discharge shall be binding on the Parties unless in
writing and duly executed by authorized representatives of both Parties. In the event of any inconsistencies between this Agreement and any schedules or other attachments hereto, the terms of this Agreement shall control. 

11.8. Language. This Agreement shall be written and executed in, and all other communications under or in connection with this
Agreement shall be in English. 
 11.9. Equitable Relief. Each Party acknowledges and agrees that the restrictions set forth
in Sections 2.3 (Restrictions), 2.7 (Non-Compete), Article 6 (Intellectual Property) and Article 7 (Confidentiality and Non-Disclosure) are
reasonable and necessary to protect the legitimate interests of the other Party and that such other Party would not have entered into this Agreement in the absence of such restrictions and that any breach or threatened breach of any provision of
such Section or Articles may result in irreparable injury to such other Party for which there will be no adequate remedy at law. In the event of a breach or threatened breach of any provision of such Section or Articles, the non-breaching Party shall be authorized and entitled to seek from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, specific performance and an equitable accounting of all
earnings, profits and other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which such non-breaching Party may be entitled in law or
equity. Both Parties agree to waive any requirement that the other (a) post a bond or other security as a condition for obtaining any such relief or (b) show irreparable harm, balancing of harms, consideration of the public interest or
inadequacy of monetary damages as a remedy. Nothing in this Section 11.9 (Equitable Relief) is intended or should be construed, to limit either Party’s right to equitable relief or any other remedy for a breach of any
other provision of this Agreement. 
 11.10. Waiver and Non-Exclusion of Remedies. Any
term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving
such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party
whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein. 

  
 - 60 - 

 11.11. No Benefit to Third Parties. Except as provided in Article 9
(Indemnity), covenants and agreements set forth in this Agreement are for the sole benefit of the Parties and their successors and permitted assigns and they shall not be construed as conferring any rights or enforceable by on any other Persons.

 11.12. Further Assurance. Each Party shall duly execute and deliver or cause to be duly executed and delivered, such
further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this
Agreement or to carry out more effectively the provisions and purposes hereof or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

11.13. Relationship of the Parties. It is expressly agreed that Genelux, on the one hand, and Newsoara, on the other hand, shall
be independent contractors and that the relationship between the two (2) Parties shall not constitute a partnership, joint venture or agency. Neither Genelux, on the one hand, nor Newsoara, on the other hand, shall have the authority to make
any statements, representations or commitments of any kind or to take any action that will be binding on the other Party without the prior written consent of the other Party to do so. All persons employed by a Party shall be employees of such Party
and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such first Party. 

11.14. Foreign Corrupt Practices Act Compliance. Newsoara hereby represents, warrants and covenants to Genelux that neither
Newsoara nor its Affiliates have given or promised to give, nor will make, offer, agree to make or authorize any payment or other transfer anything of value, directly or indirectly, to (a) any Government or Public Official; (b) any
political party, party official or candidate for public or political office; (c) any person while knowing or having reason to know that all or a portion of the value will be offered, given or promised, directly or indirectly, to anyone
described in items (a) or (b) above; or (d) any owner, director, employee, representative or agent of any actual or potential customer of Newsoara or its Affiliates, in each case if any such transfer of value would be a violation of any
Applicable Laws. Newsoara agrees on behalf of itself and its Affiliates to comply with all applicable anti-bribery laws in the countries where the Parties have their principal places of business and where they conduct activities under this
Agreement. Additionally, Newsoara represents, warrants and covenants that Newsoara and its Affiliates shall comply with the U.S. Foreign Corrupt Practices Act (“FCPA”) and the UK Anti-Bribery Act, both as revised from time to
time, as well as similar Applicable Laws of the country where Newsoara and each of its Affiliates has its principal place of business and where Newsoara and each of its Affiliates conducts activities under this Agreement, and to take no action that
would reasonably be deemed to cause Genelux to be in violation of the FCPA, the UK Anti-Bribery Act or similar Applicable Laws of the country where a Party has its principal place of business and where it conducts activities under this Agreement.
Additionally, Newsoara and its Affiliates will make reasonable efforts to comply with requests for information, including answering questionnaires and narrowly tailored audit inquiries, to enable Genelux to ensure compliance with Applicable Laws
related to anti-bribery concerns. For purposes of this Agreement, “Government or Public Official” means any officer or employee or anyone acting in an official capacity on behalf of: a government or any department or agency
thereof; a public international organization (such as the United Nations, the International Monetary Fund, the International Red Cross, and the World Health Organization), or any department, agency or institution thereof; or a government-owned or
controlled company, institution, or other entity, including a government-owned hospital or university. 

  
 - 61 - 

 11.15. References. Unless otherwise specified, (a) references in this
Agreement to any Article, Section or Schedule shall mean references to such Article, Section or Schedule of this Agreement, (b) references in any Section to any clause are references to such clause of such Section, (c) references to any
agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently amended, replaced or supplemented from time to time, as so amended, replaced or supplemented
and in effect at the relevant time of reference thereto, and (d) references to any specific law, rule or regulation, or Section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or
successor law, rule or regulation thereof. 
 11.16. Construction. Except where the context otherwise requires, wherever used,
the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The word “will” will be construed to have the
same meaning and effects as the word “shall.” Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience of reference only and in
no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including,” “include,” or “includes” as used herein shall mean
including, without limiting the generality of any description preceding such term. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either
Party. 
 11.17. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, PDF format via email, or other electronically transmitted signatures and such signatures shall be deemed to bind
each Party as if they were original signatures. 
 [SIGNATURE PAGE FOLLOWS] 

  
 - 62 - 

 THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written
above. 
  

									
	For and on behalf of 	 		 	For and on behalf of 
			
	Genelux Corporation	 		 	Newsoara BioPharma Co. Ltd
					
	By:	 	 _/s/ Thomas Zindrick
	 		 	By:	 	 _/s/ Benny Li

	Name: Thomas Zindrick	 		 	Name: Benny Li
	Title: President and CEO	 		 	Title: CEO

 [Signature Page to Collaboration Agreement] 

 Schedule 1.43 

Genelux Patents 
 [***]

 Schedule 1.60 

Licensed Virus 
 [***]

 Schedule 1.104 

V-VET1 Virus 

[***] 

 Schedule 2.4.2 

Payments for Derived Product 
 If Genelux
exercise its right to develop and commercialize any Derived Product, then Genelux shall pay the following payments to Newsoara: 
  

	●	 Milestone payments 

On a Derived Product-by-Derived Product basis, Genelux shall
pay to Newsoara the following payments within [***] ([***]) days of Genelux’s receipt of invoice issued by Newsoara for the corresponding payments after the first achievement or occurrence of each of the following milestone events by Genelux or
any of its Affiliates or sublicensees with respect to each Derived Molecule or Derived Product: 
  

					
	 Development Milestone Events outside the Territory
	  	Development
Milestone Payments	 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 

  

					
	 Commercial Milestone Events outside the Territory
	  	Development
Milestone Payments	 
	 The annual Net Sales of all Derived Product(s) in the Territory in any Calendar Year exceeds
[***].
	  	 	[	***] 
	 The annual Net Sales of all Derived Product(s) in the Territory in any Calendar Year exceeds
[***].
	  	 	[	***] 
	 The annual Net Sales of all Derived Product(s) in the Territory in any Calendar Year exceeds
[***].
	  	 	[	***] 
	 The annual Net Sales of all Derived Product(s) in the Territory in any Calendar Year exceeds
[***].
	  	 	[	***] 
	 The annual Net Sales of all Derived Product(s) in the Territory in any Calendar Year exceeds
[***].
	  	 	[	***] 
	 The annual Net Sales of all Derived Product(s) in the Territory in any Calendar Year exceeds
[***].
	  	 	[	***] 

  

	●	 Royalties 

During the royalty term*, on a Derived Product-by-Derived
Product basis, Genelux shall pay Newsoara a royalty based on the corresponding amount of Net Sales of such Derived Product outside the Territory multiplied by the applicable royalty rate in each Calendar Year, as set forth below. 

	*	 For the purpose of this definition, royalty term means, with respect to a Derived Product, and each country or
region outside the Territory, the period beginning on the date of First Commercial Sale of such Derived Product in such country or region and ending on the last to occur of: (a) the expiration of the last to expire Patent (including any
applicable patent term extension) licensed to Genelux according to Section 2.4.2 (Derived Product) in such country or region; (b) the tenth (10th) anniversary of the First Commercial Sale of such Derived Product
in such country or region; and (c) the expiration of all Regulatory Exclusivity for such Derived Product in such country or region. 

The royalty reduction set forth in Section 5.3.2 (Royalty Reductions) shall apply mutatis mutandis to royalty
payments on Net Sales of Derived Product. 
  

					
	 Annual Net Sales of a Derived Product:
	  	Royalty Rate for such
Derived Product	 
	 On the increment of annual Net Sales of any Derived Product less than or equal to [***]
	  	 	[	***] 
	 On the increment of annual Net Sales of any Derived Product greater than [***] and less than or
equal to [***]
	  	 	[	***] 
	 On the increment of annual Net Sales of any Derived Product greater than [***] and less than or
equal to [***]
	  	 	[	***] 
	 On the increment of annual Net Sales of any Derived Product greater than [***] and less than or
equal to [***]
	  	 	[	***] 
	 On the increment of annual Net Sales of any Derived Product greater than [***] and less than or
equal to [***]
	  	 	[	***] 
	 On the increment of annual Net Sales of any Derived Product greater than [***]
	  	 	[	***] 

 Schedule 4.1.4 

Development Plan 
 [***]

 Schedule 4.1.5 

NSCLC Multi-Center Trial Plan 

[***] 

 Schedule 4.1.5(f) 

NSCLC Multi-Center Trial Budget 

[***] 

 Schedule 7.4 

Public Announcements 
 [***]EX-10.19

 Exhibit 10.19 

 

			
	 FINAL
	  	
                   
                                         
                    Confidential

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 LICENSE AGREEMENT

 This LICENSE AGREEMENT (the “Agreement”) is entered into on November 15, 2021 (the
“Effective Date”) between: 
 Genelux Corporation, a Delaware corporation with its principal place of business at 2625 Townsgate
Road, Westlake Village, CA 91361 (“Licensor”), and 
 ELIAS Animal Health, LLC, a Delaware limited liability company with its
principal place of business at 10900 Clay Blair Blvd Suite 700, Olathe, KS 66061 (“Licensee”). 
 Licensor and Licensee are sometimes
referred to herein individually as a “Party” and collectively as the “Parties.” 
 RECITALS 

WHEREAS, Licensor has developed certain proprietary oncolytic virus that may be useful for the treatment
of cancer in animals; 
 WHEREAS, Licensee is engaged in the development of therapeutic products for
animal health; 
 WHEREAS, Licensor wishes to grant to Licensee, and Licensee desires to obtain, a
license to develop and commercialize such oncolytic virus for veterinary use, on the terms and conditions set forth herein. 

NOW THEREFORE, in consideration of the foregoing premises and the mutual promises,
covenants and conditions contained in this Agreement, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 As used in
this Agreement, the following initially capitalized terms, whether used in the singular or plural form, shall have the meanings set forth in this Article 1. 

1.1 “Affiliate” means, with respect to a Party, any Person that controls, is controlled by, or is under common control
with that Party. For the purpose of this definition, “control” (including, with correlative meaning, the terms “controlled by” and “under the common control”) means the actual power, either directly or indirectly
through one or more intermediaries, to direct or cause the direction of the management and policies of such Person, whether by the ownership of more than fifty percent (50%) of the voting stocking of such Person, by contract or otherwise; provided
however that Licensor and Licensee are not Affiliate of each other for the purpose of this Agreement. 

  
 1. 

Confidential 

 1.2 “Change of Control” means, with respect to a Party, (a) a
merger, reorganization, consolidation or other transaction involving such Party and any entity that is not an Affiliate of such Party as of the Effective Date, which results in the voting securities of such Party outstanding immediately prior
thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization, consolidation or other transaction, or (b) any entity that is not an Affiliate of such
Party as of the Effective Date becoming the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party or otherwise acquiring the power (whether through ownership interest, contractual
right or otherwise) to direct or cause the direction of the management or policies of such Party. 
 1.3 “Commercially
Reasonable Efforts” means those efforts consistent with the exercise of prudent scientific and business judgment in an active and ongoing program as applied by a Party to the development and commercialization of its own products at a
similar stage of development and with similar market potential. Commercially Reasonable Efforts requires that a Party, at a minimum, assign responsibility for such obligations to qualified employees, set annual goals and objectives for carrying out
such obligations, and allocate resources designed to meet such goals and objectives. 
 1.4 “Confidential
Information” means, with respect to a Party, all information that is disclosed by or on behalf of such Party or its Affiliate to the other Party or its Affiliate under this Agreement, whether in oral, written, graphic, or electronic form.

 1.5 “Control” or “Controlled” means, with respect to any material, information, or intellectual
property right, that Licensor (or any of its Affiliate, but excluding Third Party that becomes an Affiliate of Licensor after the Effective Date as a result of a Change of Control of Licensor) owns or has a license to such material, information, or
intellectual property right and, in each case, has the ability to grant to Licensee access, a license, or a sublicense (as applicable) to the foregoing on the terms and conditions set forth in this Agreement without violating the terms of any
then-existing agreement or other arrangement with any Third Party; provided however that if such material, information, or intellectual property right is in-licensed or acquired by Licensor from a Third Party
after the Effective Date, then Licensor’s Control of such material, information, or intellectual property right shall be subject to Licensee’s agreement to (a) comply with the applicable terms and conditions of the agreement under
which Licensor in-licensed or acquired such material, information, or intellectual property right; and (b) pay all amounts that Licensor would be obligated to pay in connection with the grant, maintenance
or exercise of a sublicense to Licensee under such material, information, or intellectual property right. 
 1.6 “FDA-CVM” means U.S. Food and Drug Administration, Center for Veterinary Medicine, or its successor agency. 

1.7 “Field” means the diagnosis, prevention and treatment of cancer in
non-human animals. 

  
 2. 

Confidential 

 1.8 “First Commercial Sale” means, with respect to any Product in
any country or jurisdiction, the first sale of such Product to a Third Party for distribution, use or consumption in such country or jurisdiction after all Regulatory Approvals (including MAA approval) have been obtained for such Product in such
country or jurisdiction. 
 1.9 “Generic Product” means, with respect to a Product in a country, any veterinary
product that (a) contains the same active ingredient as such Product in the same formulation, dosage form and mode of administration; (b) has obtained Regulatory Approval in such country on an expedited or abbreviated basis in a manner
that relied on or incorporated data submitted by Licensee, its Affiliates, or sublicensees to obtain Regulatory Approval for the Product, such as Abbreviated New Animal Drug Application (“ANADA”); and (c) is sold in such
country by a Third Party that is not a sublicensee of Licensee or its Affiliates and did not purchase such product in a chain of distribution that included any of Licensee or its Affiliates or sublicensees. 

1.10 “Indication” means, with respect to a particular drug product, any disease, disorder or medical condition for
which such drug product can be used to diagnose, prevent or treat. In respect of cancer, different [***] (e.g. [***]) shall be treated as different Indication, and different [***] for which [***] shall also be considered separate Indications for
this Agreement. For the purpose of this Agreement, the approval of a drug product for use to treat different [***] shall be considered approval for separate Indications. 

1.11 “Invention” means any data, results, discovery, finding, process, improvement, method, composition of matter,
article of manufacture, patentable or otherwise, that is invented, reduced to practice, or otherwise generated by either Party exercising its rights or carrying out its obligations under this Agreement, whether directly or via its Affiliates,
agents, contractors or sublicensees, including all rights, title and interest in and to the intellectual property rights therein. 
 1.12
“Know-How” means any proprietary information, including discoveries, improvements, modifications, processes, methods, protocols, formulas, data, inventions, know- how and trade secrets,
patentable or otherwise. 
 1.13 “Laws” means all laws, statutes, rules, regulations, ordinances and other
pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign. 

1.14 “Licensed Know-How” means all
Know-How that (a) is Controlled by Licensor as of the Effective Date or at any time during the Term; and (b) is necessary or reasonably useful for the use of the Licensed Virus in the Field. 

1.15 “Licensed Patents” means all Patent Rights that (a) are Controlled by Licensor as of the Effective Date or
at any time during the Term; and (b) claim the Licensed Virus (including composition of matter, method of make and use in the Field). Licensed Patents existing as of the Effective Date are set forth in Exhibit A. 

1.16 “Licensed Technology” means the Licensed Patents and Licensed Know-How.

  
 3. 

Confidential 

 1.17 “Licensed Virus” means the oncolytic virus known as V-VET1, as described in more detail in Exhibit B. 
 1.18 “Licensee Product
IP” means the data, results, Know-How and Patent Rights that are developed, used or applied by Licensee, its Affiliates or sublicensees in the Development, manufacture or Commercialization of the
Product. 
 1.19 “MAA” or “Marketing Authorization Application” means an application to the
appropriate Regulatory Authority for full approval to commercially sell a Product (but excluding pricing approval) in the Field in a particular jurisdiction and all amendments and supplements thereto, including any New Animal Drug Application
(“NADA”) filed with the FDA-CVM and application for Veterinary Biologics Product License filed with the USDA-CVB in the U.S. 

1.20 “Manufacturing Cost” means, with respect to the Licensed Virus or Product supplied by Licensor to Licensee
hereunder: 
 (a) if the Licensed Virus or Product is manufactured by Licensor’s Third Party contract manufacturer,
(i) Licensor’ actual Third Party cost of the manufacture and supply of such Licensed Virus, plus (ii) the cost (including internal cost) incurred by Licensor in connection therewith, including for manufacturing oversight, quality
assurance and supply management related thereto; and 
 (b) if the Licensed Virus or Product is manufactured by Licensor itself or
its Affiliate, the actual, fully-burdened cost for the manufacture and supply of such Licensed Virus or Product, which shall include two components: (i) all third party costs, including the actual cost of procuring raw materials and vendor
services, plus (ii) conversion costs, which shall include direct labor and benefits, and the proportionate share of indirect manufacturing costs, such costs to be determined in accordance with U.S. Generally Accepted Accounting Principles;
provided however, if manufacturing is moved outside of Licensor’s current facility, the conversion cost will reflect any changes in the proportionate share of indirect manufacturing costs with respect to the new facility. 

1.21 “Net Sales” means the gross amount invoiced by Licensee, its Affiliates or sublicensees for sale of the Product
less the following deductions to the extent (i) reasonable and customary in the veterinary industry and (ii) actually incurred or allowed with respect to such sale and not otherwise recovered or reimbursed to the selling party:
(a) trade, cash and quantity discounts or rebates; (b) credits or allowances for damaged or returned product, including recalls; (c) freight, insurance and other transportation costs directly related to the delivery of the Product;
and (d) taxes (including sales tax and VAT, but not income taxes), tariff, duty or governmental charge levied on the sales of the Product. 

Net Sales shall be calculated in accordance with U.S. Generally Accepted Accounting Principles consistently applied. For clarity, if a single
item falls into more than one of the categories set forth in clauses (a) to (d) above, such item may not be deducted more than once. Sales among Licensee, its Affiliates and sublicensees for subsequent resale shall be disregarded for the
purpose of calculating Net Sales. 

  
 4. 

Confidential 

 With respect to any sale of any Product in a given country for less than fair market value
or for any substantive consideration other than monetary consideration on arm’s length terms (which has the effect of reducing the invoiced amount below what it would have been in the absence of such
non-monetary consideration), for purposes of calculating the Net Sales under this Agreement, such Product shall be deemed to be sold exclusively for cash at the average Net Sales price charged to Third Parties
for cash sales in such country during the applicable reporting period (or if there were only de minimis cash sales in such country, at the fair market value as determined in good faith based on pricing in comparable markets). 

1.22 “Patent Rights” means all patents and patent applications (which for the purpose of this Agreement shall be
deemed to include certificates of invention and applications for certificates of invention), including all divisionals, continuations, substitutions, continuations-in-
part, re-examinations, reissues, additions, renewals, revalidations, extensions, registrations, pediatric exclusivity periods and supplemental protection certificates and the like of any such patents and
patent applications, and any and all foreign equivalents of the foregoing. 
 1.23 “Person” means any individual,
partnership, limited liability company, firm, corporation, association, trust, unincorporated organization or other entity. 
 1.24
“Product” means any and all veterinary products that contain a Licensed Virus as an active ingredient, either alone or in combination of other active ingredient (provided that such other active ingredient cannot be proprietary
to Licensor but is not a Licensed Virus), in any formulation, dosage form or mode of administration. 
 1.25 “Regulatory
Approval” means all approvals from governmental authorities that are necessary for the commercial sale of the Product in a given country or regulatory jurisdiction. 

1.26 “Regulatory Authority” means any applicable government authority responsible for granting Regulatory Approvals
for the Product, including the FDA-CVM and USDA-CVB in the U.S. and any corresponding foreign authorities. 

1.27 “Regulatory Exclusivity” means any exclusive marketing rights or data exclusivity rights (other than Patent
Rights) conferred by any Regulatory Authority with respect to the Product in a given country or regulatory jurisdiction. 
 1.28
“Regulatory Materials” means any regulatory application, submission, notification, communication, correspondence, registration and other filings made to, received from or otherwise conducted with a Regulatory Authority in order
to develop, manufacture, market, sell or otherwise commercialize the Product in a particular country or jurisdiction. 
 1.29
“Territory” means worldwide. 
 1.30 “Therapeutic Virus(es)” means virus-based cancer therapeutics,
whether a virus (replicating-competent, -non-competent, or conditional replicating) by itself, or in mixture with, attached to or inside others (e.g., other virus,
prokaryotic or eukaryotic cell, immune cell, microorganism, protein/peptide, nucleic acid, nanoparticle, chemotherapeutic agent, diagnostic agent, or other organic or inorganic materials). Exemplary virus-based therapeutics include oncolytic viruses
(e.g., replication-competent viruses selected or engineered to preferentially infect and kill cancer cells, such as Olvi-Vec), vaccines and gene therapy products. 

  
 5. 

Confidential 

 1.31 “Third Party” means any person or entity other than Licensor or
Licensee or an Affiliate of either of them. 
 1.32 “United States” or “U.S.” means the United
States of America and its territories and possessions. 
 1.33 “USDA-CVB”
means U.S. Department of Agriculture, Center for Veterinary Biologics, or its successor agency. 
 1.34 “Valid
Claim” means a claim contained in a pending patent application or an issued and unexpired patent in each case that has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent
jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through abandonment, reissue, disclaimer or otherwise. 

1.35 Interpretations. In this Agreement, unless otherwise specified: 

(a) “includes” and “including” shall mean respectively includes and including without limitation; 

(b) words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders; 

(c) words such as “herein”, “hereof”, and “hereunder” refer to this Agreement as a whole and not merely
to the particular provision in which such words appear; and 
 (d) the Exhibits and other attachments form part of the operative
provision of this Agreement and references to this Agreement shall include references to the Exhibits and attachments. 
 ARTICLE 2

 LICENSE 
 2.1
License Grant to Licensee. Subject to the terms of this Agreement, Licensor hereby grants Licensee an exclusive, and royalty bearing license under the Licensed Technology to research, develop, use, sell, offer for sale, have sold, import and
otherwise commercialize the Product in the Field in the Territory (for clarity, such license does not include the right for Licensee to manufacture the Licensed Virus or Product, but, subject to Licensor’s approval, Licensee may have the right
to have a mutually agreed Third Party manufacture the Licensed Virus and Product for Licensee in accordance with Section 3.7(e)). 

2.2 Sublicenses. Subject to the terms of this Agreement, Licensee shall have the right to grant sublicenses (through multiple tiers) to
its Affiliates, subcontractors and other Third Parties under its license in Section 2.1, provided that [***] and Licensee shall remain primarily responsible for the performance of the obligations hereunder by each of its sublicensees. Except
for sublicenses granted to Affiliates and subcontractors, Licensee shall promptly notify Licensor of the grant of any sublicense under this Agreement. 

  
 6. 

Confidential 

 2.3 License Grant to Licensor. Subject to the terms of this Agreement, Licensee
hereby grants Licensor an exclusive, worldwide, fully paid, royalty-free, sublicensable, perpetual and irrevocable license under Licensee Product IP to research, develop, make, have made, use, sell, offer for sale, have sold, import and otherwise
commercialize Therapeutic Viruses outside the Field. 
 2.4 Retained Rights. Notwithstanding the exclusive license granted to the
other Party under this Agreement, each Party retains the right to practice its Licensed Technology or Licensee Product IP (as applicable) in order to fulfil its obligations under this Agreement. For clarity, each Party retains the exclusive right to
practice, license and otherwise exploit its Licensed Technology or Licensee Product IP (as applicable) outside the scope of the license granted to the other Party under this Agreement. Licensor also retains the exclusive right to make and have made
the Licensed Virus. 
 2.5 No Implied License; Negative Covenant. Except as set forth herein, neither Party shall acquire any
license, right or other interest, by implication or otherwise, under any intellectual property rights of the other Party. Licensee covenants that it will not, and it will not permit any of its sublicensees to, use or practice any Licensed Technology
outside the Field. Licensor covenants that it will not, and it will not permit any of its sublicensees to, use or practice any Licensee Product IP in the Field. 

ARTICLE 3 
 DEVELOPMENT
AND COMMERCIALZATION 
 3.1 Overview. Subject to the terms and conditions of this Agreement, Licensee shall be solely
responsible, either by itself or through its sublicensees, for the research, development, and commercialization of the Product in the Field in the Territory. 

3.2 Diligence. Licensee shall use Commercially Reasonable Efforts to research, develop, commercialize the Product in the Field in the
Territory. Moreover, Licensee will use best efforts to obtain an MAA approval after receiving a conditional approval to commercially sell a Product in the Field in a particular jurisdiction. 

3.3 Costs. Licensee shall be solely responsible for all costs and expenses incurred in connection with the research, development and
commercialization of the Product in the Field in the Territory. 
 3.4 Technology Transfer. Within [***] days after Licensor’s
receipt of the upfront payment under Section 4.1, the Parties shall agree on a technology transfer plan for the transfer of Licensed Know-How to enable Licensee to initiate the development of the Product
in the Field (the “Technology Transfer Plan”). Pursuant to such mutually agreed Technology Plan, Licensor shall transfer Licensed Know-How to Licensee, and Licensee shall cooperate with
Licensor to facilitate the receipt of such transfer of Licensed Know-How. In connection with such technology transfer, Licensor shall also provide Licensee with reasonable technical assistance to help Licensee

  
 7. 

Confidential 

 
to understand and use such Licensed Know-How in connection with the development of the Product, including reasonable access to Licensor’s technical
personnel involved in the research and development of the Licensed Virus. Licensee shall reimburse Licensor for both out-of-pocket cost and internal cost incurred by
Licensor to provide such technical assistance. For clarity, the technology transfer provided under this Section 3.4 shall not include the manufacture of the Licensed Virus or Product. 

3.5 Development. 
 (a)
Licensee shall be solely responsible for the development of the Product in the Field in the Territory, at Licensee’s own cost and expense, including performance of all studies and clinical trials in the Territory necessary to obtain
Regulatory Approval for the Product in the Field in the Territory. For clarity, clinical trials of the Product under this Agreement are animal clinical trials, and no Product may be used in humans. 

(b) All development of the Product under this Agreement shall be conducted pursuant to a comprehensive written development plan which
sets forth the timeline and details of all material development work to be conducted by or on behalf of Licensee or its Affiliates or sublicensees in order to obtain Regulatory Approval of the Product in the Field in the Territory (the
“Development Plan”). Within [***] days after Licensor’s receipt of the upfront payment under Section 4.1, the Parties shall agree on the initial Development Plan. Thereafter, from time to time, Licensee shall prepare
updates and amendments to the Development Plan and shall submit the updates and amendments to Licensor for review and discussion before adopting such updates and amendments. 

(c) Licensee shall provide Licensor with copies of all data and results generated by Licensee, its Affiliates and sublicensee from the
development of the Product. Licensor shall have the right to use such data and results for the purpose of developing Therapeutic Viruses outside the Field. 

3.6 Regulatory. 
 (a)
Licensee shall be responsible for all regulatory activities related to the development and commercialization of the Product in the Field in the Territory, at Licensee’s own cost and expense. Licensee shall prepare and file all Regulatory
Materials necessary to obtain and maintain the Regulatory Approval of the Product in the Field in the Territory and shall be responsible for all communication and interaction with Regulatory Authorities with respect thereto. 

(b) At Licensee’s request and expense, Licensor shall provide Licensee with reasonable assistance in connection with the
regulatory activities for the Product in the Field in the Territory. Licensor shall provide Licensee access to all material preclinical and clinical data, results, communications and other information Controlled by Licensor and relating to or
resulting from any of Licensor’s clinical trials or regulatory filings relating to the Licensed Virus in the Field (the “Licensor Data”) for use by Licensee in obtaining Regulatory Approval for the Product in the Field in the
Territory, and Licensee shall have a right of access, a right of reference and a right to use and incorporate all such Licensor Data for purposes of obtaining Regulatory Approval of the Product in the Field in the Territory. 

  
 8. 

Confidential 

 (c) Licensee shall provide Licensor with drafts of all Regulatory Materials relating
to the Product a reasonable time prior to submission for review and comment, and shall consider and implement in good faith any comments received from Licensor. Without limiting the foregoing, upon Licensor’s request, Licensee shall remove from
such Regulatory Materials any information that Licensor reasonably believes would materially and adversely affect the development or commercialization of any Therapeutic Virus outside the Field, to the extent allowed by applicable laws and
regulations. In addition, Licensee shall provide Licensor with copies of any Regulatory Materials relating to the Product submitted to or received from any Regulatory Authority in the Territory within ten (10) days after submission or receipt,
and shall notify Licensor of any other material communication relating to the Product with any Regulatory Authority in the Territory within ten (10) days after such communication. 

(d) If any Regulatory Exclusivity is available for any Product in any country or jurisdiction, Licensee shall, at its own cost and
expense, use Commercially Reasonable Efforts to seek and maintain such Regulatory Exclusivity protection for such Product. If Licensee does not seek or maintain such Regulatory Exclusivity protection, then Licensor shall have the right (but not the
obligation) to do so at Licensor’s own cost and expense; provided that if Licensor successfully obtains such Regulatory Exclusivity protection, Licensee shall reimburse Licensor for all cost and expense incurred. 

(e) Licensee shall keep Licensor informed with respect to any adverse event or safety issues relating to the development or
commercialization of the Product in the Field in the Territory. The Parties may enter into a pharmacovigilance agreement setting forth the procedures for the reporting of adverse event or safety issues of the Product in order for the Parties to
comply with its reporting obligations under applicable Laws. 
 (f) Each Party shall notify the other immediately, and promptly
confirm such notice in writing, if it obtains information indicating that the Product may be subject to any recall, corrective action or other regulatory action by any Regulatory Authority (a “Remedial Action”). The Parties shall
assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action. Licensee shall be responsible for all Remedial Actions for the Product in the Field in the Territory,
including the decision to commence such Remedial Action, and shall bear all cost and expense thereof. Licensee shall, and shall ensure that its Affiliates and sublicensees will, maintain adequate records to permit Licensee to trace the distribution,
sale and use of the Product in the Field in the Territory. 
 3.7 Manufacture and Supply. 

(a) Subject to Section 3.7(e) below, Licensor shall, either by itself or through its Affiliates or Third Party contract
manufacturers, manufacture and supply to Licensee, and Licensee shall purchase from Licensor, all of Licensee’s and its Affiliates’ and sublicensees’ requirements of the Licensed Virus and Product for development and commercialization
use in the Field in the Territory. 

  
 9. 

Confidential 

 (b) Licensee shall pay for the Licensed Virus and Product supplied by Licensor at a
price equal to (i) [***] for Licensed Virus and Product supplied [***]; and (ii) [***], for Licensed Virus and Product supplied [***]. Licensor shall use Commercially Reasonable Efforts to [***] the Licensed Virus and Product. This price does not
include any sales, use, excise, value added, transfer or other taxes or duties levied or assessed by any governmental authority on the transfer and sale of the Licensed Virus and Product to Licensee, all of which shall be borne and paid by Licensee.
Licensor shall deliver the Licensed Virus to Licensee EXW (Incoterms 2020) at Licensor’s (or its Affiliate’s or contract manufacturer’s) facility, and shall invoice Licensee for the Licensed Virus and Product upon such delivery.
Licensee shall pay the amount invoiced within [***] days after the receipt of the invoice, and shall be responsible for arranging shipping, insurance, export and import clearance, all at Licensee’s own cost and expense. 

(c) The Parties may negotiate and enter into one or more supply agreements and related quality agreements for the manufacture and
supply of the Licensed Virus and Product by Licensor to Licensee, which agreements shall be consistent with the terms and conditions of this Agreement, and shall include mutually agreed and customary terms for such agreements, such as detailed
mechanism for forecast and ordering. 
 (d) To the extent the manufacture of the Licensed Virus or Product requires Licensor to
source raw materials from Third Party supplier or if the Licensed Virus or Product is to be manufactured by Licensor’s contract manufacturer, then Licensor’s obligation to supply the Licensed Virus and Product to Licensee shall be subject
to Licensor’s right to source such raw materials or the Licensed Virus or Product from its supplier or contract manufacturer, and the supply agreement between Licensor and Licensee shall be consistent with the supply agreement between Licensor
and its supplier or contract manufacturer. 
 (e) After Licensee has obtained the first MAA approval of a Product in the U.S. by FDA-CVM or USDA-CVB, Licensee may request to have a mutually agreed FDA-CVM or USDA-CVB, as
applicable, licensed facility manufacture the Licensed Virus and Product for Licensee. If Licensor approves such request, the Parties shall jointly select a mutually agreed licensed facility, and Licensor shall conduct a manufacturing technology
transfer to enable such licensed facility to manufacture the Licensed Virus and Product. Such request shall not be unreasonably denied. Licensee shall bear all costs and expenses (including both internal and
out- of-pocket) incurred by Licensor pursuant to a mutually agreed budget to provide such manufacturing technology transfer, which shall be subject to terms and
conditions (including confidentiality) that protects Licensor’s rights in the manufacturing technology. 
 3.8 Commercialization.
Licensee (either by itself or through its Affiliates and sublicensees) shall be responsible for all aspects of the commercialization of the Product in the Field in the Territory, at Licensee’s own cost and expense, including:
(a) developing and executing a commercial launch and pre-launch plan, (b) marketing and promotion; (c) booking sales and distribution and performance of related services; (d) handling all
aspects of order processing, invoicing and collection, inventory and receivables; (e) providing customer support and related functions; and (g) conforming its practices and procedures to applicable Laws relating to the marketing and
promotion of the Product in the Field in the Territory. 

  
 10. 

Confidential 

 3.9 Reports. Licensee shall keep Licensor reasonably informed on the development and
commercialization of the Product in the Field. Within thirty (30) days after the end of each calendar quarter (before the First Commercial Sale of the Product) and each calendar year (after the First Commercial Sale of the Product), Licensee
shall provide Licensor with a written report summarizing its development and commercialization activities in such calendar year and its plan for the next calendar year. Upon Licensor’s reasonable request, Licensee shall discuss with Licensor
the status, progress, results and plan of its development and commercialization activities. 
 ARTICLE 4 

PAYMENTS 
 4.1 Upfront
Payment. Licensee shall pay to Licensor a one-time, non-refundable upfront payment of sixty thousand dollars ($60,000.00) within sixty (60) days after the
Effective Date. 
 4.2 License Maintenance Fee. Licensee shall pay to Licensor annual license maintenance fee of [***] within [***]
after each anniversary of the Effective Date. For clarity, the annual license may not be credited against any other payment under this Agreement. 

4.3 Development Milestone Payments. 

(a) Milestone Events. Subject to the remainder of this Section 4.3, Licensee shall pay to Licensor the following non-refundable development milestone payments set forth in the table below upon the achievement of the corresponding milestone event: 
  

					
	 Development Milestone Event
	  	Milestone Payment	 
	 1) [***]
	  	 	[	***] 
	 2) [***]
	  	 	[	***] 
	 3) [***]
	  	 	[	***] 

 (b) Milestone Conditions. 

(i) Each development milestone payment set forth above shall be due and payable irrespective of whether such milestone event is
achieved by Licensee, its Affiliates or sublicensee. 
 (ii) Milestone [***] shall be due and payable [***]. 

(iii) Milestone [***] shall be due and payable [***]. 

(c) Notice and Payment. Licensee shall notify Licensor in writing and pay to Licensor the corresponding milestone payment within [***]
after the first achievement of any milestone set forth in the table above. 

  
 11. 

Confidential 

 4.4 Sales Milestone Payments. 

(a) Milestone Events. Subject to the remainder of this Section 4.4, Licensee shall pay to Licensor the following one-time, non-refundable sales milestone payments set forth in the table below when the aggregated annual Net Sales of the Product sold in the Territory in a calendar year
first reach the corresponding threshold value indicated below. 
  

							
	 Annual Net Sale of the Product in the
Territory
	  	Milestone Payment	 
	 1. Equal or exceed
	 	 [***]
	  	 	[	***] 
	 2. Equal or exceed
	 	 [***]
	  	 	[	***] 
	 Total
	 		  	 	[	***] 

 (b) Milestone Conditions. Each sales milestone payment set forth above shall be due and payable only
once, regardless of how many times such milestone event is achieved. For clarity, the milestone payments in this Section 4.4 shall be additive, such that if more than one sales milestone specified above is achieved in the same calendar year,
then the milestone payments for all such milestones shall be payable. The aggregate milestone payments under this Section 4.4 shall not exceed [***]. 

(c) Notice and Payment. As part of the royalty report in Section 4.5, Licensee shall provide written notice to Licensor if the
aggregated annual Net Sales of the Product in the Territory first reach any threshold value set forth in Section 4.5(a) above during the time period to which such report pertains. Licensee shall pay to Licensor the corresponding milestone
payment concurrently with the delivery of the royalty report. 
 4.5 Royalty Payments. 

(a) Royalty Rate. Subject to the remainder of this Section 4.5, Licensee shall make quarterly
non-refundable royalty payments to Licensor on the Net Sales of the Product sold in the Territory, as calculated by multiplying the applicable royalty rate set forth in the table below by the corresponding
amount of incremental, aggregated annual Net Sales of the Product sold in the Territory in the applicable calendar year. 
  

					
	 For that portion of annual Net Sale of the Product in the
Territory
	  	Royalty Rate
	 1 less than or equal to
	 	 [***]
	  	[***]
	 2) greater than
	 	 [***]
	  	[***]

 (b) Royalty Term. Licensee’s obligation to pay royalties pursuant to this Section 4.5 shall
continue, on a country-by-country basis, until the latest of: (i) tenth (10th) anniversary of the First
Commercial Sale of such Product in such country; (ii) the expiration of the last-to-expire Valid Claim in the Licensed Patents in such country that covers such
Product (including the composition of matter, manufacture or use of such Product or any component therein); and (iii) the expiration of all Regulatory Exclusivity for such Product in such country (the “Royalty Term”). 

  
 12. 

Confidential 

 (c) Royalty Reductions. 

(i) If a Product is sold in a country in the Territory during the applicable Royalty Term at a time when (A) there is no Valid
Claim in the Licensed Patents that covers such Product (including the composition of matter, manufacture or use of such Product or any component therein) in such country, or there is such a Valid Claim but Licensor declines to enforce (and does not
give consent for Licensee to enforce) such Valid Claim against a Field Infringement that involves the sale of an infringing oncolytic virus product in the Field in such country; and (B) all Regulatory Exclusivity for such Product in such
country has expired, then the royalty rate applicable to the Net Sales of such Product in such country during such time shall be reduced by [***] otherwise applicable to all Net Sales for such Product in the Territory under Section 4.5. 

(ii) If a Product is sold in a country in the Territory during the applicable Royalty Term at a time when a Generic Product is being
sold in such country, then for any calendar quarter during which the Net Sales of such Product in such country are less than [***] of the Net Sales of such Product in such country in the calendar quarter immediately before the launch of the Generic
Product in such country, then the royalty rate applicable to the Net Sales of such Product in such country during such calendar quarter shall be reduced to [***] of the average royalty rate otherwise applicable to all Net Sales for such Product in
the Territory under Section 4.5. 
 (iii) If it is necessary for Licensee to obtain a license from a Third Party to any Patent
Right owned by such Third Party that claim the Licensed Virus in order to sell the Product in a country in the Territory and Licensee obtains such a license, Licensee shall have the right to deduct, from the royalty payment that would otherwise have
been due pursuant to this Section 4.5 with respect to Net Sales of such Product in such country in a particular calendar quarter, [***] of the royalties paid by Licensee to such Third Party pursuant to such license on account of the sale of
such Product in such country during such calendar quarter. 
 (iv) Notwithstanding the foregoing, in no event shall the operation of
Section 4.5(i) or (ii) or (iii), individually or in combination, reduce the royalties paid to Licensor with respect to the Net Sales of any Product in any country in the Territory in any calendar quarter to [***] of the amount that would
otherwise have been due pursuant to Section 4.5(a) with respect to such Net Sales. 
 (d) Report and Payment. Within [***] days
after each calendar quarter, commencing with the calendar quarter during which any Net Sales of the Product are made anywhere in the Territory, Licensee shall provide Licensor with a report that contains the following information for the applicable
calendar quarter, on a country-by-country basis: (i) the amount of gross sales of the Product, (ii) an itemized calculation of Net Sales in the Territory
showing separately each type of deduction provided for in the definition of “Net Sales,” (iii) a calculation of the royalty payment due on such sales, including the application of any reduction made in accordance with Section 4.5(c),
(iv) the exchange rate for such country; and (v) the aggregate annual Net Sales and whether any commercial milestone has been achieved. Concurrent with the delivery of the applicable quarterly report, Licensee shall pay Licensor in Dollars all
royalties owed with respect to Net Sales for such calendar quarter. 

  
 13. 

Confidential 

 4.6 Currency; Exchange Rate. All payments to be made under this Agreement shall be
made in Dollars by bank wire transfer in immediately available funds to a bank account designated by written notice from the Party receiving the payment. The rate of exchange to be used in computing the amount of currency equivalent in Dollars shall
be made at the average of the closing exchange rates reported in The Wall Street Journal (U.S., Eastern Edition) for the first, middle and last business days of the applicable reporting period for the payment due. 

4.7 Late Payments. If Licensor does not receive payment of any sum due to it on or before the due date therefor, simple interest shall
thereafter accrue on the sum due from the due date until the date of payment at a per-annum rate of prime (as reported in The Wall Street Journal (U.S., Eastern Edition)) plus [***] or [***], whichever is
less. 
 4.8 Taxes. 

(a) Taxes on Income. Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising
directly or indirectly from the activities of the Parties under this Agreement. For clarity, all payment amounts in this Article 4 are on a pre-tax basis. 

(b) Tax Cooperation. The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or
similar obligations in respect of royalties, milestone payments, and other payments made under this Agreement. To the extent Licensee is required to deduct and withhold taxes on any payment to Licensor, Licensee shall deduct those taxes from the
remittable payment, pay the taxes to the proper tax authority in a timely manner, and promptly send proof of payment to Licensor. Licensor shall provide Licensee any tax forms that may be reasonably necessary in order for Licensee to not withhold
tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Licensor shall use reasonable efforts to provide any such tax forms to Licensee in advance of the due date. At the request and expense of Licensor, Licensee
shall provide reasonable assistance to enable the recovery, to the extent permitted by Law, of withholding taxes or similar obligations resulting from payments made under this Agreement. 

4.9 Financial Records and Audit of Licensee. Licensee shall maintain complete and accurate records in sufficient detail to permit
Licensor to confirm the accuracy of Net Sales reported by Licensee and the achievement of sales milestones under this Agreement. Upon at least [***] days prior notice, such records shall be open for examination, during regular business hours, for a
period of [***] from the creation of individual records, and not more often than once each calendar year, by an independent certified public accountant selected by Licensor and reasonably acceptable to Licensee, for the sole purpose of verifying for
Licensor the accuracy of the financial reports provided by Licensee under this Agreement. Licensor shall bear the cost of such audit unless such audit reveals an underpayment by Licensee of more [***] of the amount actually due for the time period
being audited, in which case Licensee shall reimburse Licensor for the costs of such audit. Licensee shall pay to Licensor any underpayment discovered by such audit within [***] days after the accountant’s report, plus interest (as set forth in
Section 4.7) from the original due date. If the audit reveals an overpayment by Licensee, then Licensee may take a credit for such overpayment against any future payments due to Licensor (if there will be no future payment due, then Licensor
shall promptly refund such amount to Licensee). 

  
 14. 

Confidential 

 4.10 Financial Records and Audit of Licensor. Licensor shall maintain complete and
accurate records in sufficient detail to permit Licensee to confirm the accuracy of Manufacturing Cost reported by Licensor. Upon at least [***] days prior notice, such records shall be open for examination, during regular business hours, for a
period of [***] from the creation of individual records, and not more often than once each calendar year, by an independent certified public accountant selected by Licensee and reasonably acceptable to Licensor, for the sole purpose of verifying for
Licensee the accuracy of the Manufacturing Costs of the Product supplied by Licensor to Licensee under this Agreement. Licensee shall bear the cost of such audit unless such audit reveals an overcharge by Licensor [***] of the amount actually due
for the time period being audited, in which case Licensor shall reimburse Licensee for the costs of such audit. Licensor shall refund to Licensee any overcharge discovered by such audit within [***] days after the accountant’s report, plus
interest (as set forth in Section 4.7) from the original due date. If the audit reveals an undercharge by Licensor, then Licensee shall pay to Licensor the amount of such undercharge within [***] days after the accountant’s report. 

ARTICLE 5 
 INTELLECTUAL
PROPERTY MATTERS 
 5.1 Inventions. Ownership of all Inventions shall follow inventorship as determined in accordance with U.S.
patent laws. Each Party shall solely own all Inventions invented or developed solely by or on behalf of such Party, including its and its Affiliate’s employees, contractors and/or agents. The Parties shall jointly own all Inventions invented or
developed jointly by both Parties. Except to the extent restricted by the licenses and other rights granted to other Party under this Agreement or any other agreement between the Parties, each Party, as joint owners, shall be entitled to practice,
license, assign and otherwise exploit its interest in the jointly owned Inventions without the duty of accounting or seeking consent from the other Party. 

5.2 Patent Prosecution. 

(a) As between the Parties, Licensor shall have (i) the first right (but not the obligation) to file, prosecute and maintain all
Licensed Patents, and (ii) the sole right (but not the obligation) to file, prosecute and maintain all other Licensed Patents, in each case of (i) and (ii), at Licensor’s own cost and expense. Licensor shall promptly notify Licensee
if it no longer intends or is able to file, prosecute and maintain any Licensed Patent that claims only the Licensed Virus in any country, in which case, Licensee shall have the right (but not the obligation) to assume the prosecution and
maintenance of the affected Licensed Patent in such country, at Licensee’s own cost and expense. If the Licensed Patent that Licensor no longer intends or is able to file, prosecute and maintain claims both the Licensed Virus and other subject
matter, upon Licensee’s request and to the extent feasible and not negatively affect such Licensed Patent, Licensor shall file a divisional application that claims only the Licensed Virus and allow Licensee to assume the prosecution and
maintenance of such divisional application at Licensee’s own cost and expense. Licensee’s assumption of the prosecution or maintenance of such Licensed Patent shall not require Licensor to assign any such Licensed Patent to Licensee, and
shall not change the Parties’ respective rights and obligations under this Agreement with respect to such Licensed Patent other than those expressly set forth in this Section 5.2(a). 

  
 15. 

Confidential 

 (b) Licensor shall consult with Licensee and keep Licensee reasonably informed of the
status of the Licensed Patents that specifically claim the Licensed Virus and shall promptly provide Licensee with all material correspondence received from any patent authority in the US or EU in connection therewith. In addition, Licensor shall
promptly provide Licensee with drafts of all proposed material filings and correspondence to any patent authority in the US or EU with respect to such Licensed Patents for Licensee’s review and comment prior to the submission of such proposed
filings and correspondences. 
 (c) Licensee shall provide Licensor all reasonable assistance and cooperation in the patent
prosecution efforts under this Section 5.2, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution. 

5.3 Patent Enforcement. 

(a) Licensee shall promptly notify Licensor if it becomes aware of any alleged or threatened infringement by a Third Party of any
Licensed Patents that involves the development or commercialization of any oncolytic virus product in the Field in the Territory (the “Field Infringement”). 

(b) As between the Parties, Licensor shall have (i) the first right (but not the obligation) to bring and control any legal action
to enforce the Licensed Patents that claim only the Licensed Virus, and (ii) the sole right (but not the obligation) to bring and control any legal action to enforce other Licensed Patents, in each case of (i) and (ii) against any Field
Infringement at its own expense and as it reasonably determines appropriate. Licensor shall notify Licensee if Licensor does not wish to bring legal action to enforce any Licensed Patent that claims only the Licensed Virus against Field
Infringement, then, subject to Licensor’s prior written consent, Licensee shall have the right to bring and control legal action to enforce such Licensed Patent against such Field Infringement. If a Party brings such an enforcement action, then
the other Party shall, at the request and expense of the enforcing Party, provide reasonable assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action
if required. If Licensor gives consent for Licensee to enforce any Licensed Patent, Licensee shall not admit invalidity or unenforceability of the Licensed Patent or the take any action that would adversely affect the Licensed Patent or other Patent
Rights in the same patent family. 
 (c) Any recoveries resulting from enforcement action under Section 5.3(b) relating to a
Field Infringement shall be first applied against payment of each Party’s cost and expense in connection therewith. Any such recoveries in excess of such cost and expense shall be shared by the Parties equally. 

(d) If the Field Infringement involves the sale of an infringing oncolytic virus product in the Field in the Territory, and Licensor
declines to bring an enforcement action against such Field Infringement and does not give consent for Licensee to bring enforcement action against such Field Infringement, then Licensee may reduce royalty payment to Licensor as provided in
Section 4.5(c)(i). 

  
 16. 

Confidential 

 (e) Licensor shall have the exclusive right to bring and control any legal action to
enforce the Licensed Patents against any infringement other than Field Infringement, at its own expense and as it reasonably determines appropriate, and shall have the right to retain all recoveries resulting therefrom. 

5.4 Defense of Licensed Patents. In the event that a Party receives notice of any claim alleging the invalidity or unenforceability of
any Licensed Patent, such Party shall bring such claim to the attention of the other Party, including all relevant information related to such claim. The Parties, through the JSC, shall discuss such claim. Where such allegation is made in an
opposition, reexamination, interference or other patent office proceeding or a declaratory judgement action, then the provisions of Section 5.2 shall apply; provided however that if Licensor wishes to bring an infringement claim to enforce the
Licensed Patent, then the provisions of Section 5.3 shall apply. Where such allegation is made in a counterclaim to an enforcement action brought under Section 5.3, then the provisions of Section 5.3 shall apply. Licensee shall
provide to Licensor all reasonable assistance in connection with the defense of the Licensed Patents, at Licensor’s request and expense. 

5.5 Defense of Third-Party Claims. If a claim is brought by a Third Party alleging infringement of a Patent Right of such Third Party
by the development, manufacture or commercialization of the Product in the Field, the Party first having notice of the claim or assertion shall promptly notify the other Party, the Parties shall agree on and enter into an “common interest
agreement” wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute, and thereafter, the Parties shall promptly meet to consider the claim or assertion and the appropriate course of action. Each Party
shall be entitled to represent itself in any litigation to which it is a party, at its own expense, unless otherwise agreed upon by the Parties or as otherwise set forth in this Agreement. Licensor agrees that [***] of the costs incurred by Licensee
in defending an infringement suit based on the use of the Licensed Virus, and any damages paid by Licensee in connection with such suit, shall be deducted from future royalty payment obligations under this Agreement in accordance with
Section 4.5(c)(iii) (and subject to Section 4.5(c)(iv)). 
 5.6 Trademarks. Licensee shall have the right to brand the
Product sold in the Field in the Territory using Licensee related trademarks and other trademarks and trade names that Licensee determines appropriate for the Product, provided that Licensee may not select any trademark or trade name that is
confusingly similar to any trademark or trade name of Licensor. Upon Licensor’s request, Licensee shall include Licensor’s name and logo on the promotional materials and product package of the Product to indicate that the Product is
licensed from Licensor. 
 ARTICLE 6 

REPRESENTATIONS AND WARRANTIES 

6.1 Mutual Representations and Warranties. Each Party hereby represents, warrants, and covenants (as applicable) to the other Party as
follows: 
 (a) Corporate Existence and Power. It is a company or corporation duly organized, validly existing, and in good standing
under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated
in this Agreement, including, without limitation, the right to grant the licenses granted by it hereunder. 

  
 17. 

Confidential 

 (b) Authority and Binding Agreement. As of the Effective Date, (i) it has the
corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement
and the performance of its obligations hereunder; and (iii) the Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in
accordance with its terms. 
 (c) No Conflict; Covenant. It is not a party to any agreement that would materially prevent it from
granting the rights granted to the other Party under this Agreement or performing its obligations under the Agreement. 
 (d) Compliance
with Law. It shall comply in all material aspects with all applicable Laws in the course of performing its obligations and exercising its rights under this Agreement. In no event shall either Party be obligated under the Agreement to take any
action or omit to take any action that such Party believes, in good faith, would cause it to be in violation of any applicable Laws. 

6.2 Additional Representations and Warranties of Licensor. Licensor represents, warrants, and covenants (as applicable) to Licensee
that, as of the Effective Date: 
 (a) Licensor has the right under the Licensed Technology to grant the licenses to Licensee as
purported to be granted pursuant to this Agreement, 
 (b) Licensor has not granted, and will not grant during the Term, any licensee
or other right under the Licensed Technology that is inconsistent with the license granted to Licensee hereunder; 
 (c) Exhibit A
includes all Patent Rights Controlled by Licensor as of the Effective Date that claim the Licensed Virus; 
 (d) Licensor has not
received any written notice from any Third Party asserting or alleging that the development of any Licensed Technology or Licensed Virus(es) prior to the Effective Date infringed or misappropriated the intellectual property rights of such Third
Party; and 
 (e) there is no pending or, to Licensors’ knowledge, threatened in writing, adverse action, suit, proceeding, or
claim against Licensor involving the Licensed Technology or Licensed Virus. 
 6.3 Disclaimer. EXCEPT AS EXPRESSLY STATED IN THIS
ARTICLE 6, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT,

  
 18. 

Confidential 

 
OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL SUCH REPRESENTATIONS AND WARRANTIES,
WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. Licensee understands that the Licensed Technology and Licensed Virus are the subject of ongoing research and development and Licensor cannot assure that the Licensed
Technology and Licensed Virus will be useful or any Product can be successfully developed and commercialized using the Licensed Technology and Licensed Virus. 

ARTICLE 7 

INDEMNIFICATION; LIMITATION OF LIABILITY 

7.1 Indemnification by Licensor. Licensor hereby agrees to defend, hold harmless and indemnify Licensee and its agents, directors,
officers and employees (the “Licensee Indemnitees”) from and against any and all liabilities, expenses and/or losses, including without limitation reasonable legal expenses and attorneys’ fees (collectively
“Losses”) in each case resulting from Third Party suits, claims, actions and demands (each, a “Third Party Claim”) arising directly or indirectly out of (a) a breach of any of Licensor’s obligations under
this Agreement, or (b) the negligence or willful misconduct of any Licensor Indemnitee. Licensor’s obligation to indemnify the Licensee Indemnitees pursuant to this Section 7.1 shall not apply to the extent that any such Losses arise
from any activities set forth in Section 7.2(a), (b) or (c), for which Licensee is obligated to indemnify Licensor Indemnitees under Section 7.2. 

7.2 Indemnification by Licensee. Licensee hereby agrees to defend, hold harmless and indemnify Licensor and its agents, directors,
officers and employees (the “Licensor Indemnitees”) from and against any and all Losses resulting from Third Party Claims arising directly or indirectly out of (a) a breach of any of Licensee’s obligations under this
Agreement; (b) the negligence or willful misconduct of Licensee Indemnitees; or (c) the research, development or commercialization of any Product by or on behalf of Licensee or its sublicensees. Licensee’s obligation to indemnify the
Licensor Indemnitees pursuant to the foregoing sentence shall not apply to the extent that any such Losses arise from any activities set forth in Section 7.1(a) or (b), for which Licensor is obligated to indemnify Licensee Indemnitees under
Section 7.1. 
 7.3 Procedure. The indemnified Party shall provide the indemnifying Party with prompt notice of the claim giving
rise to the indemnification obligation pursuant to this Article 7 and the exclusive ability to defend (with the reasonable cooperation of the indemnified Party) or settle any such claim; provided, however, that the indemnifying Party shall
not enter into any settlement for damages other than monetary damages without the indemnified Party’s written consent, such consent not to be unreasonably withheld. The indemnified Party shall have the right to participate, at its own expense
and with counsel of its choice, in the defense of any claim or suit that has been assumed by the indemnifying Party. If the Parties cannot agree as to the application of Sections 7.1 and 7.2 to any particular Third-Party Claim, the Parties may
conduct separate defenses of such Third-Party Claim. Each Party reserves the right to claim indemnity from the other in accordance with Sections 7.1 and 7.2 above upon resolution of the underlying claim, notwithstanding the provisions of this
Section 7.3 requiring the indemnified Party to tender to the indemnifying Party the exclusive ability to defend such claim or suit. 

  
 19. 

Confidential 

 7.4 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY
SPECIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES OR LOSS OF PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 7.4
IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 7.1 OR 7.2, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 8. 

7.5 Insurance. Licensee shall procure and maintain insurance, including product liability insurance if applicable, adequate to cover
its obligations hereunder and which are consistent with normal business practices of prudent companies similarly situated at all times. It is understood that such insurance shall not be construed to create a limit of Licensee’s liabilities
under this Agreement, including with respect to its indemnification obligations under this Article 7. Licensee shall provide Licensor with written evidence of such insurance upon request, and shall provide Licensor with written notice at least
thirty (30) days prior to the cancellation, non-renewal or material change in such insurance. 

ARTICLE 8 

CONFIDENTIALITY 
 8.1
Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that, for the Term and for a period of [***] years thereafter, it shall keep confidential and shall not
publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any Confidential Information of the other Party
pursuant to this Agreement. The foregoing confidentiality and non- use obligations shall not apply to any portion of the Confidential Information that the receiving Party can demonstrate by competent written
proof: 
 (a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure
by the other Party; 
 (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure
to the receiving Party; 
 (c) became generally available to the public or otherwise part of the public domain after its disclosure
and other than through any act or omission of the receiving Party in breach of this Agreement; 
 (d) is subsequently disclosed to
the receiving Party by a Third Party who has a legal right to make such disclosure; or 
 (e) is subsequently independently
discovered or developed by the receiving Party without the aid, application, or use of the disclosing Party’s Confidential Information, as evidenced by a contemporaneous writing. 

  
 20. 

Confidential 

 8.2 Authorized Disclosure. Notwithstanding the obligations set forth in
Section 8.1, a Party may disclose the other Party’s Confidential Information and the terms of this Agreement to the extent: 

(a) such disclosure: (i) is reasonably necessary for the filing or prosecuting patent rights as contemplated by this Agreement; or
(ii) is reasonably necessary for the prosecuting or defending litigation as contemplated by this Agreement; or 
 (b) such
disclosure is reasonably necessary: (i) to such Party’s directors, attorneys, independent accountants or financial advisors for the sole purpose of enabling such directors, attorneys, independent accountants or financial advisors to
provide advice to the receiving Party, provided that in each such case on the condition that such directors, attorneys, independent accountants and financial advisors are bound by confidentiality and non-use
obligations consistent with those contained in this Agreement; or (ii) to actual or potential investors, acquirors, licensors, licensees, collaborators or other business partners solely for the purpose of evaluating or carrying out an actual or
potential investment, acquisition, license or collaboration; provided that in each such case on the condition that such disclosees are bound by confidentiality and non-use obligations consistent with those
contained in the Agreement; 
 (c) such disclosure is required by judicial or administrative process, provided that in such event
such Party shall promptly inform the other Party such required disclosure and provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process
shall remain otherwise subject to the confidentiality and non-use provisions of this Article 8, and the Party disclosing Confidential Information pursuant to law or court order shall take all steps reasonably
necessary, including seeking of confidential treatment or a protective order to ensure the continued confidential treatment of such Confidential Information. 

8.3 Scientific Publication. Except to the extent required by applicable Laws, Licensee shall not publish any peer-reviewed manuscripts,
or give other forms of public disclosure such as abstracts and presentations, relating to the Licensed Technology or Licensed Virus, without Licensor’s review and approval. Licensee shall deliver to Licensor for review and approval the draft of
any proposed scientific publication or presentation relating to the Licensed Technology or Licensed Virus at least [***] days before its intended submission for publication. Licensor shall have the right to require modifications of the proposed
publication or presentation to protect Licensor’s Confidential Information. Licensor may also delay the submission of the proposed publication or presentation for an additional [***] days as may be reasonably necessary to seek patent protection
for the information disclosed in such proposed publication or presentation. Licensee agrees to acknowledge the contribution of Licensor and its employees in all scientific publication as scientifically appropriate. 

8.4 Publicity. 
 (a)
The Parties have agreed on language of a joint press release announcing this Agreement, which is attached hereto as Exhibit C, to be issued by the Parties promptly after the Effective Date. Subject to the rest of this Section 8.4,
except for such initial joint press release, no disclosure of the terms of this Agreement may be made by either Party, and no Party shall use the 

  
 21. 

Confidential 

 
name, trademark, trade name or logo of the other Party, its affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its
subject matter, without the prior express written permission of the other Party, except as may be required by Law. 
 (b) A Party may
disclose this Agreement and its terms in securities filings with the Securities Exchange Commission or equivalent foreign agency (the “SEC”) to the extent required by Law after complying with the procedure set forth in this
Section 8.4. In such event, the Party seeking such disclosure will prepare a draft confidential treatment request and proposed redacted version of this Agreement to request confidential treatment for this Agreement, and the other Party agrees
to promptly (and in any event, no less than [***] days after receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner in order to allow the Party seeking disclosure to file its request within the
time lines proscribed by applicable SEC regulations. The Party seeking such disclosure shall exercise Commercially Reasonable Efforts to obtain confidential treatment of the Agreement from the SEC as represented by the redacted version reviewed by
the other Party. 
 (c) Each Party acknowledges that the other Party may be legally required to make public disclosures (including in
filings with the SEC) of certain material developments or material information generated under this Agreement and agrees that each Party may make such disclosures as required by Law, provided that the Party seeking such disclosure first
provides the other Party a copy of the proposed disclosure, and provided further that (except to the extent that the Party seeking disclosure is required to disclose such information to comply with applicable Laws) if the other Party demonstrates to
the reasonable satisfaction of the Party seeking disclosure, within [***] business days of such Party’s providing the copy, that the public disclosure of previously undisclosed information will materially adversely affect the development and/or
commercialization of the Licensed Technology, Licensed Virus or Product, the Party seeking disclosure will remove from the disclosure such specific previously undisclosed information as the other Party shall reasonably request to be removed. 

8.5 Equitable Relief. Each Party acknowledges that a breach of this Article 8 cannot reasonably or adequately be compensated in damages
in an action at law and that such a breach shall cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party shall be entitled, in addition to any other remedies it may have under this Agreement or
otherwise, to preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of the obligations relating to Confidential Information set forth herein. 

8.6 Attorney-Client Privilege. Neither Party is waiving, nor shall be deemed to have waived or diminished, any of its attorney work
product protections, attorney-client privileges or similar protections and privileges or the like as a result of disclosing its Confidential Information to the other Party under this Agreement, regardless of whether the disclosing Party has
asserted, or is or may be entitled to assert, such privileges and protections. The Parties: (a) share a common legal and commercial interest in such disclosure that is subject to such privileges and protections; (b) are or may become joint
defendants in proceedings to which the information covered by such protections and privileges relates; (c) intend that such privileges and protections remain intact should either Party become subject to any actual or threatened proceeding to
which the disclosing Party’s Confidential Information covered by such protections and privileges relates; and (d) intend that, after the Effective Date, both Parties shall have the right to assert such protections and privileges. 

  
 22. 

Confidential 

 ARTICLE 9 

TERM AND TERMINATION 

9.1 Term. This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this Article 9 or
Section 4.1, above, shall remain in effect, on a country-by-country basis until the expiration of the Royalty Term in such country (the “Term”).
Upon the expiration (but not earlier termination) of this Agreement in a particular country, the license granted to Licensee under the Licensed Technology in such country shall continue and become perpetual and irrevocable. 

9.2 Termination for Convenience. Licensee may terminate this Agreement in its entirety for convenience upon [***] days advance written
notice to Licensor. 
 9.3 Termination for Breach. Each Party shall have the right to terminate this Agreement in its entirety
immediately upon written notice to the other Party, if the other Party materially breaches its material obligations under this Agreement and, after receiving written notice identifying such material breach in reasonable detail, fails to cure such
material breach within [***] days from the date of such notice. 
 9.4 Termination for Bankruptcy. 

(a) Each Party shall have the right to terminate this Agreement in its entirety immediately upon written notice to the other Party, if
the other Party shall file in any court or agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of
such other Party or of substantially all of its assets, or if such other Party proposes a written agreement of composition or extension of substantially all of its debts, or if such other Party shall be served with an involuntary petition against
it, filed in any insolvency proceeding, and such petition shall not be dismissed within [***] calendar days after the filing thereof, or if such other Party shall propose or be a party to any dissolution or liquidation, or if such other Party shall
make an assignment of substantially all of its assets for the benefit of creditors. 
 (b) All licenses granted by a Party to the
other Party under this Agreement are and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11, United States Code or foreign equivalent laws (the “Bankruptcy Code”), licenses of rights to
“intellectual property” as defined in Section 101 of the Bankruptcy Code. Each Party, as the licensee, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. Upon the bankruptcy of a Party (as
the licensor), the other Party (as the licensee) shall further be entitled to a complete duplicate of, or complete access to, any such intellectual property, and such, if not already in its possession, shall be promptly delivered to such other
Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement. 

  
 23. 

Confidential 

 9.5 Termination for Patent Challenge. Except to the extent the following is
unenforceable under the Laws of a particular jurisdiction, Licensor may terminate this Agreement immediately upon written notice to Licensee, if Licensee, either by itself or in association with any other person or entity, commences any legal or
administrative action or proceeding challenging the validity, patentability, enforceability or scope of any Licensed Patents. 
 9.6
Effect of Termination. 
 (a) Termination of License. Upon any termination of this Agreement for any reason, the licenses granted
by Licensor to Licensee under this Agreement shall terminate. For clarity, the license granted by Licensee to Licensor under Section 2.3 outside the Field shall continue. 

(b) Product Reversion. 

(i) Reversion License. Licensee shall and hereby does grant to Licensor, effective only upon termination of this Agreement, an
exclusive, sublicensable license under Licensee Product IP to research, develop, make, have made, use, sell, offer for sale, have sold, import and otherwise commercialize the Product in the Field in the Territory, which license shall be fully paid
and royalty free unless this Agreement is terminated by Licensee for Licensor’s uncured material breach pursuant to Section 9.3, in which case this license shall be royalty bearing at a flat royalty rate of [***]. 

(ii) Regulatory Materials; Data. Licensee shall promptly transfer and assign to Licensor, at no cost to Licensor, all Regulatory
Materials and Regulatory Approvals for the Product. Licensee shall also transfer and assign to Licensor all data from non-clinical and clinical studies conducted by or on behalf of Licensee, its Affiliates or
sublicensees on the Product, and all pharmacovigilance data (including all adverse event databases) on the Product. 
 (iii) Trademarks.
Licensee shall transfer and assign to Licensor, at no cost to Licensor, all trademarks and trade names that have been used, or were intended to be used, in connection with the commercialization of the Product (excluding any such marks that
include, in whole or part, any corporate name or logos of Licensee or its Affiliates). 
 (iv) Product Inventory. Licensor shall have
the right to purchase from Licensee all or part of the inventory of the Licensed Virus and Product held by Licensee as of the effective date of termination at a price equal to the price paid by Licensee to procure such Licensed Virus or Product from
Licensor under Section 3.7. 
 (v) Transition Assistance. Licensee shall reasonably cooperate with Licensor to facilitate
orderly transition of the development and commercialization of the Product to Licensor, including (A) assigning or amending as appropriate, upon request of Licensor, any agreements or arrangements with Third Party vendors to develop, promote,
distribute, sell or otherwise commercialize the Product or, to the extent any such Third Party agreement or arrangement is not assignable to Licensor, reasonably cooperating with Licensor to arrange to continue to provide such services for a
reasonable time after termination; (B) to the extent that Licensee or its Affiliate is performing any activities described above in (A), reasonably cooperating with Licensor to transfer such activities to Licensor and continuing to perform such
activities on Licensor’s behalf for a reasonable time after termination until such transfer is completed. 

  
 24. 

Confidential 

 (vi) Ongoing Clinical Trial. If at the time of such termination, Licensee is
conducting any clinical trials for the Product, then, at Licensor’s election on a trial-by-trial basis: (A) Licensee shall fully cooperate with Licensor to
transfer the conduct of all such clinical trials to Licensor and Licensor shall assume any and all liability for such clinical trials after the effective date of such termination; or (B) Licensee shall, at its expense, orderly wind down the
conduct of any such clinical trial which is not assumed by Licensor under clause (A). 
 (c) Return of Confidential Information. Each
Party shall promptly return to the other Party all Confidential Information of such other Party. 
 9.7 Survival. Expiration or
termination of this Agreement shall not affect the rights or obligations of the Parties under this Agreement that have accrued prior to the date of expiration or termination. Without limiting the foregoing, the following provisions shall survive any
expiration or termination of this Agreement: Sections 2.3, 4.9, 5.1, 6.3, 9.6, 9.7 and 9.8, Articles 7, 8, 10 and 11. 
 9.8 Termination
Not Sole Remedy. Termination is not the sole remedy under this Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies shall remain available except as
agreed to otherwise herein. For clarity, if this Agreement is terminated pursuant to Section 4.1, Licensee shall have no obligation to pay the upfront payment. 

ARTICLE 10 
 DISPUTE
RESOLUTION 
 10.1 Disputes. The Parties recognize that disputes as to certain matters may from time to time arise during the
Term which relate to either Party’s rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual
cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 10 to resolve any controversy or claim arising out of, relating to or in connection with any provision
of this Agreement, if and when a dispute arises under this Agreement. 
 10.2 Internal Resolution. With respect to all disputes
arising between the Parties under this Agreement, including, without limitation, any alleged breach under this Agreement or any issue relating to the interpretation or application of this Agreement, if the Parties are unable to resolve such dispute
within [***] days after such dispute is first identified by either Party in writing to the other, the Parties shall refer such dispute to the Chief Executive Officers of the Parties for attempted resolution by good faith negotiations within [***]
days after such notice is received. 
 10.3 Binding Arbitration. If the Chief Executive Officers of the Parties are not able to
resolve such disputed matter within [***] days and either Party wishes to pursue the matter, each such dispute, controversy or claim that is not an Excluded Claim (defined in Section 10.4 below) shall be finally resolved by binding arbitration
administered by [***], and judgment on the arbitration award may be entered in any court having jurisdiction thereof. The Parties agree that: 

  
 25. 

Confidential 

 (a) The arbitration shall be conducted by a single arbitrator jointly selected by the
Parties. If the Parties are unable or fail to agree upon the arbitrator within [***] days after the initiation of the arbitration, the arbitrator shall be appointed by [***]. The place of arbitration shall be [***], and all proceedings and
communications shall be in English. 
 (b) Either Party may apply to the arbitrator for interim injunctive relief until the
arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the
rights or property of that Party pending the arbitration award. The arbitrator shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damage. Each Party shall bear its own costs and
expenses and attorneys’ fees and an equal share of the arbitrator’s fees and any administrative fees of arbitration regardless of the outcome of such arbitration. 

(c) Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor the arbitrator may disclose
the existence, content, or results of the arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute,
controversy or claim would be barred by the applicable California statute of limitations. 
 10.4 Excluded Claim. As used in
Section 10.3, the term “Excluded Claim” shall mean any dispute, controversy or claim that concerns (a) the scope, validity, enforceability, inventorship or infringement of a patent, patent application, trademark or
copyright; or (b) any antitrust, anti- monopoly or competition law or regulation, whether or not statutory. Excluded Claims shall be determined by a court of competent jurisdiction. 

ARTICLE 11 

MISCELLANEOUS 
 11.1
Entire Agreement; Amendment. This Agreement, including the Exhibits hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between
the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior agreements and understandings between the Parties with respect to the subject matter hereof. There are no covenants, promises,
agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement shall be
binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 
 11.2 Force Majeure. Each
Party shall be excused from the performance of its obligations under this Agreement to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such
excuse shall be continued so long as the condition constituting force majeure continues, and the nonperforming Party takes reasonable efforts to remove the condition. For purposes of this 

  
 26. 

Confidential 

 
Agreement, force majeure shall include conditions beyond the reasonable control of the nonperforming Party, including without limitation, an act of God or terrorism, involuntary compliance with
any regulation, law or order of any government, war, civil commotion, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. If a force
majeure persists for more than ninety (90) days, then the Parties will discuss in good faith the modification of the Parties’ obligations under this Agreement in order to mitigate the delays caused by such force majeure. 

11.3 Notices. Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this
Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 11.3, and shall be deemed to have been given for all
purposes (a) when received, if hand-delivered or sent by confirmed facsimile or a reputable courier service, or (b) five (5) business days after mailing, if mailed by first class certified or registered airmail, postage prepaid, return
receipt requested. 
  

			
	If to Licensor:	  	Genelux Corporation
		  	2625 Townsgate Road
		  	Suite 230
		  	Westlake Village, CA 91361
		  	Attention: Thomas D. Zindrick, J.D.
		
	If to Licensee:	  	ELIAS Animal Health, LLC
		  	Suite 700
		  	10900 S. Clay Blair Blvd
		  	Olathe, Kansas 66061
		  	Attention: Tammie Wahaus
		  	Fax: 913.492.2243

 11.4 No Strict Construction; Headings. This Agreement has been prepared jointly and shall not be
strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The headings of each Article and Section in
this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. 

11.5 Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written
consent of the other, except that a Party may make such an assignment without the other Party’s consent to an affiliate or to a successor to substantially all of the business of such Party to which this Agreement relates (whether by merger,
sale of stock, sale of assets or other transaction). Any permitted successor or assignee of rights and/or obligations hereunder shall, in writing to the other Party, expressly assume performance of such rights and/or obligations. Any permitted
assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 11.5 shall be null, void and of no legal effect. 

  
 27. 

Confidential 

 11.6 Further Actions. Each Party agrees to execute, acknowledge and deliver such
further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

11.7 Severability. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of
competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace
any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

11.8 No Benefit to Third Parties. Except as provided in Article 9 (Indemnity), covenants and agreements set forth in this Agreement are
for the sole benefit of the Parties and their successors and permitted assigns and they shall not be construed as conferring any rights or enforceable by on any other Persons. 

11.9 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other
matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period of
time. 
 11.10 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative
and in addition to any other remedy referred to in this Agreement or otherwise available under law. 
 11.11 Independent Contractors.
Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall be construed to
create the relationship of partners, principal and agent, or joint-venture partners between the Parties. 
 11.12 English Language.
This Agreement was prepared in the English language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement. To the extent this Agreement requires a Party to provide to the other Party
Information, correspondence, notice and/or other documentation, such Party shall provide such Information, correspondence, notice and/or other documentation in the English language. 

11.13 Governing Law. This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed
by and construed under the laws of the State of Delaware, without giving effect to any choice of law principles that would require the application of the laws of a different state. 

11.14 Counterparts. This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. 
 {SIGNATURE PAGE FOLLOWS} 

  
 28. 

Confidential 

					
	FINAL	  		  	Confidential

  

 IN WITNESS WHEREOF, the Parties have executed this License Agreement in duplicate
originals by their duly authorized officers as of the Effective Date. 
  

			
	 Genelux Corporation

 
 By: /s/ Thomas D.
Zindrick                                       
 
 Name: Thomas D. Zindrick

Title: President & CEO
	  	 Elias Animal Health, LLC

 
 By: /s/ Tammie
Wahaus                                       
 
 Name: Tammie Wahaus

Title: Managing Member & CEO

  
 Confidential 

					
	FINAL	  		  	Confidential

  

 List of Exhibits: 
  

			
	Exhibit A:	  	 Licensed Patents

	Exhibit B:	  	 Licensed Virus

	Exhibit C:	  	 Joint Press Release

  
 Confidential 

 EXHIBIT A: LICENSED PATENTS 

[***] 

  
 Confidential 

 EXHIBIT B: EXCLUDED VIRUS 

[***] 

  
 Confidential 

 Exhibit C: Press Release 

 
 

 
 Genelux Announces Exclusive Out-Licensing Agreement with ELIAS
Animal Health for V- VET1, a Proprietary Oncolytic Vaccinia Virus Treatment for Pets with Various Cancers 
  

	 	•	 	 V-VET1, a clinical-stage animal health-specific product candidate, is
a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis) 

  

	 	•	 	 Terms of the agreement grant ELIAS the worldwide right to development and commercialization of V-VET1 for the diagnosis, prevention and treatment of cancer in veterinary medicine 

 WESTLAKE
VILLAGE, Calif., Nov. 9, 2021 /PRNewswire/ — Genelux Corporation, a clinical- stage immunotherapy company, today announced an exclusive worldwide licensing agreement for V-VET1, its clinical stage
animal health product candidate, with ELIAS Animal Health, a biotechnology company advancing its novel T cell-based immunotherapies for the treatment of cancer in veterinary medicine. V-VET1 is a vaccinia
viral strain which selectively replicates in cancer cells causing cell death (apoptosis). 
 ELIAS Animal Health plans future clinical trials to evaluate
and develop V-VET1 as a potential new immunotherapy option for veterinary oncologists. Under the terms of the agreement, Genelux will receive an upfront payment, development and sales milestones, and royalties
on product sales. 
 Genelux conducted a Phase 1 study in which V-VET1 was administered to canines with several
different types of cancer, including mast cell tumors, osteosarcoma, soft tissue sarcoma, anal gland carcinoma and T-cell lymphoma. No maximum tolerated dose was reached in this dose- escalation trial and dogs
tolerated their infusions well. Evidence of antitumor responses and of disease control were observed. 
 Cancer is the leading cause of death for dogs and
the number one pet health concern for dog owners in the United States. In addition to surgery, currently available canine cancer treatment typically provides limited survival benefit. The National Cancer Institute’s Center for Cancer Research
Comparative Oncology Program has reported that as many as six million pet dogs and six million pet cats are diagnosed with cancer annually in the United States. 

“We are excited to be working with ELIAS Animal Health to advance V-VET1 for the treatment of dogs and other non-human animals with various cancers,” said Thomas Zindrick, J.D., President and CEO of Genelux. “Unfortunately, few veterinary-only drugs currently exist to treat companion animals with cancer. ELIAS is
doing tremendous work to advance novel treatments for animal health, including cutting-edge adoptive T cell therapy combined with surgery and radiotherapy, and we are proud to partner with them.” 

“We are thrilled to announce our exclusive license for V-VET1 to help veterinarians treat the many pets who are
diagnosed with cancer every year,” said Tammie Wahaus, CEO of ELIAS 
 35 W. 35th
Street, 11th Floor | New York, NY 10001 | 212 827 0020 | www.tiberend.com 

  
 Confidential 

 Exhibit C: Press Release 

 
 

 
 Animal Health. “This therapeutic showed promising data in the Phase 1 study, and we look forward to expanding our
portfolio to broaden the cancer treatment options available in veterinary medicine.” 
 About Elias Animal Health 

Based in Olathe, Kan., Elias Animal Health is a medical biotechnology company advancing its novel targeted T cell-based immunotherapies for the treatment of
canine cancers. The Elias cancer immunotherapy is being distributed to veterinarians commercially under 9 CFR 103.3 as an experimental autologous prescription product for the treatment of canine osteosarcoma. The company’s novel therapeutic
approach offers the promise of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated. For more information, visit www.eliasanimalhealth.com. 

About Genelux Corporation 
 Genelux is a clinical-stage
biopharmaceutical company focused on developing a pipeline of next- generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-
treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a
large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company’s proprietary CHOICETM platform from which the Company has developed
an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com. 

Contacts 
 Genelux Corporation 

info@genelux.com 
 Tiberend Strategic Advisors,
Inc. 
 Lisa Sher (Investors) 
 lsher@tiberend.com

 David Schemelia (Media) 
 dschemelia@tiberend.com

 35 W. 35th Street, 11th
Floor | New York, NY 10001 | 212 827 0020 | www.tiberend.com 

  
 Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]